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1 Introduction  
In the medical field, synthetic or natural biomaterials can be considered in any medical 
device or implant inserted into living tissue; dental implants and replacement heart 
values are examples. In recent years, biomaterials such as biopolymers, titanium 
alloys, stainless steel, ceramics, and composites have increased in prominence, 
especially for use in implants and musculoskeletal medicine[1]. Because of the ageing 
population which is in particular affected by degenerative diseases, the number of 
implantations performed has increased considerably[2]. Unfortunately, implantation of 
medical devices is a major source of nosocomial infections during the perioperative 
period[3]. Primary sources of contamination are the implant surface, surgical theater, 
surgical equipment, the surgeon and medical personnel, and patients[2][3]. Implant-
associated infections are typically caused by microorganisms, including bacteria that 
grow in biofilms and cause chronic inflammation[4]. Besides high contamination 
sources, implanted foreign materials are highly suseptible to bacterial and fungal 
infection and implant-associated infection might occurs as long as they are in the body 
through the heamatogenous route. Because the mouth is a particularly suitable 
environment for the growth of microorganisms, this thesis focuses on dental implants 
and solving the challenge of preventing the formation of biofilm on the implant by 
providing solutions with infection-controlled release of antibacterial agents.  
A biofilm is described as a collective of one or more types of microorganisms 
nonrandomly distributed in a glycocalyx coating that proliferate on a surface. Such a 
biofilm on the surface of an implant can cause severe medical complications. Biofilm 
formation involves six steps, beginning with the formation of a thin layer of proteins and 
glycoproteins, lodged by the saliva[5]. Primary adhesion involves the rapid adhesion of 
coaggregated planktonic bacteria on the protein layer (Figure 1-1, Step 1). The forces 
associated with bacterial adhesion include surface charge, Van der Waals forces, and 
hydrophobic interactions[6], collectively known as DVLO (Derjaguin, Verwey, Landau, 
and Overbeek) forces[7]. DVLO theory describes the interactions between cells and flat 
surfaces that involve a balance between the attractive Van der Waals interactions and 
repulsive forces. Furthermore, substratum roughness and properties such as ionic 
strength influence the attachment of bacteria. Primary adhesion is followed by cellular 
proliferation and intercellular adhesion (Figure 1-1, Step 2). Polysaccharides named 
extracellular polysaccharide substance (EPS) are excreted by the bacteria, resulting 
in an irreversible attachment. EPS is a well-organized and structured matrix released 
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by bacterial cells that accomplishes the following beneficial activities. First, EPS assists 
nutrient dissemination, which is necessary for cell growth. Second, the diverse 
composition of the charged polysaccharide facilitates the binding of external nutrient 
molecules, which leads to cells sustenance and growth[8].Third, cells encapsulated in 
the EPS matrix are well protected against external antagonistic agents such as 
antibiotics[9], disinfectants, and dynamic environments[10]. As part of the EPS matrix, 
intercellular signaling or quorum sensing enables the system to communicate through 
small diffusible signal molecules, and this significantly benefits bacteria in their effort 
to stave off competitors and rapidly adapt to changing environments[11]. The formation 
of biofilm creates satisfactory conditions for maturation and bacterial cell cluster 
formation (Figure 1-1, Step 3). Intercellular interactions that are mediated by adhesins 
and bacterial cell wall proteins contribute to clustering and subsequent microcolony 
formation[11]. Subsequently, three-dimensional growth and further biofilm maturation 
occur (Figure 1-1, Step 4). In Step 5 (Figure 1-1), the biofilm reaches a critical mass 
and disperses planktonic bacteria, which are able to colonize other surfaces[12] (Figure 
1-1, Step 6).  
 
Figure 1-1 Schematic representation of biofilm development on a solid surface (Figure adapted from Monroe[13] 
under the creative commons license. Image credit: D. Davis). 
    
Factors related to the failure of dental implants because of implant associated 
infections can be divided into four sources[14]: 
 Implant: surface roughness, purity and sterility, oral exposure time. 
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 Patient (local and systemic factors): smoking, alcoholism, bone quality. 
 Surgical technique/environment: perioperative bacterial contamination (e.g. 
saliva, instruments, gloves).  
 Mechanical overloading: traumatic occlusion due to inadequate restorations. 
 
To prevent implant-associated infections some basic nontechnological 
recommendations are proposed. Because it is known that contamination may occur 
through the inoculation with just a few microorganisms during implantation, adopting 
hygienic measures is the most efficient approach to prevent implant-asssociated 
infections. Therefore, meticulous antisepsis during surgery, strict adherence to basic 
hygienic rules such as effective hand disinfection, appropriate individual behavior in 
the operating room, and a clean air environment are essential for the prevention of 
implant-associated infections. Preventing rather than being forced to cure such 
infections is fundamental.  
In addition to the aforementioned precautions, numerous strategies have been 
implemented in an effort to avoid implant-associated infections. Among them, some 
have focused on the development of various implant coating materials for use as the 
controllable means of delivering antibiotic in a sustained manner[15]. For instance, 
polymer coatings can locally release drugs, thereby reducing the toxicity and side 
effects associated with the use of high antibiotic doses[16].  
More generally, antibacterial implant coatings can be divided into two categories: those 
with a repelling effect and those with a killing effect. Both types prevent the primary 
adhesion of living planktonic microbial cells on the implant. Repelling microbes is 
possible by using hydrogel coatings, which are mostly based on highly negatively 
charged polymers or incorporate ultrahydrophobic modifications. For instance, 
systems based on poly(2-alkyl-2-oxazoline), which is a hydrophilic polymer, strongly 
inhibit bacterial adhesion[17]. As a further example Tsibouklis et al. generated coatings 
from poly(methylpropenoxyfluoroalkylsiloxane)s and poly(perfluoroacrylate)s capable 
of inhibiting bacterial colonization on surfaces. The use of these polymers with low 
surface energy that can form smooth coatings is a potential means of inhibiting 
bacterial adhesion on surfaces[18]. 
Coatings in the killing effect category use antimicrobial materials to cause the death of 
bacteria. Such elimination of bacteria may be achieved through two different strategies: 
the release of an active ingredient or the use of antibacterial polymers that kill the 
bacteria upon contact. For example, it has been found that polycations exhibit 
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antibacterial effects against various bacteria[19]. The efficacy of such antibacterial 
polymers highly depends on incorporating hydrophobic moieties; effectiveness 
depends on the type, distribution, and amount of the hydrophobic component[20]. Both 
cationic and hydrophobic components enable the synthesis of a broad range of 
antimicrobial cationic polymers. Jingwei et al. designed and synthesized polymers with 
quaternary ammonium salts and various alkyl chain lengths. Eight of those polymers 
exhibited compelling antimicrobial activity, which could be further enhanced by 
increasing the hydrophobic chain length[21]. Another approach is the encapsulation or 
conjugation of bioactive substance, in order to have a sustained and controlled release. 
Khuller et al. have encapsulated an antibiotic, Streptomycin, in Poly-lactide-co-
glycolide nanoparticles. They were able to increase the bioavailability of encapsulated 
streptomycin compared with intramuscular free and maintain steptomycin levels for 
four days in the plasma and for seven days in organs[22]. 
Roseeuw et al. developed a macromolecular transport system composed of dextran 
and mannose for targeting macrophages and conjugated norfloxacin as an antibiotic. 
Norfloxacin was linked to the polymer through various tetrapeptide linkers, such as 
Gly-Phe-Ala-Leu and Gly-Phe-Leu-Gly, which are cleaved by proteases such as 
cathepsin B[23]. Norfloxacin was linked to the C-terminal part of the peptide through a 
reaction with the piperazine moiety. The release was activated by pH variation and 
incubation with cathepsin B. On the other hand Tolle et al. described nanoparticles, 
which were generated through ionic gelation of negatively charged alginate and a 
positively charged enzyme-cleavable peptide[24]. The cleavage was triggered by a 
specific enzyme released during infections and induced the drug release. 
Of these strategies, the latter one seems to be the most appropriate for the successful 
prevention of biofilm formation. By contrast, a coating with antimicrobial cationic 
polymers is efficient but only after making contact with the bacteria. Moreover, dead 
bacteria or proteins may overlay the coating, diminishing its efficacy. Therefore, even 
after absorption of surrounding proteins or dead bacteria, using nanocarriers to release 
drugs might be an effective approach to combat a pathogenic situation. 
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2 Aim 
The long-term successful development of dental implants depends largely on the ability 
to keep them free of infections and therefore obviate any further surgical treatment. 
The aim of this research is to generate an encapsulation system to reduce drug usage, 
and prevent the growth of biofilms. The degradation of the material used in the system 
should take place as a direct consequence of a trigger, leading to the release of an 
antibiotic. The antibiotic should only be released during an infection or inflammation as 
a reaction by pathogenic bacteria contamination. Therefore, the focus of the 
dissertation was the production and characterization of suitable nanocarriers and their 
immobilization as a drug delivery system on implant surfaces such as titanium. 
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3 Drug delivery systems 
Synthesizing and bringing new drugs to market is usually a long and expensive 
process. As a consequence, conventional drugs that are deficiently soluble, lose 
efficacy after administration, or have unfavorable pharmacokinetics[25]. Many of these 
problems can be improved upon by using drug delivery systems. Among many different 
types, as described in chapter 3.1, a DDS can, for instance, be composed of 
hydrophobic polymers and, therefore create a suitable environment by adjusting drug 
solubility and enhancing protection. Moreover, drug clearance by the kidneys occurs 
rapidly, necessitating high doses or continuous infusion. To counter this, DDS offer a 
high degree of protection against rapid clearance of small molecules and also reduce 
toxicity affecting healthy tissues. A key advantage of DDS is their ability to increase 
drug concentrations in a specific location such as a tumor or infection site [25]. Ligand-
mediated targeting by DDS can also improve specific targeting of tissues[26]. To ensure 
the success of a system, further factors need to be taken into consideration:  
 Rapid and easy processing. 
 Biocompatibility of materials used. 
 High resistance to sterilization, drying, or packaging[27].   
3.1 Different types of systems  
In addition to conventional oral and intravenous drug delivery, new systems of delivery 
have been investigated with the intention of devising a system with the ability to control 
and concentrate drug release at a specific location. For this purpose, several DDS 
have been created and investigated for various pharmaceutical applications. These 
DDS make use of liposomes, nanoparticles, hydrogels, micelles, dendrimers, and 
polymersomes. These systems are briefly described in an overview presented in the 
following chapter.  
3.1.1 Micelles 
Polymeric micelles are self-assembled core-shell structures formed by amphiphilic 
copolymers. Formation of these structures is driven by hydrophobic interactions and 
hydrogen bonds, which lead to a decrease of free energy, leading to the formation of 
micelles. This formation occurs when the concentration reaches a specific 
concentration: critical micelle concentration (CMC). At the CMC, hydrophobic 
segments begin to aggregate to minimize contact with water, leading to the formation 
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of micelles[28]. Most micelles are fabricated by an amphiphilic copolymer with one or 
more hydrophobic component, such as the following:  
 AB-type diblock copolymer[29] 
 ABA-type triblock copolymer[30] 
 ABC-type triblock copolymer[31]. 
According to the literature and amoung many others, polyesters as the hydrophobic 
segment, such as poly(lactide), poly(lactide-co-glycolide), poly(lactide-co-
caprolactone), poly(p-dioxanone), poly(p-dioxanone-co-lactide), and poly(orthoester) 
could be used. As hydrophilic moiety, poly(ethylene glycol), poly(vinyl alcohol), poly(N-
(2-hydroxypropyl) methacrylamide), poly(N-vinylpyrrolidone), poly(acrylic acid) and 
chitosan are  widely employed[32]. 
The most common methods for preparing micelles are the following:  
 Solvent evaporation: typically, the block copolymer is dissolved in an organic 
solvent such as aceton, and then the solution is added dropwise into distilled 
water. Afterwards, the organic solvent is evaporated under reduced pressure to 
obtain the micelle solution[33]. 
 Oil in water emulsion: This consists of dissolving the polymer and the drug in an 
organic solvent. The resultant solution is then emulsified in an aqueous phase 
containing a surfactant. This latter process prevents the organic solvent droplets 
from coalescing. The micelles are formed through stirring under appropriate 
temperature conditions[34]. 
 Dialysis methods: If the solvent is, for instance, water/dimethylformamide (DMF) 
miscible, the DMF solvent can be exchanged by dialysis against water, and this 
consequently generates the micelles[34]. 
Micelles have the ability to encapsulate poorly water-soluble drugs through various 
methods:  
 Direct dissolution and complexation: a charged drug is incorporated into 
micelles through electrostatic interaction with ionic block segments.  
 Direct dissolution and physical entrapment: hydrophobic drugs are solubilized 
with the copolymer and encapsulated into the hydrophobic core during the 
micellization process.  
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 Chemical conjugation: the drug is conjugated to the block copolymer through 
pH or enzyme-sensitive linkers that can be cleaved to trigger drug release[35][36]. 
In addition to the ability to encapsulate molecules, polymeric micelles are able to 
protect loaded drugs from harsh conditions, extend the circulation time of a drug in the 
body, and cause the accumulation of drugs at a localized site of action[37]. In 
conclusion, micelles have become an appealing structure in which hydrophobic drugs 
can be encapsulated and which have been demonstrated to be responsive to various 
exogenous (magnetic field, ultrasound intensity, electric field, variations in 
temperature, magnetic field, or light) or  endogenous stimuli (enzyme concentration, 
changes in pH or redox gradients)[38].    
3.1.2 Hydrogels 
A hydrogel comprises three-dimensional cross-linked networks of water-soluble 
polymers capable of absorbing a high amount of water or biological fluid. The networks 
are generally made of chemically or physically cross-linked polymers, providing highly 
satisfactory stability and insolubility in aqueous solution.  
 
Figure 3-1 Schematic representation of hydrogel as drug delivery system. 
 
Furthermore, hydrogels can be formulated in a variety of physical forms such as 
nanoparticles, microparticles, coatings, and films [39]. They are commonly used in a 
range of medical applications such as tissue engineering[40], diagnostics[41], cellular 
immobilization[42], separation of biomolecules[43], and DDS[44]. The physical properties 
of hydrogels have aroused particular interest within the drug delivery field. In fact, their 
mesh-size can be tuned by the cross-link density, which allows for control over the rate 
of diffusion of encapsulated molecules through the hydrogel[39]. This enables the 
system to maintain a high local concentration of the drug in the surrounding tissues 
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over an extended period[45]. A major advantage of hydrogel is its similarity to the 
extracellular matrix and its capacity to absorb a high amount of water, thus providing 
good biocompatibility[46]. In addition, biodegradability may be incorporated into 
hydrogel using different strategies. Enzymatic, hydrolytic pathways or naturally 
occurring environmental variations in pH and/or temperature[47][48][49] can be used to 
trigger the degradation and release of a drug. Due to the hydrophilic properties of 
hydrogels, hydrophilic drugs are the most suitable for encapsulation. The homogeneity 
and loading capacity of the encapsulation of hydrophobic substances are limited [50]. 
Because of their high water absorption and porosity, hydrogels are also limited by an 
effect called burst release[51]. This effect can be described as a high rate of release 
that occurs rapidly at the beginning of the release process and represents the main 
drawback of hydrogels. 
3.1.3 Nanoparticles[52] 
In the field of delivery systems, nanoparticles (NPs) are defined as structures with a 
diameter ranging from 10 to 100 nm[53][54]. They can be obtained among others from 
biopolymeric materials such as chitosan, alginate, xanthan gum, and cellulose or 
synthetic polymers such as poly(ε-caprolactone), poly(acrylamide), and poly-
acrylate[55]. According to their structural organization, nanoparticles are classified as 
nanocapsules or nanospheres[52] (Figure 3-2). Nanocapsules are core-shell structures 
that are similar to micelles and liposomes. In such systems, the drug is confined or 
contained within the core cavity, which is surrounded by a polymer membrane. 
Nanospheres are matrices, where the encapsulated drug is physically and uniformly 
dispersed in the polymer matrix. Both hydrophobic and hydrophilic substances can be 
entrapped with high efficiency. Lipophilic drugs are encapsulated in the entire polymer 
matrix, and hydrophilic compounds are adsorbed at the particle’s surface. For both 
systems, release in a targeted tissue occurs through the processes of diffusion and 
degradation. These processes are directly related to the biodegradability and 
permeability of the particle matrix. If diffusion occurs more quickly than degradation, 
this implies that the mechanism of release is governed by the diffusion process and 
can be used to maintain a high drug concentration at a specific location over an 
extended period of time. The rapid initial burst release is the main challenge faced by 
such systems and is mainly caused by weak interactions between the active ingredient 
and the NP[56]. Another strategy is to control drug releases by a targeted degradation 
of the DDS. This has led to novel investigations of synthetic methods, bioconjugation 
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techniques, and a rapid proliferation of strategies using targeted chemical reactions 
and degradation processes to trigger changes in structure, shape, chemistry, and 
degradation rates of DDS. Degradation can be triggered, with high specificity, by 
enzyme release, temperature or pH changes, electromagnetic radiation, the influence 
of a magnetic field, ionic strength variation, or reduction-oxidation reactions[57]. For 
instance, in pathological conditions (tumors or inflammation), the expression of specific 
enzymes (protease, phospholipase, or glycosidase) is observed and used to release 
the drug at a desired location[58]. Such stimuli-responsive systems are further 
discussed in chapter 3.2.  
Furthermore, NPs offer many other advantages such as the ability to travel through 
capillaries, avoid drug clearance by the immune system, penetrate cells, and reduce 
the side effects of the drug[59].       
 
 
Figure 3-2 Schematic representation of a nanoparticle. 
 
Particle formation can proceed through various mechanisms[60]: 
 desolvation 
 emulsion/solvent extraction 
 electrospraying  
 self-assembly through hydrophobic interactions 
 ionic gelation  
Ionic gelation has many advantages because of the simple procedure and mild 
conditions for particle formation. In fact, the use of hazardous organic solvents and 
high shear forces are avoided, which minimizes the risk of affecting the activity of 
encapsulated active ingredients[61]. 
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3.1.4 Liposomes[62] 
Liposomes were called a “magic bullet” by the German bacteriologist Paul Ehrlich 
because of their unique property to selectively kill abnormal cells without any effect on 
healthy ones[63]. This specificity has been improved through various approaches based 
on physical and chemical properties.  
Liposomes are formed by lipids, which are amphiphilic molecules with hydrophilic 
(head) and hydrophobic (tail) parts. Due to hydrophobic and hydrophilic interactions, 
they are able to generate bilayer-structured vesicles with a hydrophilic compartment in 
the core and hydrophobic compartments in the lipid bilayers (Figure 3-3)[62].  
  
 
Figure 3-3 Schematic representation of the structure of a liposome. 
 
Liposomes can be classified according to their size, number of bilayers, charge, lipid 
composition, and surface modification with polymers and ligands able to govern their 
stability in vitro and in vivo[64][65][66][67]. 
They are categorized either as unilamellar or multilamellar, depending on their single 
bilayer and multibilayer separated by a hydrophilic compartment. Unilamellar 
liposomes are subdivided into small (20-100 nm), large (>100 nm) and giant (10-1000 
µm) vesicles[68][69]. From a chemical point of view, Bangham et al. defined liposomes 
as vesicles with a small size and spherical shapes that can be generated from 
phospholipids, cholesterols, nontoxic surfactants, and even membrane proteins. Those 
phospholipids can occur naturally, such as the well-known phosphotidylcholine, or can 
be synthetic molecules inspired by the natural ones[68]. Many studies concerning 
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liposomes have shown their advantages for use as delivery systems because of the 
capacity to carry a variety of compounds in the core section[70]. In fact, the 
multicompartment structures enable a high drug loading and can deliver both 
hydrophilic and hydrophobic substances[68]. Additionally, they can increase the stability 
and efficacy of the drug[71] and reduce both the toxicity of the encapsulated agent and 
the exposure of sensitive tissues to toxic drugs. Moreover, liposomes offer other 
benefits such as biocompatibility, physicochemical and biophysical properties through 
which to control and adapt their biological characteristics [72]. They can be modified to 
improve stability, enhance their circulation time in the bloodstream, or generate a 
ligand-targeted liposome. For instance, hydrophilic polyethylene glycol has been an 
interesting moiety to stabilize liposomes in-vivo [73]. The incorporation of polyethylene 
glycol as steric barrier improves the efficacy of encapsulated agents by reducing the 
rapid recognition and uptake by the mononuclear phagocyte system. In addition to 
reducing the elimination of drugs by prolonging blood circulation and providing 
accumulation at pathological sites, liposomes also attenuate side effects of drugs[73]. 
3.1.5 Dendrimers[74] 
Dendrimers are a polymeric system with a well-defined structure, high water solubility, 
and polyvalence, which have made them an object of considerable attention and a 
possible system for use in biomedical applications. Dendrimers are three-dimensional 
branched molecules that have a low polydispersity index. The name dendrimer is 
derived from the Greek word “dendron,” which means “tree,” and refers to the tree-like 
branching structure of dendrimers. The architecture can be distinguished into a core 
moiety that is followed by branched sections, which are called generations. Each 










Surface group   







 generation  
 Figure 3-4 Schematic representation of dendrimers. 
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Moreover, functional groups can be found at the external surface of a dendrimer. The 
higher the number of generations, the more groups are available for further 
modifications. The molecular size and surface groups offer considerable potential for 
making several surface modifications. For instance, multivalency has enabled the 
appearance of many guest-host complexes, with a wide range of applications[75] and 
possibilities to target their actions in various body locations. Applications can be 
achieved by multifunctionalizing the dendrimer with vector devices[76][77]. Additionally, 
dendrimers also have the capacity to encapsulate drugs in their molecular hydrophobic 
and hydrophilic cargo spaces through physical or chemical bonds (Figure 3–4). For 
example, Kannan et al. designed a poly(amidoamine) dendrimer-N-Acetylcystein 
conjugated with a cleavable disulfide linkages for use as delivery vehicles[78]. One key 
advantage, when used as a delivery system, is their ability to cross cell barriers via 
both paracellular and transcellular pathways, allowing these nanocarriers to efficiently 
deliver drugs into cells[79]. Furthermore, their nanoscopic scale ranges in size (1 to 100 
nm), and a low polydispersity index enables them to overcome the macrophage 
system[80]. 
Even though dendrimers possess a wide range of applications in the field of 
biomedicine, their toxicity was reported as a considerable obstacle in their usage [81]. 
Furthermore, dendrimers remain challenging systems due there high degree of 
complexity in the synthetic preperation[82] and the low control over the attachement of 
active substance[83]. Indeed, there is mainly a random conjugation of drug and targeting 
ligand to the surface of dendrimers results in poorly-defined compound mixtures that 
are unlikely to pass regulatory revision and translate into the clinical trials [83]. Therefore, 
dendrimer’s mixtures might have significant batch-to-batch variations of active 
ingredient that leads to non-reproducible pharmacokinetic behavior [83]. To advance 
dendrimer-based materials into clinical trials it is necessary to develop well-defined 
multifunctional dendrimers with controlled number and location of drugs [83]. 
3.1.6 Polymersomes  
Similar to liposomes, polymersomes are structures based on amphiphilic molecules 
and consist of hydrophobic components, which minimize direct exposure to water, and 
hydrophilic components delimiting the two interfaces of a typical bilayer membrane. 
Unlike liposomes and as the name suggests, the polymerome is composed of 
amphiphilic polymers, which are thermodynamically driven into self-assembled 
ordered structures such as, bilayer or multilayer structures[84][85]. Factors such as the 
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characteristics of hydrophilic groups, weight percent, the length and chemistry of the 
hydrophobic components play a crucial role in the shape of the polymer aggregate.  
Assembly into those different structures is governed by the packing parameter (p), 
which can be used to predict the shape formed during the self-assembly process. The 
(p) is related, to (V), the volume of the hydrophobic chain, to (a), the interfacial area 
per molecules, and (l) the length of the hydrophobic chain via the following 
formula[86][87]: 
    





Depending on the (p) value, three different structures might be generated, 
polymersome, worm-like micelles and spherical micelles.  
Each structure can be defined by p values: 
if 𝑝 < 
1
3




 < 𝑝 < 
1
2




 < 𝑝 < 1, polymersomes are generated[87][88] 
 
In other words, the hydrophilic part (f) is a determining factor in the formation of 
different structures and can also be predicted by the balance between hydrophilic and 
(f). For instance, if the (f) value in the structure is higher than 50%, the formation of 
spherical micelles is possible, and with an (f) value between 40% and 50%, worm-like 
structures are more likely. Finally, if the (f) value is between 25% and 40%, which is 
similar to natural phospholipids, polymersome formation is more favorable[89]. 
The structure of polymersomes can be described as a bilayer-based core-shell 
structure with a hydrophobic compartment and hydrophilic core (Figure 3-5). Hence, 
one of their beneficial attributes for use as drug carriers is the ability to incorporate 
hydrophilic (Figure 3-5, A) and hydrophobic (Figure 3-5, B) drugs with a high loading 
capacity[90][91]. 
(V): volume of the hydrophobic chain  
(a): interfacial area per molecule 
(l): length of the hydrophobic chain 
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Figure 3-5 Schematic representation of liposome structure: purple, hydrophobic tail; blue, hydrophilic head and its 
compartments. 
 
Loading capacity is one of the most important factors for any drug delivery system. For 
instance, DDS with low encapsulation efficiency would require a higher quantity of 
polymeric materials to achieve the appropriate drug concentration and can lead to a 
stronger immune response. Besides polymersomes were proven to be more stable 
and less water‐permeable compared to liposomes like phospholipid vesicles[85]. 
Indeed, liposomes have been described as leaky structures with poor retention 
efficiencies. On the other hand, polymersomes offer the possibility to control the 
diffusion rate by varying the amount/length of the hydrophobic segment[92][93]. 
Moreover, natural and synthetic lipids, to generate liposomes, cannot be easily 
functionalized. Even small modifications at the head group can have a significant 
impact on the properties and thus on the self‐assembly into liposomes. On the other 
hand, modification of the lipid tails requires often several synthetic steps[94]. On the 
contrary, polymersomes surface‐functionalization can be achieved by using polymers 
that carry functional groups on their chains[85]. The ability to functionalize the surface 
with specific targeting groups or ligands offers a range of possible targeted release 
sites in the body and thus minimizes unwanted side effects of a drug (Figure 3-5, C). 
For instance, targeting groups or ligands can be biotin receptors, insulin, or antibodies 
such as Anti-ICAM-1, which is used to target inflammatory tissues[95]. Moreover, 
B  C  
D  A  
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responsiveness (Figure 3-5, D) can be incorporated and the polymersome designed to 
release an active ingredient only under specific conditions or upon the application of a 
particular stimulus[96].   
3.2 Stimuli-responsive DDS 
An ideal drug delivery system must first demonstrate biocompatibility, efficiency, and 
then controlled-release functions. Therefore, many studies have focused on DDS that 
integrate stimuli-responsive characteristics. Stimuli responsiveness is especially 
important for disease pathologies, in which specific conditions occur. For instance, 
biological stimuli that can be exploited to target solid tumors include pH, temperature, 
and the enzyme and redox microenvironment[97][98][99][100]. Another strategy is to 
physically trigger the release by external stimuli such as a magnetic field[101], 
ultrasound[102], or light[103].   
3.2.1 pH-responsive DDS 
It is well known that the physiological pH is approximately 7.4. However, due to 
different situation or location, the pH might diverge from the pysiological pH. For 
instance, decrease in pH is observed in pathological tissues upon inflammatory 
conditions or tumor environment[90]. Under normal conditions, the pH might also vary, 
in endosome and lysosome compartments with a variation range of 4.5 to 5.5. For this 
reason, the pH may be an interesting means of triggering the release of an active 
ingredient. The pH of an infected environment; primary tumor, or metastasized tumors 
is lower than that in normal tissue[104]. In fact , it can drop from 7.4  to 6.5, after an 
inflammatory reaction[105]. A tumor environment exhibits pH fluctuations ,ranging from 
5.7 to 7.8[106][107].  
Anticancer treatments are generally associated with unwanted side effects because of 
the nonspecific distribution of drugs into normal tissue. Therefore, selective drug 
targeting is of high interest for treating cancer. As mentioned previously, the pH is 
significantly lower in a tumor mass than in normal tissues and could therefore be used 
to release drugs in a localized manner. One reason for this is that tumors proliferate 
very rapidly and their vascularization is often insufficient to supply adequate nutrients 
or oxygen; leading to hypoxia and production of lactic acid. The hydrolysis of adenosine 
triphosphate also contributes to acidification of tumor environments [108]. One approach 
for triggering drug release is to introduce ionizable chemical groups such as amine or 
carboxylic acids. Those groups can accept or donate protons and therefore undergo 
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pH-dependent physical or chemical changes [109]. For instance, weak polyacids such 
as poly(methacrylic acid) accept protons at a low pH and release protons at a neutral 
or high pH. Conversely, weak polybases such as poly[(2-dimethylamino)ethyl 
methacrylate] accept protons at a low pH and generate a positively charged polymer 
chain. The consequence of these modifications is a variation in the swelling or 
solubility, causing drug release. Kocak et al. summarized many other examples for pH 
responsive polymers[109]. 
Another approach is to use acid-labile chemical bonds to attach drug molecules to 
nanocarriers, which can be incorporated into the system. These bonds are stable at a 
neutral pH but hydrolyze under acidic conditions. The bonds usually used are 
orthoester[110], acetal, hydrazine[111][112], and imine[113] (Figure 3-6). 
 
  
Figure 3-6 Acid-labile chemical bonds. 
 
For example, under acidic conditions, the oxygen of the acetal group is protonated. 
This facilitates the attack of a water molecule and leads to the cleavage of the bond 
through formation of an aldehyde and an alcohol[114][115][116]. 
Several pH-sensitive delivery systems have been developed, including 
polymersomes[117], polymeric micelles [118], nanospheres[119], hydrogels[120], 
liposomes[121], and dendrimers[122]. Griset et al. cross-linked NPs using hydrophobic 
acrylate polymers, which integrate hydroxyl functions protected by an acid labile group. 
The NPs are stable at a neutral pH, but at a lower pH, the protecting group is cleaved, 
liberating the hydroxyl group. As a consequence, the polymer becomes hydrophilic, 
leading to the swelling of NPs and drug release. Drug release was shown to be under 
10% at pH 7.4. However, at pH 5, nearly all the encapsulated drug was released within 
24 hours[123]. 
Zhang et al. developed pH-sensitive micelles by linking tretinoin and dextran via a 
hydrazone bond[124]. The micelles were able to encapsulate doxorubicin (DOX) as an 
antitumor substance and an accelerated drug release, under acidic conditions, was 
shown. Under this condition, the cleavage of the hydrazone bond occurs, leading to 
the disruption of particles. Systems that integrate cleavable acid bonds to link drugs 
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and polymers have also been used to control drug release. Bae et al. [125] developed a 
system that conjugates DOX to an amphiphilic block copolymer, poly(ethylene glycol) 
poly(aspartate hydrazone DOX via a hydrazone bond and that is able to generate 
polymeric micelles. The DOX is conjugated to the side chain of the poly(aspartate) 
segment. The pH dependence of DOX release was confirmed and used to accumulate 
the drug in the nuclei of cancer cells. To conclude, harnessing the acidic conditions of 
the cancer environment or infection site has proven to be a powerful and effective 
strategy for drug delivery nanosystems.  
3.2.2 Thermoresponsive DDS 
In addition to pH, temperature-sensitive DDS are one of the most widely explored 
classes of environmentally sensitive polymers. They are easy to control, to prepare, 
and to handle. Generally, thermosensitive systems exhibit a shape and volume change 
at a specific temperature, leading to a drug release[126]. A slight shift in the temperature 
causes a significant transformation in their macroscopic properties, which makes them 
valuable in the biomedical[127][128], pharmaceutical[129][130], and engineering[131] fields.  
Temperature variations naturally occur in pathological tissues, and varying 
temperature is an intriguing means of triggering the release of active ingredients. Thus, 
various thermo-responsive DDS have been developed to release a drug at a specific 
temperature. Such systems should be able to protect the active ingredient in the 
circulatory system and accumulate the drug in locally heated regions. The main 
characteristics of sensitive polymers are the presence of hydrophobic components 
such as methyl, ethyl, or propyl groups, which are responsible for the appearance of a 
critical solution temperature[132]: 
 Lower critical solution temperature (LCST): the temperature below which the 
polymers are miscible in the solution. 
 Upper critical solution temperature (UCST): the temperature above which the 
polymers are miscible. 
In the case of LCST polymers, their solubility decreases with an increasing 
temperature, and systems based on such polymers shrink as the temperature 
increases above the LCST. This swelling/deswelling effect occurs because of an 
increasing number of hydrophobic interactions[132][133]. As mentioned previously, these 
polymer chains contain a mixture of hydrophilic and hydrophobic segments. At lower 
temperatures, hydrogen bonds between the hydrophilic component and water 
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enhances dissolution, but at a higher temperature, hydrophobicity increases, resulting 
in hydrogel shrinking[132]. 
One of the most studied synthetic thermosensitive polymers is poly(N-
isopropylacrylamide), which is also used in DDS[132]. The advantage of this polymer is 
its LCST at body temperature. For the purpose of a DDS, the phase-transition can be 
adjusted to the specific temperature of 40°C, which occurs in pathological tissues. This 
is achieved by incorporating into the polymer hydrophilic comonomers such as N, N-
dimethylacrylamide[134][135]. 
3.2.3 Redox-responsive DDS 
Disulfide is a well-known bond that is subject to rapid cleavage by glutathione 
(GSH)[136]. Therefore, it is an interesting tool that can be used to integrate redox 
sensitivity into DDS. GSH is an antioxidant capable of preventing cellular damage 
caused by heavy metals and reactive oxygen species (ROS) such as free radicals, 
peroxides, or lipid peroxides[137]. GSH also controls the cellular oxidation-reduction 
environment mainly through the formation or fragmentation of disulfide bonds and the 
reaction with ROS. 
 
Figure 3-7 Metabolism of glutathione into glutathione disulfide. 
 
Studies have demonstrated that GSH/glutathione disulfide is an abundant redox 
couple in mammalian cells (Figure 3-7). In the cytosol and nuclei, the concentration of 
GSH reaches 10 mM, and outside the cell, the concentration drops to 2-20 μM[138]. 
Moreover, in vivo studies have reported that the concentration of GSH in tumor cells 
was at least fourfold higher than GSH concentrations in normal tissue[139]. The same 
variation can be observed in humans[140]. Thus, differences in reducibility of the 
environment between normal and tumor cells provide strategies for targeted therapy 
against cancer progression[141]. Specific environmental traits of tumors were used to 
develop a unique means of degrading redox-sensitive nanocarriers in tumor cells and 
releasing encapsulated molecules in a localized manner. Three main advantages to 
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such an approach can be highlighted. First, redox-sensitive nanocarriers exhibit 
satisfactory stability in a healthy environment, which reduces toxicity and side effects 
of the drug simultaneously. Then, the nanocarriers exhibit a specific response to the 
high GSH concentration in tumor cells, which enables a triggered release. Finally, 
compared with other locations, cytoplasm is often expected to achieve superior 
therapeutic results[142][143]. In the last decade, many reductive-sensitive systems have 
been developed on the basis of polymers containing disulfide links that connect 
polymer blocks together[144]. Disulfide bonds can be easily cleaved by GSH into 
sulfhydryl functions, subsequently leading to degradation of the DDS and the release 
of the encapsulated drug. For instance, Navath et al. synthesized two conjugates 
based on a cationic and an anionic poly(amidoamine) dendrimer with a N-
acetylcysteine payload of 16 and 18 per dendrimer. N-acetylcysteine is an antioxidant 
and anti-inflammatory agent. Their results indicated that the system generated a higher 
local N-acetylcysteine concentration inside the cells[78]. This strategy enabled many 
other system such as liposomes[145] or disulphide cross-linked nanogels[146]. 
Moreover, accumulation of ROS in inflammatory tissues has also been intensively 
explored for generating redox-responsive systems. Indeed, thioketals are frequently 
used as a protection group for a carbonyl group as well as a reagent in organic 
chemistry and can be cleaved by oxidation. For instance, Wilson et al. developed 
thioketal-based NPs for oral delivery to inflamed intestinal tissues that exhibit 
abnormally high levels of ROS[147]. In addition to disulfide bonds, diselenide (Se-Se) 
bonds have been explored. Indeed, they have a similar redox-responsive behavior as 
disulfide bonds[148][149]. Se-Se and C-Se bonds have lower energy bonds than S-S, 
making them even more redox sensitive[150].  
To conclude, redox-responsive DDS have been recognized as a valuable strategy for 
achieving efficient drug delivery. The differences between the microenvironments of 
tumor cells and normal cells appear to be sufficient to generate stable and powerful 
redox-responsive delivery systems.      
3.2.4 Enzyme-responsive DDS 
The expression of specific enzymes (protease, phospholipase, or glycosidase) is 
observed under pathological conditions (tumors or inflammation)[58] and can be used 
to generate DDS to transport the drug to a desired location[151]. Most of these systems 
exploit the presence of enzymes in the extracellular matrix as the trigger for drug 
release, and this has the advantage of exhibiting selectivity to their substrates. For 
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instance, nanocarriers that incorporate these substrate moieties can significantly 
improve drug accumulation at the tumor site, reducing nonspecific uptake by other 
tissues and allowing a specific and controlled release[26]. Drug release can be triggered 
through integration of specific enzymatic cleavable moieties in the main or side chains 
of materials, making them enzyme responsive (Figure 3-8). A wide number of polymers 
have been designed to generate different enzyme-responsive DDS[152][153]. 
Encapsulation of the drug is achieved through different methods, including the 
following: 
 Covalent attachment of the drug through an enzymatic cleavable peptide 
sequence (Figure 3-8, B). 
 Physical encapsulation involving cross-linking by an enzymatic cleavable 
peptide sequence (Figure 3-8, C). 
 Encapsulation into a nanocarrier based on a block copolymer linked through an 
enzymatic cleavable peptide sequence (Figure 3-8, A).  
In all these cases, release is driven by the cleavage of the peptide. Drug carriers can 
also be activated by a specific enzyme capable of exposing targeting ligands that are 
needed for internalization into the cells (Figure 3-8, D). 
 
Figure 3-8 Schematic of enzyme-responsive nanomaterials for controlled drug delivery. (A-C) Drugs can be directly 
released from different carriers upon specific cleavage by enzymes. (D) Drug carriers can be activated by enzymes 
to expose targeting ligands for a subsequent cellular delivery. 
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Hahn et al. described self-assembled systems that incorporate enzyme-responsive 
linkers that are recognizable by a biocatalyst to execute drug release with spatial and 
temporal control[154]. Ge et al. generated an enzyme-responsive polymeric micelle, by 
integration of a matrix metalloprotease (MMP)-responsive peptide linker into the block 
copolymer chains[155]. The MMP-responsive block copolymer, PEG-GPLGVRGDG-
P(BLA-co-Asp), was synthesized through copper click chemistry, which was followed 
by ring-opening polymerization (ROP) of N-carboxyanhydride and a partial hydrolysis 
of poly(β-benzyl L-aspartate). The micelles generated from the copolymer were able 
to encapsulate DOX with a high loading capacity. Controlled drug release inside the 
tumor cells was successfully achieved through the cleavage of the GPLGVRGDG 
peptide linker. The lysosomal cysteine protease called cathepsin B is overexpressed 
in tumor cells and was used in the system of Kern et al.[156] to trigger release from NPs. 
They developed enzyme-cleavable micelles based on a diblock copolymer with the aim 
of delivering a proapoptotic peptide into the intracellular compartment. The first block 
was composed of a macro-chain transfer agent and a pH responsive endosomolytic 
copolymer made of N,N-diethylaminoethyl methacrylate and butyl methacrylate. The 
second polymer block was made of the cleavable peptide BIM capped with a four 
amino acid cathepsin B substrate (FKFL) and polyethylene glycol methacrylate. BIM is 
a peptide that was recently described as antitumor substance. The copolymer was able 
to self-assemble into polymeric NPs. The change of pH in the tumor environment led 
to the destabilization of the polymeric micelle and subsequent cleavage of the FKFL 
peptide sequence, resulting in the release of the BIM proapoptotic peptide.  
Enzyme-responsive systems can be used to detect various diseases. Schiffer et al. 
created an enzyme-responsive polymer for microbial infection detection. The use of 
proteins, polysaccharides, and mixed polymers in a system provides a sensitive tool 
for identifying a low concentration of protease and glycosyl hydrolases produced in 
response to an infection[157].   
In conclusion, enzyme-responsive systems exhibit therapeutic and detection potential 
for cancer and other diseases that involve enzymes. The systems described here are 
mainly based on polymers, which are modified into an enzyme-responsive system. 
Moreover, they appear to be very promising for overcoming the limitations and 
drawbacks of conventional infection and tumor responsive systems through their 
abilities with respect to specificity and early-stage detection[157][158].  
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3.2.5 Physically responsive DDS 
In addition to chemical stimuli-responsive DDS, physically responsive systems 
sensitive to light, temperature and magnetic field have been intensively used for 
medical applications. In the case of magnetic field-sensitive systems, two mechanism 
for treatment have been reported. One mechanism involves magnetic field-induced 
hyperthermia[159], to release substances, and the other one involves magnetic field to 
guide the encapsulation system at a specific location and then have a targeted drug 
delivery[160]. The main advantage of such a system is the ability to target a specific 
location in the body, where the drug is accumulating without causing collateral 
damages to the surrounding tissues. Moreover, such systems do not require any 
specific cell-receptor recognition[161]. Magnetic-responsive systems are based on 
materials such as magnetite, maghemite, iron, nickel, cobalt, and samarium-cobalt, 
and respond to the application of a magnetic field to drive and trigger drug releases.  
Alexiou et. al describe magnetic nanoparticles labelled  with a  chemotherapeutic  
agent. The particles  can be  injected  intraarterially  into  the  tumor-supplying  artery   
and  were driven to the  tumor  region  thanks to   an external  magnetic  field.  Hence 
the chemotherapeutic agent was guided and released towards the specific tumor 
area[162]. Indeed, magnetic fields can then heat magnetic responsive particles,  
inducing hyperthermia and thus, trigger the drug release by using thermoresponsive 
materials[163]. Nguyen et. al, have synthesized paramagnetic iron oxide (core) and 
alginate (shell) based NP, for the encapsulation of doxorubicin. In a magnetic field, the 
Fe3O4 core was able to generate enough heat for doxorubicin release from the alginate 
shell for chemotherapy[164]. 
Moreover, electric fields can also be used in drug delivery systems to trigger and 
regulate drug release. DDS responsive to electrical fields can be composed of 
positively and negatively charged polyelectrolyte polymers. Those ionizable groups 
promote responsiveness to an electric field stimulus. A weak electric field can be 
applied to achieve pulsed and sustained drug release. For instance, NPs based on 
conductive polymers (polypyrrole) showed triggered drug release as a result of 
electrochemical reduction-oxidation under the influence of an electric field[165]. The 
major challenge of such systems is the low tissue penetration of the stimulus and the 
possibility of undesired tissue damages[103]. 
Additionally, light-triggered and ultrasound-triggered DDS also may represent effective 
and minimally invasive methods. Ultrasound waves can trigger drug release, for 
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instance, through hyperthermia or cavitation phenomena. Hyperthermia generally 
promotes the fusion of the nanocarrier and the heating of the surrounding tissue, 
enhancing drug permeation[166]. Moreover, in the field of cancer treatment, the 
hyperthermia produced through ultrasound improves the efficacy of chemotherapy and 
radiotherapy. The cavitation process can be described as the formation of microscopic 
gas bubbles in a medium exposed to ultrasound. The bubble formation leads to a 
compression that generates an increase in pressure and temperature at the site of 
action, leading to the release of the drug[167]. Finally, light-responsive systems are of 
considerable interest because of their possible spatiotemporal characteristics and 
specific drug release activities after radiation at a specific wavelength. The drug 
release is based on a one-time or repeatable on-off event triggered by 
photosensitiveness, which induces structural modification of nanocarriers[168]. 
3.3 Solution approach 
Enzyme-responsive systems have shown to be promising DDS thanks to the 
overexpression profile of specific enzymes observed in pathological conditions such 
as inflammation. The research described in this dissertation, explored two enzyme-
responsive systems designed as smart DDS, for an implant coating, to prevent implant-
associated infections. In both cases, the aim was to encapsulate an antibiotic into a 
nanocarrier and trigger its release upon inflammation or infection of the environment 
surrounding the implant.  
Chapter 4 describes the synthesis of an enzyme-sensitive chitosan-g-[poly-L-lysine-b-
ε-caprolactone] copolymer that is able to self-assemble into polymersomes and to 
encapsulate hydrophilic and hydrophobic substances in different compartments of the 
system (Chapter 3.1.6). Its particularity is the presence of an enzyme-cleavable 
peptide linker between the main hydrophilic chitosan chain and the hydrophobic poly-
ε-caprolactone side chain. The peptide was incorporated to intend the degradation of 
the system by enzymes and subsequently induce the drug release.  
Chapter 5 outlines the second system, based on previous studies on alginate, cross-
linked via an enzyme-cleavable peptide sequence, which is covalently linked to an 
antibiotic. The resulting system has the advantages of being enzyme degradable, of 
avoiding unspecific release and of preventing unwanted drug diffusion across the 
system.  
Both systems were analyzed using dynamic light scattering and scanning electron 
microscopy (SEM) in order to determine the size distribution and morphology of the 
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particles. Moreover, the degradation of particles in solution was observed and 
measured by incubating them with various relevant enzymes and by monitoring the 
size distribution during the degradation process. Furthermore, the transfer from 
particles in solution into a coating of titanium materials was investigated. Indeed, 
titanium is known as a relevant material for implant. Morevoer, ellipsometry was used 
to determine the thickness of the coating and to study its degradation. 
Finally, with respect to the system described in Chapter 5, an antibiotic was modified 
in order to link it to the polymeric system. Partners at Hannover Medical School 
cooperated to test the antibacterial efficacy of the different drugs and to assess the 
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4 Biopolymer-based polymersomes: chitosan-g-[poly-L-lysine20-ε-
caprolactone] 
Polymersomes are of great interest because of there low permeability and high loading 
capacity which allow them to have an efficient drug encapsulation. Moreover, as 
described previously, their core-shell structures have the interesting ability to 
encapsulate hydrophobic and hydrophilic substances. They have been used for the 
development of controlled release to encapsulate therapeutics ranging from small 
molecule anti-cancer drugs to siRNA and therapeutic proteins [169]. More information 
concerning polymersome formation, applications and advantages can be found in 
Chapter 3.1.6. Based on these advantages and for the development of an enzyme-
responsive system, a copolymer has been designed to self-assemble into 
polymersome. To achieve that end, three components were required to generate the 
copolymer: chitosan, poly-ε-caprolactone and a peptide. Chitosan is a well etablished 
and known biopolymer for many different drug delivery systems. It is hydrophilic and 
biocompatible, which is required for a drug delivery system. Poly-ε-caprolactone is a 
hydrophobic and biocompatible polymer, which can be easily functionalized by ring 
opening polymerization. An enzyme cleavable peptide sequence has been used to 
integrate enzyme responsivness to the system. For instance, Tolle et al. have 
incorporated a peptide sequence into an alginate/poly-L-lysine DDS to make the 
system enzyme and inflammation responsive[24]. Based on the same strategy, the 
peptide sequence was used and integrated into the polymeric system. Indeed, chitosan 
and poly-ε-caprolactone have been linked through the peptide sequence, to create an 
amphiphilic graft copolymer. Hydrophobic poly-ε-caprolactone was grafted onto 
chitosan with a specific amount to generate the core-shell structures. The intergration 
of a peptide sequence as a linker has been investigated, to study the degradation of 
the graft copolymer based polymersome through enzymatic cleavage of the peptide. 
Specific peptidases that are released as a result of an inflammation could be exploited 
to trigger drug releases by cleavage of a specific sequence. All materials used are 
described below. 
4.1 Chitosan  
After cellulose, chitosan is the second most abundant semisynthetic biopolymer. This 
amino polysaccharide naturally occurs as a partially deacetylated form of chitin. Chitin, 
which is extracted from sea animals, insects, and microorganisms, is deacetylated 
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through an alkaline or enzymatic reaction, resulting in chitosan with varying degrees of 
acetylation[170]. As depicted in Figure 4-1, chitosan is a linear copolymer composed of 
2-amino-2-deoxy-glucose (D-glucosamine) and β-D-(acetylamino)-2-deoxy-
glucopyranose (N-acetylglucosamin) units. 
 
Figure 4-1 Structural formula of chitosan with n) D-glucosamine and m) N-acetylglucosamine units. 
 
The solubility and properties of chitosan are usually strongly influenced by the degree 
of N-acetylation (DA), which is determined by the ratio of N-acetylglucosamin and 
glucoamine moiety[171]. The DA process frees amino groups that can be protonated in 
acidic conditions, thereby increasing chitosan’s solubility, which is contrary to the 
situation regarding chitin, which has a high DA (over 50%) and is poorly water soluble. 
In addition to amino groups, two hydroxyl groups also contribute to chitosan’s 
hydrophilicity and can be used to functionalize the chitosan. For instance, De Cassan 
et al. used them to initiate polymerization of PCL, thereby generating a chitosan-
grafted PCL copolymer[172]. 
Furthermore, amine groups offer huge opportunities for additional functionalization, 
such as amidation, which has been accomplished to introduce  thiols[173], dyes[174][175], 
fatty acids[176], or other polymers[177]. Therefore, chitosan is one of the most used 
biopolymers for various applications, such as DDS, seed and fertilizer coatings in the 
agriculture field, immobilizing enzymes for biotechnology applications, promoting 
tissue growth, and various uses in the cosmetics and food industries[178]. 
Polycationic chitosan often served as a carrier in polymeric NPs for DDS[179]. It can 
form NPs upon ionic gelation with polyanions such as sodium triphosphate [24] or 
through hydrophilic-hydrophobic interaction in aqueous solution[180]. 
Moreover, because of its good biocompatibility and biodegradability, chitosan is used 
in many biomedical applications and offers various opportunities for in vivo application. 
Chitosan biocompatibility is due to its structural similarities to hyaluronic acid and 
glycosaminoglycan extracellular matrix molecules[181]. Ikada et al. and Thanou et 
al.[182][183] described the biodegradability of chitosan in the human body. In the case of 
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the systemic absorption of a hydrophilic polymer, such as chitosan, molecular weight 
(Mw) plays a crucial role. If chitosan does not have a suitable Mw, it undergoes 
degradation, resulting in small fragments suitable for renal clearance. Various 
possibilities exist for degrading chitosan: chemical degradation through acid-catalyzed 
degradation in the stomach, oxidation-reduction depolymerization, or free radical 
degradation[182][184]. Furthermore, chitosan can be degraded by enzymes such as 
lysozyme, which occurs in body fluids (blood, saliva, tears, or wound secretions) and 
hydrolyzes the glucosamine-N-acetyl-glucosamine/N-acetyl-glucosamine-N-acetyl-
glucosamine linkage. Ikada et al. demonstrated the possibility of controlling 
degradation by using different deacetylated chitosans[184].  
Thanks to its good biocompatibility, availibility and functionalization possibilites, 
chitosan was chosen to generate the encapsulation system. Indeed, through amide 
coupling, chitosan has been modified by amide coupling with maleimide functions, 
used to link the peptide sequence. The strategy will be further described in the course 
of this dissertation. The amide coupling can be illustrated by the following mechanism: 
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To begin the catalytic cycle, Hydroxybenzotriazol (HOBt)  and chitosan were stirred 
overnight to form a water-soluble complex (a)[186] between HOBt and amines of 
chitosan. Next, Dimethylaminopropyl)carbodiimide (EDC) was added and protonated 
by HCl to form a reactive carbocation intermediate, which was described by Cox et 
al.[187][188] as EDClH22+. Following this step, two possible reactions were considered: 
the hydrolysis of the compound and the reaction with 3-maleimidopropionic acid to 
form O‐acylisourea (b). Subsequently, the active O-acylisourea (b) reacts with the 
complex (a), generating the HOBt-active ester (c) and urea as a byproduct. Finally, the 
rearrangement of the complex (c) leads to the final modified chitosan (Figure 4-2). All 
byproducts as well as the non-reacted carboxylic acid were removed during the dialysis 
step. 
4.2 Poly-ε-caprolactone 
During the years 1970s and 1980s, poly-ε-caprolactone (PCL) has received attention 
because of its high potential for applications within the biomaterials field and for drug-
delivery devices. Its popularity has declined due to the arrival of faster resorbable 
polymers. Consequently, PCL has been percieved as the forgotten polymer. However, 
recently, FDA approval as well as inexpensive production routes have propelled PCL 
back into the biomaterials-arena such as medical devices, drug delivery and tissue 
engineering[189]. For instance, it can be used in in-vivo or in-vitro porous scaffolds to 
support cell attachment for tissue formation. These scaffolds provide a suitable porous 
structure in which to encapsulate growth factors to create a cell-friendly environment 
with physical and biochemical stimuli to promote optimal cell growth[190][191]. As 
mentioned previously, PCL is also used to build vehicles for drug encapsulation 
through different methods, such as emulsion evaporation[192], solvent extraction[193], 
spray drying[194], and melt encapsulation[195]. To generate NPs, PCL is combined with 
hydrophilic polymers to form various amphiphilic copolymers. For instance, Jelvehgari 
et al. developed micelles based on poly-ε-caprolactone-co-polyethylene glycol-
co-poly-ε-caprolactone to enhance the ocular bioavailability of poorly water-soluble 
drugs. The resulting micelles are interesting for decreasing the dose frequency by 
having a sustained release and fulfilling the patient compliance for ocular delivery[196]. 
Two routes can be considered for the synthesis of PCL: the condensation of 
hydroxycarboxylic acids[197] and the ring opening polymerization (ROP)[198]. A few 
studies have described the polycondensation of 6-hydroxy-hexanoic by removing 
water molecules formed during the reaction, which consequently shifts the equilibrium 
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towards polymer formation. The reaction is usually performed without catalyst at 
temperatures between 80°C and 150°C.  
ROP of -caprolactone can be performed through four different methods: 
 anionic ROP, involving the formation of an anionic molecule capable of 
attacking the carbonyl carbon of the monomer;  
 cationic ROP, involving a cationic species, which can be attacked by the 
carbonyl oxygen the monomer;  
 monomer-activated ROP, involving the activation of the monomer molecules by 
a catalyst; and 
 coordination-insertion ROP[199]. 
The last method (coordination-insertion ROP), is the most common approach for 
synthesizing functionalized PCL and has been used in this study. It proceeds through 
the coordination of ε‐caprolactone to a metal‐based catalyst. The ROP mechanism has 
been reported by Albertsson et al. for 1,5-dioxepan-2-one and l-lactide as monomers  
and Sn(Oct)2 as catalyst[200]. The ROP of ε-caprolactone can be described by the same 
mechanism and is presented in Figure 4-3. The first step involves the coordination of 
alcohol, the initiator and Sn(Oct)2, which forms the structure (a) (Figure 4-3). During 
this step, two six-membered rings are generated through hydrogen bonds that include 
octanoate and the alcohol. Then, ε-caprolactone coordinates with the Sn2+ in this 
complex and forms a five-coordinated complex (b) (Figure 4-3). Subsequently, the 
alcohol O and the carbonyl C of the ε-caprolactone react and a ring structure with four 
members (c) is formed (Figure 4-3).  Following this step, the bond between the carbon 
of the carbonyl function and the oxygen of the alcohol increases, and the Sn-O(alcohol) 
and the double (C=O) bond decrease to form structure (d) (Figure 4-3). In the final 
step, the ring opening occurs, which forms structure (e) (Figure 4-3), and the  system 
of C=O is restored to generate a new alcohol. The catalytic cycle can then restart.  
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Figure 4-3 Reeaction mechanism of ROP of ε-caprolactone based on the mechanism described by Albertsson et 
al. for 1,5-dioxepan-2-one and l-lactide as monomer. 
 
Moreover, via coordination-insertion ROP the PCL can easily be end-functionalized by 
using functionalized alcohols as initiators. In Figure 4-3, R- can be different functional 
groups. For instance, Bach et al. synthesized a clickable alkyne end-functional PCL by 
using stannous octanoate as the catalyst and propargyl alcohol as initiator [201].  To 
conclude, PCL can be easily synthesized, functionalized and has been proved to be 
biocompatible. Therefore, it is employed in many biomedical applications [202][203] and 
for this study, it serves as the hydrophobic component of the copolymer. To ensure the 
binding to chitosan, PCL has been modified with an alkyne function through the same 
mechanism described above. 
4.3 Peptides 
Peptides and proteins are fundamental components of cells that perform crucial 
biological functions. Peptides can be defined as short chains of amino acid monomers 
linked by peptide bonds. The main difference between proteins and peptide is their 
size and structure. Peptides are defined as molecules that contain between 2 and 50 
amino acids, whereas proteins are made up of over 50 amino acids. Furthermore, 
peptides tend to have less defined and complex structures than proteins, which are 
able to adopt conformations known as secondary, tertiary, and quaternary structures. 
Depending on their size, peptides can be subdivided into oligopeptides and 
polypeptides. Proteins are formed from polypeptides[204] that interact through disulfide 




 Biopolymer-based polymersomes: chitosan-g-[poly-L-lysine20-ε-caprolactone] 32 
 
Peptide sequences are increasingly perceived to be a powerful tool in biomedical 
applications such as the replacement of antibiotics or diagnosing and preventing 
diseases. Many antimicrobial peptides have been described[206][207], and many of them 
have demonstrated efficacious activity against microorganisms resistant to 
conventional antibiotics; they have been shown to be able to kill bacteria at 
concentrations ranging from 0.25 to 4 µg/mL-1[208]. Stayton et al. generated enzyme-
cleavable polymeric micelles for the intracellular delivery of proapoptotic peptides. A 
peptide was directly integrated into a diblock copolymer capable of assembling into 
polymeric micelles[156]. The peptide was composed of a sequence called BIM and a 
four amino acid sequence cleavable by the enzyme cathepsin B. This four amino 
peptide sequence was capable of releasing the BIM sequence into the cel l to 
accomplish intracellular drug release[156]. BIM peptide was recently described as 
antitumor substance. Tolle et al. incorporated an aggrecanase-labile sequence 
ARGSV↓NITEGE into an alginate/poly-L-lysine DDS. In this case, the peptide 
integrated an aggrecanase-labile sequence, a spacer (RGD), and positively charged l-
lysine units to generate NPs with negatively charged alginate. Exposure to 
inflammation-related protease led to the degradation of particles and the subsequent 
release of encapsulated drugs[24]. Therefore, the final goal is to integrate the 
aggrecanase-labile sequence ARGSV↓NITEGE into an encapsulation system in order 
to make it enzyme and consequently inflammation responsive.  
4.4 Poly-L-lysine 
In a preliminary study, poly-L-lysine (PLL) (Figure 4-4), as readily available and 
cleavable peptide, was introduced to investigate the feasibility to generate a system 
which can be degraded by the cleavage of the peptide.  
PLL can be cleaved by various enzymes such as trypsin, chymotrypsin, or proteinase 
K[209][210] and can be synthesized through various methods. The first method employs 
ring opening polymerization of the corresponding N-carboxyanhydride (NCA)[211]. 
Second, peptide sequences can be synthesized on a preactivated resin. Here, the first 
step consists of coupling a protected Fmoc amino acid to the resin[212]. Subsequently, 
a base is used to deprotect the Fmoc-protected group, to enable the coupling of 
another amino acid. The coupling reagent HCTU (2-(6-Chlor-1H-benzotriazol-1-yl) 
together with Diisopropylethylamin are often used to activate this amide coupling[213]. 
Finally, the peptide and protecting groups are removed with a TFA-containing 
cocktail[214]. 
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Figure 4-4 Structural formula of poly-L-lysine.       
 
Poly-L-lysine (PLL) was used and integrated as a linker to investigate the feasibility of 
the system.  Both C-terminus and the N-terminus side of the poly-L-lysine were 
functionalized with an azide and thiol function. The thiol function enables the 
conjugation to chitosan through thiol-ene reaction with maleimide. Generally, the 
reaction between thiol and a double bond can be initiated with different catalysts, such 
as organometallics, bases, Lewis acids, metals, and nucleophiles[215]. Light[216], 
heat[217], or radical initiators[217] are also used to initiate the reaction by generating a 
thiol radical capable to undergo the reaction[218]. 
A uniqueness of the maleimide function is the presence of carbonyl groups in cis-
conformation coupled with ring-strain/bond-angle distortion, which increases the 
reactivity of the double bond towards the thiol function with the help of the solvent. In 
fact, it is common for such reactions to be performed in the presence of, e.g. DMF as 
solvents and catalyst[219]. Solvents such as DMSO and DMF possess a high dielectric 
constant, which promotes the spontaneous dissociation of thiol into nucleophilic 
thiolate anion. Subsequently, the thiolate is able to react with the double bond of the 
maleimide function[220]. Choudhary et al.[221] reported the mechanism of thiol-ene-
Michael addition between a maleimide derivative and a thiol. The reaction starts with 
the formation of a nucleophilic thiolate anion (a), formed by the DMF (Figure 4-5). Two 
other methods exist to generate thiolate ions: one method entails the addition of a base 
and the other entails the addition of nucleophiles[222]. In the next step, a thiolate anion 
undergoes an attack by the π-bond of mal function, resulting in a basic enolate 
intermediate (b) (Figure 4-5). The compound (b) deprotonates a thiol into thiolate to 
form the product. Finally, the cycle restarts with the newly formed thiolate.  
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Figure 4-5 Reaction mechanism of thiol-ene-Michael addition. 
 
The azide function of the PLL enables the ligation to poly-ε-caprolactone through a 
copper-catalyzed Azide-alkyne Huisgen cycloaddition with the alkyne function and can 
be described by the following mechanism. Hein et al.[223] reported the mechanism of 
copper-catalyzed azide-alkyne cycloaddition. The first step entailed the π-coordination 
of an alkyne to copper. This subsequently acidified the terminal hydrogen of the alkyne 
(Step 1, A, Figure 4-6). Afterwards, the proton was deprotonated to form the σ-
acetylide intermediate (Step 2, B). In step 3, the azide function was coordinated to 
copper to generate complex C (Figure 4-6). During this step, the σ-acetylide became 
more nucleophilic and the azide function more electrophilic. This synergic effect led to 
a C-N bond to form the copper metallacycle D (Figure 4-6, Step 4). Then, D underwent 
a rearrangement by releasing a copper to generate the triazole complex E (Figure 4-6, 
Step 5). Finally, the protonation of E intermediate produced the final triazole (Figure 
4-6, Step 6).  
Despite many studies on the topic, the mechanism of copper(I)-catalyzed alkyne-azide 
cycloaddition is still highly controversial. 
(a) 
(b) 
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Figure 4-6 Reaction mechanism of 1,3-Huisgen dipolar cycloaddition catalyzed by copper. 
 
Among the several advantages of Azide-alkyne Huisgen cycloaddition, two important 
features make this reaction particularly attractive for the drug conjugation. Firstly, this 
cycloaddition proceeds well in aqueous medium and, therefore, may efficiently 
performed under mild conditions. Moreover, it is an extremely chemoselective reaction 
and thus, can be used for modifying highly functional biomolecules such as 
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5 Alginate/peptide NPs system  
Ionic gelation is a very advantageous method for the preparation of nanogel particles 
due to the mild conditions. It is considered as a simple and efficient way to obtain 
nanoparticles, which allow encapsulation of sensitive therapeutic proteins[227]. 
Moreover, tunability through functionalization of the surface enables a wide range of 
application in the field of drug delivery system. Biopolymers are preferred for forming 
such systems and possess advantageous properties, including biocompatibility, 
biodegradability, low immunogenicity and can be easily modified thanks to their 
functionalities. Among them, polyions such as chitosan, hyaluronic acid, heparan 
sulfate or alginate are widely used to generate bio-based NPs. Alginate is considered 
as a good candidate for drug delivery systems: it is readily available and relatively 
inexpensive in comparison to other biopolymers. The use of alginate as a matrix for 
the encapsulation and delivery of biomolecules like proteins, DNA, or cells has been 
intensively studied[228][229][230].  Moreover, this polyanion has the capacity to generate 
particles via ionic gelation with cations such as chitosan, calcium and positively 
charged peptide. Tolle et al. described nanoparticles prepared via an ionic gelation of 
negatively charged alginate and a positively charged enzyme cleavable peptide[24]. The 
cleavage was triggered by a specific enzyme released during an inflammation and 
induced the drug release. However, the retention of the model protein interferon  was 
limited and a strong burst release was observed[24]. 
Based on the advantage of alginate and enzyme cleavable peptides, an enzyme-
responsive system made of alginate and a peptide-conjugated drug has been 
designed, in this study. The system was able to self-assemble into nanoparticle as a 
potential drug delivery system (Figure 5-1).  
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Figure 5-1 Schematic representation of alginate/peptide NPs with A) ionic gelation process, B) enzyme-triggered 
release, and C) the residue released from the particle. 
 
Based on these promising results and in an effort to address the main drawback of 
unspecific burst release, this study presents a new enzyme-responsive 
alginate/peptide nanogel, in which the model drug ciprofloxacin is conjugated to the 
peptide linker. Hence, ciprofloxacin was modified and conjugated with an enzyme-
cleavable peptide sequence. Since this was an early-stage study, poly-L-lysine (PLL) 
was used as a peptide sequence to identify the ability of conjugated peptide to 
generate nanoparticles with alginate (Figure 5-1, A). The integration of a peptide 
sequence as a linker has been investigated to study the degradation of the particles 
through enzymatic cleavage of the peptide (Figure 5-1, B) and the release of active 
ingredient (Figure 5-1, C). All materials used are described below. 
5.1 Alginate 
Alginate is a naturally occurring anionic polymer that can typically be extracted from 
brown seaweed including Laminaria hyperborea, L. digitate, L. japonica, Ascophyllum 
nodosum, and Macrocystis pyriferaolav[231]. 
It is known to have low toxicity, good biocompatibility and low cost[228]; therefore, 
alginate has been successfully demonstrated in many biomedical applications. 
Alginate is a linear copolymer of (1-4)-linked β-D-mannuronate and its C-5 epimer α-
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Figure 5-2 Structural formula of alginate and probable binding mode between calcium ions. 
 
Furthermore, water-soluble sodium alginates have the capacity, through carboxylic 
acid, to produce hydrogels with multivalent cations, such as calcium and peptides such 
as PLL[232][233][234]. The ions exhibit different affinities with alginate, depending on the 
alginate’s guluronic acid (G) block content. A high amount of G generates hydrogels 
with higher mechanical strength than alginate rich in mannuranate (M) moiety. One of 
the reason for it is that G residues exhibit stronger interaction with divalent ions (e.g. 
Ca2+) than M residues and, therefore, appear to support the formation of junction zones 
(Figure 5-2)[235][236]. The gelation ability and the structural similarity to extracellular 
matrices of alginate enable a wide range of applications; for instance, wound healing, 
which is achieved through maintenance of a physiologically moist microenvironment 
and minimization of bacterial infection. It is also used for the delivery of bioactive 
molecules like drugs and proteins[237][238]. Biocompatibility has been intensively 
evaluated in vitro as well as in vivo, and the debate is ongoing regarding the influence 
of alginate composition on biocompatibility. For instance, Espevik et al.[239] reported 
that high M content is immunogenic and approximately ten times more efficient in 
inducing cytokine production than low M content alginate. Yet, other studies have 
found low or no immunoresponse around alginate implants[240]. Such absence of or 
minimal response might be due to impurities remaining in raw alginates such as heavy 
metals, endotoxins, proteins, or polyphenolic compounds that are present in nature. 
Therefore, in vivo use requires purification of alginate through a multistep extraction 
procedure. After purification, alginate does not induce any significant reaction in the 
body when implanted into animals[236]. Furthermore, no significant inflammatory 
response was observed in a study[241]. 
Regarding degradability, no enzyme in the human body can degrade alginate. The only 
option for degrading alginate-based hydrogels is to exchange multivalent ions with 
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surrounding monovalent sodium ions. Afterwards, dissolved alginate chains are 
removed by kidney clearance if the molecular weight is under 50 KDa[242]. One 
drawback, is that, at a higher Mw, renal clearance cannot occur and alginate remains 
in the body[243]. A possible approach for making alginate biodegradable under 
physiological conditions is to partially oxidize the alginate chains. Slightly oxidized 
alginate can be degraded in aqueous media and has been demonstrated to have 
potential as a drug delivery vehicle in various applications[244]. 
In conclusion, thanks to low toxicity, good biocompatibility and its ability to generate 
hydrogels with multivalent cations, alginate has been chosen to generate the 
encapsulation system.  Indeed, alginate was used in combination with a positively 
charged peptide to self-assemble into nanoparticle. The peptide sequence is described 
in the following chapters. 
5.2 Peptide NVTEGE↓ALGSV aggrecanase-labile sequence[24][245][246] 
In addition to PLL, another peptide with the enzyme cleavable sequence 
NVTEGE↓ALGSV has been studied in order to integrate it in an alginate/peptide-NP 
system. This sequence can be cleaved by enzyms such as aggrecanase. The protease 
aggrecanase belongs to the family of ADAM (a disintegrin and metalloprotease) 
proteins and will be described further below. This enzyme is mainly secreted during 
the early stages of inflammations, for instance, in osteoarthritis and leads to the 
degradation of cartilage. Tolle et. al demonstrated the ability of customized 
aggrecanase-labile sequence, with a spacer and lysine units to generate nanoparticle 
with alginate[24]. 
As the aim of this study is to covalently link ciprofloxacin to a nanoparticle system, the 
peptide of Tolle et. al have been redesigned. The aggrecanase-labile sequence is 
equipped with tripeptide spacers, lysine units on each side and a functional group. This 
peptide is designed to generate nanoparticle and link a bioactive substance through 









(1) Cleavable peptide sequence, (2) spacer, (3) cation, (4) reactive groups  
  Figure 5-3 Amino acid sequence of the aggrecanase-labile sequence with K – lysine, G – glycine, R – arginine, D – 
aspartic acid, N – asparagine, V – valine, T – threonine, E – glutamic acid, A – alanine, and S – serine. This sequence 
represents the mouse aggrecanase-labile sequence. 
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The right side of the sequence represents the C-terminus, and the left side represents 
the N-terminus tail. On the N-terminus side, a lysine unit functionalized with an azide 
group was coupled to four other lysine units. The azide function enables an extremely 
chemoselective reaction conjugation of bioactive molecules through azide-alkyne 
Huisgen cycloaddition[224][225][226], whereas the lysine units provide positive charges to 
generate NPs through ionic gelation, with negatively charged polymers (e.g. alginate).   
Then, GRD or DRG sequence acts as a spacer between the lysine units and the 
cleavable sequence (Figure 5-3). Regarding the aim of this study, sequence (1) (Figure 
5-3) was chosen because of its property whereby it can be cleaved by an enzyme 
released during an inflammation (e.g. aggrecanase). This enzyme can cleave the 
sequence between glutamic acid and alanine amino acids. The linker can also be 
cleaved by thermolysin or trypsin. The cleavage sites are represented by arrows in 
Figure 5-4.  
             
 
 
Trypsin can potentially hydrolyze bonds on the C-terminus side of a lysine and arginine 
unit and have therefore ten cleavage sites. Thermolysin is a thermostable 
metalloproteinase enzyme produced by the gram-positive bacteria Bacillus 
thermoproteolyticus. The cleavage sites can be found at the N-terminus side of 
hydrophobic amino acids such as isoleucine (I), leucine (L), valine (V), and 
phenylalanine (F). According to the sequence, there are three possible sites to cleave 
the peptide (Figure 5-4). Finally, aggrecanase can specifically hydrolyze at one 
cleavage site. Therefore, it was interesting to integrate this sequence in an 




Figure 5-4 Cleavage site of thermolysin, trypsin, and aggrecanase enzymes on the aggrecanase-labile sequence. 
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5.3 Aggrecanase     
The aggrecanases are metalloproteases that belong to the family of extracellular 
proteases and are also known as ADAMTS. Two different aggrecanases, ADAMTS-4 
and ADAMTS-5, appear in higher concentrations in arthritis, which are members of the 
“A Desintegrin And Metalloproteinase with ThromboSpondin motifs” gene family[245]. 
Both of them cleave aggrecan at five different sites, and all the resultant fragments 
have been identified in cartilage explants undergoing matrix degradation. Aggracan is 
one of the most important components of the extracellular matrix in joint cartilage and 
is responsible, together with collagen fibrils, for elasticity[247]. The ability to accept 
highly compressive force is due to the water absorption capacity of aggrecans[248]. 
Figure 5-5 presents a schematic of the protein that holds three globular domains: G1 
and G2 on the N-terminus side and a G3 domain on the C-terminus side. The amino 
acid sequence between G2 and G3 possesses a high amount of substituted keratan 
sulfate (subdomain KS) and chondroitin sulfate (Cs), which is organized into two 
distinct subdomains, Cs-1 and Cs-2. On the N-terminus part, the gap between G1 and 
G2 is an interglobular domain with 150 amino acids. The G1 domain has high binding 
specificity with hyaluronan, a glycosaminoglycan present in the extracellular matrix. 
The binding is reinforced by a link protein[245]. 
In a disease environment, like osteoarthritis, the rate at which the extracellular matrix 
degrades is higher than the production rate, resulting in a decrease of cartilage matrix 
amount. This degradation can be explained by the release of matrix-
metalloproteinases responsible for aggrecanolysis. Thus far, two aggrecanase 
isoforms have been identified: ADAMTS-4 and ADAMTS-5. Along their substrate, 
multiple sites can be cleaved. The most critical one is located between the G1 and G2 
domains and is called the interglobular domain (Figure 5-5). 
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Figure 5-5 Aggrecanase cleavage sites in aggrecan protein.  
Schematic showing aggrecan protein with globular G1, G2, and G3 domains. The core protein is substituted with 
chondroitin sulfate (Cs; wavy lines) and keratan sulfate (KS; straight lines) chains. The aggrecanase cleavage 
sequences are shown for human (human, black character) and mouse (mouse, grey character). The numbers above 
the boxed sequences denote the preferred order of enzymatic cleavage (interglobular domain). Scheme has been 
drawn according to Huang et. al [245]. 
 
A consequence of the cleavage is a release of the C-terminus part, which is an 
important element for the mechanical properties of cartilage[247][245]. The cleavage at 
Glu373-374Ala has been actively studied and is considered to be a signature of 
aggrecanase activities. Lohmander et al. demonstrated that GAG-containing aggrecan 
fragments were present in the synovial liquid of patients affected by rheumatoid arthritis 
and other types of inflammatory arthritis. In all cases, the presence of Ala-Arg-Gly-Ser 
sequences could be observed and indicated aggrecanase mediated degradation[249]. 
Moreover, ADAMTS-4 and ADAMTS-5 also hydrolyze, in the human organism, four 
other peptide sequences belonging to the subdomains CS-1 and CS-2 between the 
globular domains G2 and G3 (Figure 5-5). These include the cleavage site Glu1545-
1546Gly, Glu1714-1715Gly, Glu1819-1820Ala, and Glu1919-1920Leu. The mouse aggrecanase-
labile sequences are slightly different and are described in Figure 5-5[246]. By extending 
the research of Tolle et al., the aim of the study was to integrate the aggrecanase 
cleavable sequence -GRDNVTEGE↓ALGSVDRG- in order to generate a drug delivery 
system responsive only during inflammatory state. For this study, the residue 
KKKKGRDNVTEGE, which represents the sequence that remains on the drug after 
peptide cleavage has been linked to an antibiotic to test its influence on the drug 
efficacy. 
5.4 Ciprofloxacin 
Ciprofloxacin, depicted in Figure 5-6 is a second-generation fluoroquinolone with good 
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introduced a few decades ago for the treatment of various bacterial infections, 
including those of the lung, skin, bones, and soft tissue[250]. Ciprofloxacin (CIP) was 
chosen as a model drug with broad spectrum antibacterial activity as it is readily 
available and deep knowledge of its structure-activity relationships enable structural 
modification not negatively impacting the antibacterial activity[251]. 
Regarding its structure, two functionnalities, piperazine and carboxylic acid, provides 
the opportunity to synthesize ciprofloxacin derivatives. Liu et al. summarized the 
research progress, made with respect to the discovery of CIP derivatives used as 
antibacterial agents. Many of them have exhibited considerable in vitro and in vivo 
potency against both drug-sensitive and drug-resistant organisms. Yet, some of the 
CIP derivatives have demonstrated reduced efficacy. Indeed, it is known that 
carboxylic acid and carbonyl are essential for the formation of the bound gyrase 
complex[252]. If these groups are chemically modified or removed, the antimicrobial 
activity is strongly reduced[253]. However, modifications at the piperazine ring via 
alkylation or acylation can result in highly active derivatives[253][251][252][254][255]. 
 
Figure 5-6 Structural formula of Ciprofloxacin. 
 
Since then, numerous CIP derivatives have been developed, with diverse properties 
and activity against the following: tuberculosis[256][257], bacteria[193], fungi[194], 
malaria[258], HIV[259], oxidation[260], and tumors[261]. However, the antibacterial effect 
with a broad spectrum of activity[262] against bacterial infections remains the dominant 
research field of ciprofloxacin derivatives. CIP is also commonly used for periimplentitis 
or dental infection treatment[263][264]. 
To better understand this study, a short overview regarding the mode of action of CIP 
is necessary. This antibiotic acts by inhibiting the bacterial DNA gyrase and IV 
topoisomerase, which are necessary for cell division[265]. Bacteria have a circular 
double-stranded DNA, it contains the unique genetic code for all the proteins required 
for the bacterial survival[266]. Bacteria replicate through a process known as binary 
fission and separate into two daughter cells. First, the bacterium generates an identical 
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copy of its complete circular DNA. DNA replication requires that the two DNA strands 
separate in order for the genetic code to be read and a complementary strand of each 
original strand is generated. Various enzymes are involved in this process[267]. DNA 
helicase breaks the hydrogen bonds between the bases in the DNA strands to separate 
and stabilize the exposed single strands by preventing them from joining back 
together[268]. The point where the strands are separated to enable the replication is 
known as the replication fork. At this location, DNA polymerase is able to move along 
the DNA strands, synthesizing a new complementary DNA strand. This process 
generates a superhelical twist in the DNA ahead of the polymerase. The supercoiling 
must be removed to continue the replication[269]. The bacterial enzyme DNA gyrase is 
responsible for removing the DNA twist, enabling the DNA replication process to 
proceed[270]. After completion of replication, two new interlinked double DNA strands 
are formed. To separate them, the enzyme topoisomerase IV is needed; then, they 
can be segregated into two new bacterial cells[265]. CIP acts by inhibiting the activity of 
both DNA gyrase and topoisomerase IV enzymes. For most of the gram-negative 
bacteria, DNA gyrase is the primary target of CIP[271]. CIP is known to bind specifically 
to the complex of gyrase and DNA rather than the gyrase alone. CIP appears to 
stabilize the complex, which in turn results in breaks in the DNA that lead to the death 
of the bacteria[252]. Furthermore, in most of the gram-positive bacteria, topoisomerase 
IV is the main target of CIP, which acts by disrupting the separation of the two double 
DNA strands, leading to bacteria death[252]. The potency of CIP derivatives depends 
on the affinity for either DNA gyrase or topoisomerase IV[272]. One of the most common 
mechanisms by which bacteria acquire resistance to CIP is through a spontaneously 
occurring mutation in the DNA gyrase or topoisomerase gene that modifies the 
structure of those enzymes. An effective mutation is dependent on the number and 
location of mutations. A mutation mainly results in a reduction in the affinity for CIP, 
and this results in resistance[273]. 
In conclusion, piperazine ring of ciprofloxacin enables modifications through alkylation 
or acylation for a subsequent conjugation to peptide sequences. Therefore, CIP was 
chosen as antibacterial agent to develop a drug delivery system for preventing implant-
associated infection.  
 Analytical methods 45 
 
6 Analytical methods  
6.1 Dynamic light scattering[274][275][276][277] 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy, is the 
most popular method to determine the size of small particles or macromolecules, in 
solution. DLS is based on the Brownian motion of dispersed particles. This means that 
the particles dispersed in a solution are moving randomly in all directions. The principle 
of Brownian motion is that particles are constantly colliding with solvent molecules. 
These collisions generate a certain amount of energy to be transferred, inducing the 
movement of particles. These movements are correlated to their size and shape as 
well as to the temperature and viscosity of the solution. Therefore, it is crucial to control 
temperature and viscosity of the solution in order to determine the size by measuring 
the speed of the particles. The relation between the speed of the particles and their 
size is described by the Stokes-Einstein equation. Their speed is described by the 
diffusion coefficient D.  
A laser beam can be used to determine the coefficient D and calcule the size of the 
particles. When entering into direct contact with a particle, the incident laser light gets 
scattered in all directions. The scattered light intensity is then recorded, over time, at a 
certain angle and this signal is used to determine the diffusion coefficient and the 
particle size by the Stokes-Einstein equation. Indeed, the scattered light intensity 
fluctuates due to the continuous Brownian motion of the particles in solution. This 
motion gives rise to a Doppler effect and so the scattered light possesses a range of 
frequencies shifted very slightly from the frequency of the incident light. Due to 
frequency shifting, the scattered lights will either result in mutually destructive phases 
and cancel each other out or in mutually constructive phases to produce a specific 
light-scattering intensity signal. It will constantly fluctuate and the measurement over 
time will help to determine how rapidly the intensity fluctuates, which can be related to 
the diffusion behaviour and size of macromolecules.  
The main drawback of DLS measurements is that larger particles overwhelm the 
scattered light of smaller ones. Therefore, DLS is inappropriate for measuring a 
solution of particles ranging from 10 nm to 1000 nm. The contribution of smaller 
particles to the intensity of scattered light is extremely low and is, therefore, not taken 
into account in the determination of size distributions. Indeed, the light-scattering 
intensity is strongly related to the size of the particles. According to Rayleigh 
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approximation, the intensity is proportional to d6, with d = particle diameter. For 
instance, a 50 nm particle scatters light 106 times more than a 5-nm particle. 
The Zetasizer Nano ZS is described in the next chapter. In this study, it was used to 
characterize the size, stability, and degradation of particles.   
6.1.1 Zetasizer Nano ZS 
 
Figure 6-1 Schematic of the Zetasizer Nano ZS (From www.malvern.com)[275].  
 
Figure 6-1 is a schematic representation of the Zetasizer Nano ZS. To measure particle 
size, a He-Ne laser with a wavelength of 633 nm, is used as light source, which 
illuminates the particle suspension within the cell holder. When the beam hits the 
solution, most of the light passes through it and is then neutralized through beam 
dump. Some of the light is scattered by the particles in all directions. A detector placed 
at 174.65° for backscatter detection is used to measure the intensity of the scattered 
light. The analysis at this specific angle helps to minimize the measurement of the light 
scattered by contaminants such as dust particles. Another critical aspect is the range 
of intensity received by the avalanche photodiode detector. Samples with small 
particles or a low concentration result in low intensities and the signal needs to be 
increased. By contrast, in samples with larger or higher particle concentrations, the 
scattered light intensity increases and leads to a saturated signal. In this case, the 
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signal needs to be decreased. Therefore, an attenuator is placed to reduce or increase 
the intensity of the laser. Then, the signal is transmitted to a correlator that compares 
the scattering intensity at successive time intervals and determines the rate of the 
intensity fluctuation. Finally, the signal is forwarded to a computer, which analyzes and 
translates the signal into size information.   
6.1.2 Particle size[274] 
The measurement of particle sizes is based on the movement and travel speed of the 
particles, which are responsible for intensity fluctuation. The movements are governed 
by Brownian motion, which is the random and uncontrolled movement of particles in a 
solution, as they constantly collide with the solvent or other molecules. Moreover, 
speed is strongly affected by the size of the particles. In fact, smaller particles move 
faster than larger particles, which is reflected in rapid intensity fluctuations (Figure 6-2, 
A and B).                
 
Figure 6-2 Typical intensity fluctuations for large (A) and small (B) particles. 
 
Fluctuation is measured by the correlator, which compares the intensity at different 
times, I(t) and I(t+τ), with I: intensity and τ: time interval. If the signal intensity is 
compared after a very short time (τ), a strong relationship, called correlation, can be 
found. If the signal at I(t) is compared with the intensity at t+2τ, the correlation can be 
seen to decrease with time. As mentioned previously, the intensity fluctuation is 
dependent on the speed and the size of the particles. Thus, the presence of large 
A 
B 
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particles that are moving slowly results in low intensity fluctuation and thus a slow 
correlation decrease (Figure 6-3, black curve). Small particles that are moving quickly 
results in a rapid intensity fluctuation and therefore a fast correlation decrease (Figure 
6-3, grey curve). 
 
Figure 6-3 Typical correlogram from a sample containing large particles (black curve) and a sample containing small 
particles (gray curve). 
 
Based on the time and correlation coefficient, correlograms (Figure 6-3) yield different 
information about the sample. At point (1), the curve starts to decrease and is related 
to the mean size of the particles. The gradient (2) indicates the polydispersity index of 
the sample, and the baseline smoothness point (3) represents information about the 
quality of the measurement. For instance, smoothness can be influenced by the 
formation of aggregates or dust in the solution. The polydispersity index describes the 
size distribution of the particles and ranges between 0 and 1. At a value of 0, the 
particles in the system have a monodisperse size distribution, whereas a value 
between 0.5 and 1 indicates a polydisperse system with a wide range of particle sizes.  
Mathematically, the time correlation G(τ) of monodisperse and circular particles in a 
Newtonian fluid can be described by the following equation:  
𝑮(𝛕) = 𝒆−𝑫𝒒
2𝛕                       equation 1 
D represents the diffusion coefficient, τ the correlator delay time, and q the scattering 
vector. 
The diffusion coefficient (D) is characterized by the Stokes-Einstein equation: 




3 𝜋 𝜂 𝐷
                       equation 2 
where kB represents the Boltzmann constant, T the temperature, d(h) the 
hydrodynamic diameter, and η  the viscosity of the solution.  
Regarding both equations, the time correlation is influenced by external factors such 
as temperature and viscosity. Additionally, convection and sedimentation processes 
influence Brownian motion and consequently the time correlation.  
In the case of noncircular particles, the equations yield an approximation of the 
diameter, and the object is perceived as a round object.   
6.1.3 Zeta potential[274] 
Zeta potential measurement is a technique for determining the surface charge of NPs 
in solution. A charged particle attracts counter ions and forms a double layer (Stern 
layer), which travels with the NP. Therefore, a potential difference between the solvent 
and the double layer occurs. This is known as the zeta potential of particles and has 
values that typically range from +100 to −100 mV. The magnitude of the zeta potential 
predicts the particle stability in suspension.  
The electrical double layer of negatively charged particles can be described as follows: 
The first layer is known as the Stern layer, which is generated by positive counterions 
that are attracted by the particle surface and become closely attached to it through 
electrostatic force. Due to the different size of ions present in the solution, the negative 
charges cannot be fully compensated by cations to reach a potential of 0. For this 
reason, a second layer called the diffuse or Gouy-Chapman layer is formed. The 
diffuse layer contains free ions, with a majority of counterions. The electrical potential 
within the electric double layer has a maximum value on the particle surface (Stern 
layer). Then, it decreases with increasing distance from the surface and reaches 0 at 
the border of the electric double layer. When a particle moves through the solution, a 
layer of surrounding ions remains attached to the particle. The boundary of this layer 
is called the shear plane. The value of the electric potential at the shear plane is called 
the zeta potential, which is a critical parameter concerning the stability of particles and 
can be determined by the Zetasizer Nano ZS device.  
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Figure 6-4 Schematic showing of the electrical double layer that surrounds a particle in an aqueous medium and 
the position of the shear plane. The zeta potential is the electrical potential at this plane. 
 
The Zetasizer Nano series calculates the zeta potential by determining the 
electrophoretic mobility of particles and then by applying the Henry equation. The 
electrophoretic mobility can be determined by using an electrophoresis experiment on 
the sample and measuring the velocity of the particles using Laser Doppler 
Velocimetry.  
In practice, an electric field is applied across charged particles and is consequently 
attracted towards the electrode of opposite charge. Viscous forces acting on the 
particles tend to oppose this movement. When the equilibrium is reached, between 
these two opposing forces, the particles move with constant velocity. The velocity of 
the particle is dependent on different factors such as the strength of electric field or 
voltage gradient, the dielectric constant of the medium, the viscosity of the medium 
and the zeta potential. The velocity of a particle subjected to an electric field is 
commonly referred to as its electrophoretic mobility. The technique used to determine 
the velocity is called laser Doppler velocimetry. The light scattered at a specific angle 
is combined with the reference beam. The movement of particles produces a 
fluctuating intensity signal where the rate of fluctuation is proportional to the migration 
speed of the particles. The migration speed can be divided by electric field strength to 
obtain the electrophoretic mobility (UE).  
Zeta potential and UE can be linked via the Henry equation, to define the zeta potential: 
𝑈E =
2  𝑧 𝑓(𝜅𝑎)
3𝜂
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With  UE electrophoretic mobility, ε the dielectric constant, z the zeta potential, f(κa) 
the Henry´s function and η the viscosity. Two values are used as approximations for 
f(κa) determination, 1.5 or 1.0. Electrophoretic determinations of zeta potential are 
commonly done in aqueous solution and moderate concentration. In this case, f(κa) is 
1.5 and is referred to as the Smoluchowski approximation. Therefore, calculation of 
zeta potential from the mobility is straightforward for systems that fit the Smoluchowski 
model, i.e. particles larger than 0.2 microns dispersed in electrolytes containing more 
than 10-3 molar salt. For small particles, low dielectric constant media f(κa) becomes 
1.0 and allows the use of a specific calculation. This is referred to as the Huckel 
approximation. Non-polar solvent measurements generally use this equation. 
6.2 Ellipsometry[278][279] 
Ellipsometry is a powerful and nondestructive technique for determining optical 
properties (refractive index or extinction coefficient) of surfaces and coatings. In 
addition, it provides information about intrinsic and structural properties of materials. 
The measurement is based on amplitude changes in polarized light upon light 
reflection. A light beam, with a known polarization state (mainly linear), is used to 
radiate a sample (Figure 6-5). The device is composed of a laser, a polarizer, a 
compensator (λ/4), a rotating analyzer, and a detector. The laser beam is first linearly 
polarized by the polarizer and subsequently guided to the compensator (C; λ/4). (C) is 
described as an anisotropic optical device placed at an angle of 45° to the light beam. 
It transforms a linearly polarized light into a circularly polarized one (Figure 6-5). 
Afterwards, the light hits the surface of the sample, resulting in a reflected beam with 
an altered state of polarization. The reflected beam is then guided to a second polarizer 
(rotating analyzer: RA). The RA is adjusted so that the resulting reflection beam is 
linearly polarized. The orientation is determined by alternately adjusting the polarizer 
and the analyzer until the null value is identified.  
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Figure 6-5 Schematic of ellipsometry. 
 
The polarization state of incident and reflected light can be decomposed into s (for 
perpendicular) and p (for parallel) components (Figure 6-6). The parameters Δ (phase 
difference) and Ψ (amplitude component) are used to describe the properties of the 
sample. 
 
Figure 6-6 Schematic of ellipsometry before and after reflection with E: electric field resolved into its p and s 
components. 
 
Mathematically, the amplitude can be described by equation 3. The amplitudes s and 
p of the reflected light are respectively denoted by the reflection coefficients R s and Rp. 
The factor tan Ψ represents the magnitude of the reflectivity ratio, with Ψ ranging 




                       equation 3 
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Moreover, the change in polarization of reflected light is represented by the phase 
difference Δ (equation 4), with δ1 representing the phase difference between p and s 
components of the incoming light wave and δ2 representing the outgoing wave.    
 𝛥 = 𝛿1 − 𝛿2                        equation 4 
Both parameters Ψ and Δ are defined during measurement and are related to the 
following equation (equation 5).  






    equation 5 
These parameters enable the definition of the refractive index, film thickness, surface 
roughness and extinction coefficient of the substrate. These properties are found by 
using the measured Ψ and ∆ in various equations and algorithms to produce a model 
that describes the interaction between light and sample. After the sample 
measurement, a model is constructed to describe the sample. The model is used to 
calculate the predicted response from Fresnel’s equations, which describe each 
material with thickness and optical constants. If these values are not known, an 
estimation is given for the purpose of the preliminary calculation. The calculated values 
are compared to experimental data. Any unknown material properties can then be 
varied to improve the match between experiment and calculation. Finding the best 
match between the model and the experiment is typically achieved through regression.  
The measurement of the uncoated substrate is necessary, and the result is compared 
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7 Results: chitosan-g-[poly-L-lysine-b-ε-caprolactone] 
The scope of this study entailed the synthesis of a chitosan-g-[poly-L-lysine-b-ε-
caprolactone] with a specific grafting degree (Figure 7-1, A). The graft-copolymer can 
be self-assembled into polymeric micelles or vesicles through the solvent shift method 
(Figure 7-1, B) and generates well-defined core-shell structures suitable for 
encapsulation. The hydrophobic (PCL) and the hydrophilic (CS) parts were linked via 
a biocompatible peptide in order to make it enzyme-cleavable. A suspension of 
polymersomes was used to coat a titanium plate and resulted in a highly stable coating 
at body temperature, which is an essential requirement for a drug delivery system. 
Furthermore, degradability was studied by incubating polymersomes with two 
enzymes: peptidase and chitosanase. Specific peptidases that are released as a result 
of an inflammation could be used to trigger drug releases (Figure 7-1, C).  
First, the synthetic route involves the functionalization of chitosan with maleimide 
groups[281] and PCL with an alkyne end-group[282]. Thiol-maleimide click-chemistry and 
azide-alkyne Huisgen cycloaddition were used to link chitosan and poly-ε-caprolactone 
chains via a thiol- and azide-functionalized peptide (Figure 7-1). For a preliminary 
study, to investigate the feasibility of the system, PLL was employed as a readily 
available and cleavable peptide linker. The size, shape, and enzyme-triggered 
degradability were studied through DLS/cryo-SEM. Finally, the ability to form a coating 
on a titanium substrate was also analyzed. 
Part of the results described in this chapter have been published: Y. Bourgat, B. 
Tiersch, J. Koetz, H. Menzel, Enzyme degradable polymersomes from Chitosan-g-
[poly-L-lysine-b-ε-caprolactone] copolymer Macromol. Biosci. published online 
2.12.2020 (2020). DOI: 10.1002/mabi.202000259[198]. 
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Figure 7-1 Schematic of A) chitosan-g-[poly-L-lysine-b-ε-caprolactone] copolymer, B) polymersome structure, and 
C) degradation. 
 
7.1 Synthesis of chitosan-g-[poly-L-lysine-b-ε-caprolactone] 4 
The graft polymer chitosan-g-[poly-L-lysine-b-ε-caprolactone] (CS-g-[PLL-PCL]) was 
synthesized in four steps. In the first step, maleimide groups were introduced as side 
chains at the chitosan backbone, with different degrees of substitution (DS) (Figure 
7-2, step 1). This step was followed by the synthesis of propargyl-terminated poly-ε-
caprolactone (Figure 7-2, step 2), the grafting of poly-L-lysine20-N3 onto chitosan 
(Figure 7-2, step 3) and finally the link between poly-ε-caprolactone and CS-[poly-L-
lysine20-N3] (Figure 7-2, step 4). 
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Figure 7-2 Reaction scheme of chitosan-g-[poly-L-lysine-b-ε-caprolactone]3%. 
 
Synthesis of chitosan conjugated with N-maleoyl-β-alanine step 1 (Figure 7-2) 
The maleimide group was conjugated to chitosan with varying DS through a reaction 
between the carboxylic acid of N-maleoyl-β-alanine and the amine function of chitosan. 
This reaction was optimized, using chitosan from various sources and with various 
molecular weight, and by exploring different synthetic pathways. 
 
 
Figure 7-3 Conjugation of chitosan with N-maleoyl-β-alanine 1. 
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The reaction was first performed with a 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-
morpholinium chloride (DMTMM) as coupling reagent (Table 7-1, CS6) or NHS-
activated ester of N-maleoyl-β-alanine (Table 7-1, CS7). Both ways led to insoluble or 
minimally substituted product. Chirachanchai et al.[281] proposed a pathway using 
1-hydroxybenzotriazole (HOBt), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) as coupling reagents and DMSO as a cosolvent to increase the solubility of the 
intermediate[281]. When an inappropriate amount of DMSO (lower than 50%) is used, 
the DS was found to be low and to lead to an insoluble product. This can be explained 
by the formation of a poorly water-soluble intermediate or the occurrence of a side 
reaction between grafted maleimide and the amine functions of chitosan during the 
dialysis process (e.g., 1.4‐addition of amino group, transamidation, etc.[283]). This last 
hypothesis can be validated through infrared spectroscopy. In fact, the peak intensity 
ratio between the carboxylic groups of chitosan at 1645 nm-1 and the double-bond peak 





A decrease in maleimide groups entails a possible cross-linking with the amine 
functions of chitosan. Indeed, it is known that at a certain pH (approximately 8), the 
reactivity of maleimide with amines increases[284]. Therefore, to avoid this side reaction, 
performing dialysis against acidic solutions was necessary. As described in Table 7-1, 
several experiments were needed to optimize the reaction. Variations in 
Dimethylsulfoxid (DMSO) amount (Table 7-1, CS1 and CS3), coupling reagents (Table 
7-1, CS4 and CS5), and molecular weight of chitosan (Table 7-1, CS1 and CS2) were 
relevant factors in obtaining a coupling efficiency (CE) of up to 67%. Moreover, the 
following conclusions can be drawn from the experiments described in Table 7-1:  
 Experiment CS1 and CS2 are using the same DMSO content and theoretical 
grafting degree but different molecular weight. This leads to an increase of 
212% of the CE by using a lower molecular weight chitosan from fungal sources.  
 Experiment CS4 and CS5 are using different coupling reagents as EDC and 
lead to low CE. These two experiments were performed at the very begin of this 
study and the dyalisis against acidic condition, to avoid side reaction, was not 
respected. This could explain the low grafting degree. 
 Experiment CS3 and CS1 are using different amount of DMSO, respectively 
50% and 91% of total volume. This leads to an increase of 34% of the CE by 
using higher amount of DMSO. 
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Further investigation will be described in a future publication of Christ et. ali. 
 









































20 0.05 0.25 0 DMTMM 190–310 
CS5-
Shrimp 
50 2.2 4.4 0 NHS 190–310 
 
Fourier-transform infrared spectroscopy (FT-IR) and proton nuclear magnetic 
resonance (1H-NMR) spectra were used to prove the conjugation of chitosan with 
3-maleimidopropionic acid. In FT-IR spectra a signal assigned to the amide I group at 
1645 cm-1 was found, which increased with increasing DS (Attached file 2, A). By 
contrast, the signal at 1511 cm-1, representing primary amine bending, decreased with 
increasing substitution. These findings were regarded as a consequence of the 
reaction between amines of chitosan and carboxylic acid, resulting in amide bonds. 
Furthermore, a signal at 1704 cm-1 was found, and is the characteristic vibrational 
frequency of aromatic -C=C- bending, originating from the maleimide functions. 
The protons of the N-acetyl-D-glucosamine, D-glucosamine unit of chitosan and two 
proton signals of the maleimide double bond (6.85 ppm) were also noticed in the 1H-
NMR spectra of maleimide substituted chitosan (Attached file 1). The DS was 
calculated from the 1H-NMR spectra, using the ratio of maleimide protons at 6.85 ppm 
and the signal at 2.00-2.08 ppm, which represents 3 protons of the chitosan backbone. 
By using different sources of chitosan and DMSO content, the highest coupling 
efficiency that could be reached was 67% (Theoritical grafting degree of 30%). This 
demonstrates the limitation of this condition to graft malemide functions on chitosan.  
                                              
iH. A. Christ, Y. Bourgat, H. Menzel, Optimization of critical parameters for carbodiimide mediated production of 
highly modified chitosan Carbohyd. Polym. Submitted. (2021)   
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In order to understand the parameters that influence the reaction, a brief overview on 
the mechanism is discussed in chapter 4.1.  
The rate-determining step of the reaction is governed by the reaction between 
EDClH22+ and carboxylic acid (see Figure 4-2, page 28). Thus, EDC must be 
protonated to react with the deprotonated acid. Cox et al. described the reaction of 
acetic acid and EDCl as a coupling reagent. They observed a maximum conversion 
rate at pH = ((pKa (RCO2H) + pKa (EDClH2))/2. Acetic acid and EDCl with a respective 
pKa of 4.7 and 3.1, have an optimal pH of 3.9 for synthesis. A rapid decrease at pH > 
4.7 (reduced levels of EDClH22+) and pH < 3.1 (reduced the amount of deprotonated 
carboxylic acid) is evident. Thus, the rate of the reaction is strongly pH dependent. 
Another key element to improve the reaction rate is to use additives, which suppresses 
the formation of N-acylurea and promotes the formation of O-acylisourea (see Figure 
4-2, page 28). In fact, N-acylurea is undesirable because it leads to consumption of 
the 3-maleimidopropionic acid and no further formation of the desired ester. The 
commonly used N-acylurea-suppressing additives are benzotriazole derivatives, 
including HOBt and 1-hydroxy-7-azabenzotriazole.  
In conclusion, there are three impacting parameters that highly influence amide 
coupling and can be used to optimize the reaction:  
 Hydroxybenzotriazole which acts as a catalyst and an N-acylurea-suppressing 
substance. 
 Dimethylsulfoxid which increases the solubilty of intermediate. 
 And the pH, which influences the protonation of amines and carboxylic acid. 
Synthesis of propargyl-terminated poly-ε-caprolactone step 2 (Figure 7-2) 
The “clickable” side chain was synthesized as propargyl-terminated poly-ε-
caprolactone 2 through ROP of ε-caprolactone (ε-CL) by using Tin(II) 2-ethylhexanoate 
(Sn(oct)2) as the catalyst and propargyl alcohol as the initiator (Figure 7-4).  
 
Figure 7-4 Reaction scheme of polymer 2. 
 
The molar ratio of ε-CL, propargyl alcohol, and Sn(oct)2 was determined to be 83:2:1. 
More details regarding the synthesis conditions can be found in the experimental part 
(2) 
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of Chapter 10. The 1H-NMR spectra (Attached file 3) was used to confirm the presence 
of both alkyne function and PCL backbone signals. The peaks at 4.68 and 2.43 ppm 
represent, respectively, HC≡C- and C-CH2- protons of the propargyl function. The 
protons at 1.36, 1.62, 2.27, 4.03, and 3.62 ppm represent the PCL backbone protons. 
Furthermore, FT-IR analysis (Attached file 2, B) was carried out to corroborate the 
success of the synthesis. The characteristic vibrational bands of 2 appear at 1720 cm-
1 (C=O stretching) and 1238 cm-1 (C-O-C asymmetric stretching). The signal at 3261 
cm-1 (H-C≡C- stretching) highlighted the end-terminal alkyne function. Finally, the Mw 
= 5755 g/mol was calculated from the 1H-NMR spectrum. The calcuation was based 
on the integration of proton peaks of CH from the alkyne function at 4.68 and from the 
PCL backbone at 4.03 ppm. The theoretical Mw calculated from the ratio of initiator 
and monomer was Mwtheor = 6770 g/mol. 
 
Synthesis of CS-[poly-L-lysine20-N3] (CS-g-[PLL20-N3]) Step 3 (Figure 7-2) 
The ligation between the thiol end-functionalized peptide and the maleimide-
functionalized chitosan to synthezise CS-g-[PLL20-N3] 3, was carried out by thiol-ene 
click chemistry, also known as Thiol-Michael addition (Figure 7-5)
 
Figure 7-5 Reaction scheme of CS-[poly-L-lysine20-N3] 3. 
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As previously mentioned, It is common for such reactions to be performed in the 
presence of, e.g. DMF as solvents and catalyst[219]. Solvents such as DMSO and DMF 
possess a high dielectric constant, which promotes the spontaneous dissociation of 
thiol into nucleophilic thiolate anion. Subsequently, the thiolate is able to react with the 
double bond of the maleimide function[220]. Nevertheless, DMSO is also known to 
catalyze undesired disulfide bond formation[221]; therefore, DMF was chosen as the 
optimal solvent for this synthesis. In addition to solvent choice, pH plays a crucial role. 
The reaction between a maleimide and thiol function specifically occurs at 
physiological pH (6.5-7.5), generating a stable thioester bond. At a pH above 8.0, the 
reactivity between the double bond and amines of chitosan is significantly increased, 
which leads to side reactions[283][284]. 
More details about the synthesis conditions can be found in the experimental section. 
The reaction was checked by 1H-NMR spectroscopy, which showed the disappearance 
of the maleimide double bond protons at 6.85 ppm; these protons are involved in the 
reaction with the thiolate. New signals at 1.43, 1.70, 2.98, and 4.31 ppm characteristic 
for the protons of the PLL backbone indicated the presence of the peptide (Attached 
file 4).  The FT-IR analysis (Attached file 2, C) was also conducted to confirm the 
reaction and to demonstrate the appearance of a vibrational band at 2126 cm-1, which 
is characteristic of the azide function grafted on the chitosan.  
 
Synthesis of chitosan-g-[poly-L-lysine-b-ε-caprolactone] (CS-g-[PLL-PCL]) Step 
4 (Figure 7-2) 
The ligation between azide functionalized CS-[poly-L-lysine20-N3] and the alkyne-
functionalized poly-ε-caprolactone to synthezise CS-g-[PLL-PCL] 4 was carried out by 
1,3-Huisgen dipolar cycloaddition, also known as the «copper click reaction».  
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Figure 7-6 Reaction scheme of chitosan-g-[poly-L-lysine-b-ε-caprolactone] 4. 
 
The reaction occurs between the azide function of the peptide already grafted onto CS 
and the alkyne function of the PCL. The reaction was catalyzed by CuSO4·5H2O and 
sodium ascorbic acid as agent to reduce unreactive Cu(II) to Cu(I). 
The purification step consisted of a dialysis against tetrahydrofuran (THF), to remove 
unreacted ε-caprolactone, followed by a dialysis against a saturated aqueous solution 
of ethylenediaminetetraacetic acid EDTA to remove copper[285]. The alcohol and amine 
groups on the chitosan are excellent ligands to coordinate with copper to obtain a 
chitosan-metal complex. Because EDTA is a better ligand than chitosan, the formation 
of the (EDTA)-copper complex is favored[285] and removed during the dialysis process. 
More details regarding the synthesis condition can be found in the experimental part, 
chapter 10.5.5.  
1H-NMR spectroscopy, operated at a temperature of 50°C, to ensure the solubility of 
the copolymer, was carried out to validate the synthesis of chitosan-g-[poly-L-lysine-b-
ε-caprolactone] copolymer (Attached file 5). The peaks at 4.24; 2.80; 1.64 and 1.41 
ppm are characteristic for PLL protons in DMSO/H2O mixture. The peaks at 4.95; 3.86-
3.73; 2.93; 1.87 ppm are originating from the chitosan backbone. Finally, the peaks at 
3.99, 2.27, 1.54, and 1.30 ppm are characteristic for the PCL backbone protons. In 
addition, the disappearance of the peak at 2121 cm-1 in the IR-spectrum confirmed the 
consumption of the azide groups (Attached file 2, D). The chitosan and PLL backbones 
20 
20 
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can be characterized by the band at 1646 cm-1 (C=O stretching of amide I) and strong 
bands at 3287, 3340 cm-1 that correspond to N-H and O-H stretching. The bands at 
1045 cm-1 correspond to C-O stretching of chitosan. The DS was calculated from the 
1H-NMR spectra, using the ratio of PCL protons at 3.99 ppm and 3 protons of chitosan 
backbone at 1.87 ppm. 
In conclusion, all parts of the copolymer, maleimide modified chitosan and propargyl-
terminated poly-ε-caprolactone were succesully synthesized and characterized before 
they were linked together via a poly-L-lysine sequence.   
7.2 Formation and characterization of polymersome  
After the successful synthesis of amphiphilic graft copolymer, its self-assembly into 
polymersomes and their degradability by enzymes were studied. Polymersome 
formation depends on different factors, an important one is the hydrophilic to 
hydrophobic ratio. Studies have suggested that a hydrophilic mass fraction from 20% 
to 45% is a unifying rule for achieving self-assembly into polymersomes[286]. Based on 
this rule, two graft copolymers, with mass fractions in or near the recommended range, 
were synthesized: CS-g-[PLL-PCL]3% with a hydrophilic mass fraction of  50%, and 
CS-g-[PLL-PCL]5% with hydrophilic mass fraction of 40%. As described in the 
experimental part, the polymersomes were generated by the solvent shift method to 
induce the self-assembly process. Briefly, this method includes the dissolution of the 
copolymer in DMSO/H2O and the careful removal of the DMSO by dialysis against 
H2O. During this process, the hydrophobic and hydrophilic parts self-assembled into 
polymersomes through hydrophobic interactions. DLS was performed to measure the 
size of the polymersomes. 











Figure 7-7 DLS size distribution of CS-g-[PLL-PCL]5% and CS-g-[PLL-PCL]3% and Zeta potential of CS-g-[PLL-
PCL]3% polymersomes in deinized H2O at rt. 
 
Both graftpolymers gave polymersomes with a monomodal size distribution. Compared 
with polymersomes prepared from CS-g-[PLL-PCL]3%, with a mean size of 258 nm, 
CS-g-[PLL-PCL]5% leads to particles with an average size of 427 nm (Figure 7-7).  The 
increase can be explained by the relation between shape, weight fraction of the 
hydrophilic part, Mw, and the interaction strength of the hydrophobic fraction with 
water. Furthermore, polymersomes can be predicted according to the equation p = 
v/a·l, where “p” is the packing parameter, “v” is the volume of the hydrophobic chains, 
“a” is the optimal area of the head group, and “l” is the length of the hydrophobic tail[87]. 
Therefore, the ratio between hydrophilic and hydrophobic fraction affects the 
size/shape of polymersomes. With the increase in size, the polydispersity index (PDI) 
also increased from 0.129 for 3% to 0.351 for 5%. Drug delivery systems applications, 
using carriers with PDI of 0.3 and below, are considered to be acceptable and indicates 
an homogeneous population of particles[287]. Moreover, DLS measurements (Figure 
7-7) indicated a positive zeta potential of approximately +41 ± 4.3 mV. This is an 
indication that amine functions of chitosan are oriented toward the outer water phase, 
as represented in Figure 7-8 II. Cryo-SEM was used to confirm the shape and 
morphology of polymersomes in suspension. 
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Figure 7-8 SEM micrographs of cryo-fractured surface of I) CS-g-[PLL-PCL]3% polymersomes solution in ultrapure 
water and II) schematic representation of polymersomes with A/E, chitosan; B/D, poly-L-lysine; C, poly-ε-
caprolactone. 
 
Cryo-SEM micrographs (Figure 7-8 (I)) revealed well-defined core-shell structures for 
the polymersomes (Figure 7-8 (II)), with a size range centered around 300 nm, which 
is consistent with the size measured by DLS. 
For testing the colloidal stability, the particle size was monitored via DLS while 
polymersomes were incubated in H2O at pH 5.6 (Figure 7-9). The tests were performed 
at 37°C. Compared with room temperature measurements (Figure 7-7), CS-g-[PLL-
PCL]3% polymersomes at 37°C exhibited an increased initial size (Figure 7-9, Time = 
0), which is a consequence of measuring at a higher temperature. During the 
incubation period, the size decreased slightly at a rate of approximately 0.43 nm/h 
(Figure 7-9). This is due to some sedimentation of larger, probably aggregated 
particles, during the DLS measurements. However, this is not attributed to a chemical 
degradation of the graft-polymers, as coatings prepared from the particle suspensions 
are very stable (vide infra). Similar tests were performed in a 63 mM sodium phosphate 
buffer, at pH 7.6, to observe the stability of polymersomes at physiological pH. Again, 
some decrease in particle size were observed after 6 days, which is very similar to the 
situation at pH 5.6 (Figure 7-10). 
(II) 
(I) 
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Figure 7-9 Particle size of chitosan-g-[poly-L-lysine-b-ε-caprolactone]3% incubated in ultrapure H2O for 40 hours at 
37°C. 
 
In conclusion, CS-g-[PLL-PCL]3% was found to be the ideal copolymer, with a specific 
amount of hydrophobic fraction, to enable  the formation of polymersomes with a well 
defined core-shell structure.  
As the system is supposed to be degraded by specific peptidases, stability and 
degradability toward different enzyme is studied in the following chaper. 
7.3 Enzymatic degradation of polymersome 
The degradability of the well-defined polymersome was studied by incubating them 
with different enzymes, namely trypsin, which is able to cleave poly-L-lysine[209] and  
chitosanase, which endohydrolyzes β-1,4-linkages of partially acetylated chitosan[288]. 
As described in the experimental part, the polymersome suspension was treated with 
a 4 µg/mL trypsin solution and a 5 µg/mL chitosanase solution. DLS measurements  
were performed to determine particle sizes before and after incubation (Figure 7-10 
and Figure 7-11).  















































Figure 7-10 Particle size before     and after    incubation of CS-g-[PLL-PCL]3% polymersome at 37°C for 6 days 
in different media. A: H2O pH = 5.6; B: H2O, pH = 5.6 with trypsin (4 µg/mL) and C: 63 mM sodium phosphate buffer 
pH = 7.6. 
 
Incubation tests (Figure 7-10, B) with trypsin indicated no relevant variation in particles 
size, compared to the incubation in water (Figure 7-10, A) or buffer (Figure 7-10, C). In 
fact, in experiments A and C, without trypsin (Figure 7-10), a similar slight decrease in 
size was observed after 6 days, which was probably due to the sedimentation of larger 
aggregated polymersomes. Thus, polymersomes were stable against trypsin. 
However, incubation with chitosanase (Figure 7-11, A) resulted in a significant increase 
in particle size, while for incubation without chitosanase, again, a slight decrease was 
observed (Figure 7-11, B). Counterintuitive increase in particle size, link with the 
degradation, can be explained by the reduction in the hydrophilic part (chitosan), 
hydrolyzed by chitosanase, which consequently results in an increase in the 
hydrophobic fraction in the graft copolymer. Since shape and size of the polymersomes 
depend on the weight fraction of the hydrophilic part, Mw, and the interaction strength 
of the hydrophobic fraction with water[87]. As a consequence, a change in the 
hydrophilic amount, formed due to the degradation of the chitosan, results in variations 
of the aggregation or shape of particles, inducing in both cases a change in particle 
size.  
 
   
 
   
 

























Figure 7-11 Particle size before  and after 72h incubation  of CS-g-[PLL-PCL]3% polymersome at rt. A:  with 
chitosanase (5 µg/mL) and B: without. 
 
A further stability test was carried out with films, on titanium substrates, prepared by 
spray-coating: a suspension of polymersomes (chitosan-g-[poly-L-lysine-b-ε-
caprolactone]3%. After drying, the films were incubated in water and in a mixture of 
water and chitosanase or trypsin. After certain incubation times, the dry thickness of 
the films was determined via ellipsometry.  Figure 7-12 depicts the variation in layer 
thickness during incubation with either water (blue curve), water with chitosanase (5 
µg/mL; red curve) or with trypsin (4 µg/mL; black curve) for 11 days. The solutions 
were refreshed daily to ensure the degradation capability of enzymes. 
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Figure 7-12 Layer thickness of chitosan-g-[poly-L-lysine-b-ε-caprolactone]3% coated on Ti plate during incubation 
with  chitosanase  (5 µg/mL) and trypsin  (4 µg/mL), and  without enzyme   at 37°C. 
 
After 11 days of incubation, with just water or a trypsin solution, no significant decrease 
in dry thickness was noticed; these observations confirmed a stable coating. However, 
after incubation in a chitosanase solution, a decrease, by 52%, in the layer thickness 
was noted (Figure 7-12). Contrary to the particle size increase, observed for the 
polymersomes in suspension (Figure 7-10), here, indeed, a decrease in film thickness 
is noticed. This is due to the degradation of the chitosan chains resulting in less 
material being bound to the surface. A similar behavior (particle growth and film 
thickness reduction) has been identified before for chitosan/tripolyphosphate 
nanoparticles and coatings, respectively[289]. The degradation of the polymersomes via 
a specific cleavage of the PLL-linker by trypsin was not confirmed. This might be 
explained by the difficulty of the enzyme to reach the PLL layer: (Figure 7-13 (B) and/or 
(D)). PLL is located at the border of the polymersome compartments, between the 
hydrophobic PCL (C) layer and hydrophilic chitosan (A) and (E) layer (Figure 7-13). 
For this reason, trypsin must diffuse through the chitosan layers (A) or (C) (Figure 
7-13), to reach the substrate (PLL). According to Buck et al. bovine trypsin has an 
isoelectric point (pI) of 10.5[290] and thus, is positively charged at pH<7.6, which is the 
highest pH for the degradation tests. Consequently, the enzyme is subjected to 
repulsive interactions with the positively charged chitosan. On the other hand, 
chitosanase has an isoelectric point (pI) of 9.6 and at a pH of 5.6, has therefore a net 
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positive charge and is still able to reduce the thickness of a coating prepared with the 
polymersomes[291]. An explanation for these findings is that chitosan is localized at the 
surface of the polymersome and thereby is easily accessible for enzymes. In 
conclusion, with the chitosan outer layer, the linker region is not easily accessible for 
proteases like trypsin. Likewise, the chitosan layer will protect any peptide in the inner 
compartment from degradation by trypsin or other proteases. The chitosan shell, 
however, can be enzymatically degraded by specialized enzymes like chitosanase. In 
human body, due to the lack of chitosanase, chitosan can be very stable depending 
on the degree of deacetylation[292]. 
 
Figure 7-13 Schematic representation of polymersomes based on cryo-SEM micrographs. 
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7.4 Conclusion  
A new amphiphilic graft-copolymer, based on two biocompatible polymers, has been 
synthesized. Chitosan (CS) and poly-ε-caprolactone (PCL) were linked via a peptide 
to form a graft-polymer, which is able to self-assemble into polymersomes, using the 
solvent shift method. A relationship between the particle size and the amount of 
hydrophobic PCL was demonstrated. This might be interesting for optimizing the 
encapsulation and diffusion rate of encapsulated drugs. These polymersomes were 
characterized via dynamic light scattering and cryo-SEM. Cryo-SEM images 
highlighted well-defined spherical core-shell structures. The stability of the polypeptide 
linker, against degradation by trypsin, was proved for both the polymersomes and the 
coatings prepared therefrom. The stability was attributed to the chitosan layer which 
cannot be penetrated by the trypsin. However, incubation with chitosanase, known for 
hydrolysis of chitosan, led to a degradation of the graft-polymer as indicated by an 
increase in particle size for the polymersomyes and a reduction of the layer thickness.  
To conclude, the graft-copolymer shows good stability against peptidases such as 
trypsin and therefore, can be used to generate a chitosanase-responsive drug delivery 
system against plant fungal diseases. For instance, Okazaki et al., purified chitosanase 
produced from the pathogenic plant fungus, Fusarium solani f. sp. phaseoli[293]. An 
infection of the plant by this fungus, would lead to the release of chitosanases, which 
can degrade the chitosan based responsive delivery system. Furthermore, the 
polymersome system could also be employed as a blocking layer, to control the drug 
release of multilayer delivery systems. However, further investigations are needed to 
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8 Aginate/peptide-NPs 
The scope of this study entailed the synthesis of modified ciprofloxacin in order to build 
an enzyme-responsive drug delivery system as described in chapter 5. The system is 
based on three different components: a positively charged peptide functionalized with 
an azide group, a modified ciprofloxacin and a negatively charged alginate. Through 
the positive and negative charges, the system was able to self-assemble into 
nanoparticle. The process is know as ionic gelation and is described in chapter 3.1.3.  
Tolle et al. have described NPs that are generated through ionic gelation of negatively 
charged alginate and positively charged enzyme-cleavable peptide[24]. The cleavage 
was triggered by a specific enzyme, released during an inflammation state, inducing 
the release of a model substance. However, the retention of the model protein 
interferon  was limited and a strong burst release was observed, leading to a low 
encapsulation efficiency. This low yield could be explained by the complicated interplay 
of electrostatic and  entropic forces, mediated by van der Waals interactions and 
hydrogen bonding, which have to be taken into account to understand the binding and 
release of polymeric carrier and protein[294]. Based on the promising results of inducing 
drug release by enzymatic cleavage of a peptide and in an effort to counter the main 
drawback of premature and not triggered release, this chapter presents a new enzyme-
responsive alginate/peptide nanogel, in which the model drug ciprofloxacin is 
conjugated to the peptide linker.  
Ciprofloxacin has two functional groups: carboxylic acid and piperazine, which have 
been used in many studies for its modification[253]. In order to graft ciprofloxacin to a 
peptide sequence, it has been modified, on the piperazine side, with different functional 
groups. More details about the modification of ciprofloxacin on the piperazine side is 
described in chapter 5.4.  
As the conjugation of ciprofloxacin may affect its antibacterial efficacy, the conjugated 
ciprofloxacin 5 and other derivatives of ciprofloxacin (11, 12b, 13b and 14b, Figure 
8-1) were tested for their antimicrobial activity against Staphylococcus aureus. S. 
aureus was used because it is one of the pathogens that often caused orthopedic 
implant-associated infections[295]. 
At first, ciprofloxacin was modified with a terminal alkyne moiety by alkylation (Figure 
8-1, 5), which allow conjugation with PLL or other peptides via copper(I) catalyzed 1,3 
dipolar cycloaddition leading to a 1,2,3-triazol link. Then, to propose a copper click free 
chemistry strategy, ciprofloxacin was modified with a cyclooctyne function (Figure 8-1, 
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7). A 6-aminohexanoic acid linker has also been integrated between the ciprofloxacin 
and the cyclooctyne to reduce any sterical hinderance, which could affect the 
antimicrobial efficacy (Figure 8-1, 10).  
Subsequently, the modified drugs were linked to different peptide sequences. Since 
this was an early-stage study, PLL was used as an enzyme cleavable peptide 
sequence to identify the ability of conjugated peptide 11 to generate nanoparticles with 
alginate. The literature suggests that non-conjugated PLL has the capacity to generate 
NPs with alginate[24].   
Finally, several moieties were conjugated to ciprofloxacin to study the effect of the 
resulting triazol link on drug efficacy. Compound 10 was used to graft a peptide 
sequence and to synthesize 12b (Figure 8-1). This peptide would represent the part 
which remains on the active ingredient after release from the encapsulation system, 
generated with the peptide described in chapter 5.2 and 5.3. Therefore, by testing the 
antimicrobial activity of 12b (Figure 8-1), the final active ingredient released from the 
drug delivery system can be analyzed. More details about the cleavage site of the 
peptide sequence can be found in chapter 5.2 and 5.3. 
Then, two other moeities: polyethylene glycol and homoalanine, respectivily compound 
13b and 14b (Figure 8-1), were grafted onto ciprofloxacin. Both molecules were used 
to understand the relation between modification and antimicrobial efficacy. 
Particle size, enzymatic degradation, and drug release were studied by DLS 
measurements and ultraviolet-visible spectroscopy (UV-Vis). UV-Vis was performed to 
determine the amount of ciprofloxacin released during the degradation process. The 
NP suspension was used to coat titanium substrates, a material commonly employed 
for dental implants. Ellipsometry was carried out to measure the layer thickness and 
degradability of the coating. Finally, the antimicrobial efficacy of conjugated CIP was 
tested in cooperation with partners at Hannover Medical School.  
Part of the results described in this chapter have been published: Bourgat, Y.; Mikolai, 
C.; Stiesch, M.; Klahn, P.; Menzel, H. Enzyme-Responsive Nanoparticles and Coatings 
Made from Alginate/Peptide Ciprofloxacin Conjugates as Drug Release System. 
Antibiotics (2021). DOI: 10.3390/antibiotics10060653.  
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Figure 8-1 General overview of the synthesis of modified ciprofloxacin.  
8.1 Alkyne-functionalized Ciprofloxacin 5 
As described in chapter 5, many ciprofloxacin derivatives, with diverse properties, have 
been developed via the modification on the carboxylic acid or piperazine function[251]. 
As mention in chapter 5.4, if these the carboxylic acid is chemically modified or 
removed, the antimicrobial activity is strongly reduced[253]. However, modifications at 
the piperazine ring via alkylation or acylation can result in highly active derivatives 
[251,255]. Therefore, the conjugation was carried out by modification of the piperazine 
ring. 
In this study new ciprofloxacin derivatives have been synthesized and linked to 
different peptide linkers. In order to specifically link azide functionalized peptides, 
ciprofloxacin was modified with alkyne function. Both peptide and ciprofloxacin can 
then be linked via copper click chemistry. Indeed, as mentioned previously, click 
chemistry is an extremely chemoselective reaction and can therefore be used to 
specifically link two molecules [224][225][226]. The antimicrobial efficiencies of conjugated 
ciprofloxacin derivatives were then tested on S. aureus, to study the effect of the 
modification. 
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Synthesis of alkyne modified ciprofloxacin (CIP-alkyne) 5 
Herczegh et al. described the synthesis of 1-hydroxybisphosphonate derivatives of 
ciprofloxacin (CIP), gatifloxacin and moxifloxacin, synthesized by using Cu(I) catalyzed 
azide-alkyne through a 1,3-dipolar cycloaddition reaction[296]. The 1,2,3-triazol 
derivative of CIP exhibited antibacterial activity, comparable to the parent antibiotic. 
Therefore, alkyne modified CIP 5 has been considered as a strong candidate and 
synthesized, with the aim of conjugating CIP to the peptide sequence through a 1,2,3-
triazol link.  
 
Figure 8-2 Reaction scheme of CIP-alkyne 5 with numbered protons. 
 
Mechanism for the synthesis of 5 (Figure 8-3) 
According to Herczegh et al., the synthesis required an alkylation between the amine 
of CIP and or 4-Bromo-1-butyne[297]. More details about the synthesis conditions can 
be found in the experimental part of chapter 10.6.1. 
As mentioned above, the alkylation of CIP is a nucleophilic substitution (Type Sn2). 
The nucleophilic amine attacks the carbon next to the bromide (Figure 8-3, a) and the 
bromide is then displaced to form an ammonium salt intermediate (Figure 8-3, b). 
Finally, the ammonium salt intermediate is deprotoned by a base (NaHCO)3, yielding 
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Figure 8-3 Reaction mechanism of ciprofloxacin alkylation. 
 
Characterisation of 5 
1H-NMR was performed to confirm the synthesis success. Numbers have been 
assigned to each protons in order to facilitate the characterization (Figure 8-2). The 
signals at 8.7, 7.96, 7.3, 3.48, 3.38-3.28, 2.8-2.7, 1.38-1.27, and 1.14 ppm represent 
the framework protons of CIP (Attached file 6). Moreover, the presence of five protons 
at 2.25 (H2), 2.39 (H3), and 1.95 (H1) ppm confirmed the presence of the grafted 
butyne.   
Hence, after this successful synthesis, efficacy tests have been performed on molecule 
5. The CIP derivative 5 exhibited antibacterial activity, comparable to commercial 
ciprofloxacin. For concentration ranging from 1.7 to 13.3 µg/mL, a bacterial growth of 
0% was observed. 
8.2 Synthesis of modified CIP for copper-free click chemistry 
As previously described, ciprofloxacin was modified with an alkyne in order to link it to 
the peptide via Cu(I) catalyzed cycloaddition. The reaction between 5 and PLL9-N3 has 
been tested, but the copper catalyst could not be fully removed from the product. 
Indeed, copper ions forms very stable complexes with peptides. For instance, Ottaviani 
et al. studied PLL dendrigraft-Cu(II) complexes, which are of particular interest for their 
application in bio catalysis[298]. However, the copper is antibacterial and cytotoxic and 
mediates the generation of reactive oxygen species[299][300], therefore any activity tests 
or further investigation with copper containing samples are not meaningful.  
Cyclooctynes are reported to react selectively with azides without any copper(I) 
catalyst avoiding cytotoxic effect of copper(I) in the product[301]. Therefore, it has been 
selected to be grafted onto ciprofloxacin to link an azide-functionalized peptide via 
Copper-free click chemistry.  
Influence of the modification on the antimicrobial efficacy, has been studied by 
synthezising different ciprofloxacin derivatives, one with (10) and one whitout (7) linker 
in between cyclooctyne and ciprofloxacin (Figure 8-1). The aim of the linker was to 
minimize the risk of reducing efficacy by separating the bulky triazole-cyclooctyne bond 
and the ciprofloxacin.  
8.2.1 Cyclooctyne-functionalized ciprofloxacin without linker 7 
The synthetic route for the preparation of the ciprofloxacin derivative 7 to enable the 
link with poly-L-lysine is depicted in Figure 8-4. (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-
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ylmethanol (BCN-OH) was reacted with p-nitrophenyl chloroformate in the presence of 
pyridine (Figure 8-4, step 1) to obtain the p-nitrophenyl carbonate 6. Subsequently, 
the BCN-moiety was installed at the free amino function of ciprofloxacin by reaction 
with the p-nitrophenylcarbonate 6 in the presence of N-methyl morpholine (NMM) as a 
base to form compound 7 (Figure 8-4, step 2).  
 
Figure 8-4 Reaction scheme of cyclooctyne-functionalized ciprofloxacin 7 with numbered protons. 
 
Mechanism of step 1  
The first step of the mechanism (Figure 8-5) involves a nucleophilic attack of pyridine 
on the positive carbon atom of the acyl chloride (Figure 8-5, I) (Schotten-Baumann 
conditions). Known for its basicity, pyridine is also an excellent nucleophile. In fact, 
pyridine is more nucleophilic than the alcohol and therefore, rapidly attacks the acyl 
chloride. Subsequently, a displacement of the chloride occurs, leading to a highly 
electrophilic intermediate (Figure 8-5, a), which undergoes a nucleophilic attack by the 
alcohol (Figure 8-5, II), a deprotonation by a pyridine (Figure 8-5, III), and a 
displacement of the pyridine (Figure 8-5, IV), forming the final carbonate ester 6. 
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Characterization of 6  
The 1H-NMR was consistent with previous work[302], and all signals could be assigned 
to the corresponding protons (Attached file 7). 
 
Mechanism of step 2  
Ciprofloxacin was functionalized with a bicyclooctyne through a reaction between the 
amine of ciprofloxacin and the carbonate ester 6 (Figure 8-4, step 2). In order to avoid 
thermal degradation of the BCN moiety, ciprofloxacin was first dissolved at 82°C and 
the solution cooled down to 23°C before the compound 6 was added. 
The mechanism of step 2 (Figure 8-4), can be described as follow: it involves a 
nucleophilic attack of the ciprofloxacin amine on the positive carbon of the carbonate 
7 (Figure 8-6, I). Next, a deprotonation by N-methylmorpholine (Figure 8-6, II) occurs, 
and finally, elimination (Figure 8-6, III) of the nitrophenyl group occurs to generate the 
final product 7. Flash chromatography through silica gel was performed to purify the 
residue. 
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Characterization of 7  
1H-NMR spectroscopy was performed to prove the reaction and the structure of 
compound 7. Numbers have been assigned to each protons in order to facilitate the 
characterization (Figure 8-4). In 1H-NMR spectra of the product, the signals of 
ciprofloxacin and bicyclooctyne proton were detected, which demonstrates the 
successful synthesis of the compound 7 (Attached file 8). The signals at 8.67 (H12), 
7.92 (H11), and 7.29 (H10) ppm represent the quinolone framework protons of 
ciprofloxacin. The presence of a doublet at 4.17 (H7) ppm confirmed the presence of 
BCN moiety. Moreover, four protons of the nitrophenyl-leaving group disappeared. 
Finally, the expected number of protons and their signal correlations were also 
determined (Attached file 8). Electrospray Ionisation Mass Spectrometry (ESI-MS) was 
used to further confirm the synthesis. Peaks were found at 508.22, 530.20, and 
1037.42 m/z, which represent the following ions: [M + H]+ = 508.22 m/z, [M + Na]+ = 
530.20 m/z, [2M + Na]+ = 1037.42 m/z. M represents the calculated mass for 
C28H30FN3O5 = 507.22 g/mol. 
The predominant ions observed were [M + Na]+ and a dimer species. McNair et al[303] 
have studied pseudo‐molecular ion formation, in electrospray ionization mass 
spectrometry (ESI‐MS), of six anti‐inflammatory pharmaceuticals with similar 
functionality as in ciprofloxacin. Some of the compounds were able to form dimers, 
during the measurement, through the interaction of their carboxylic acid function and 
sodium ion. This behavior was observed during ESI-MS measurements of ciprofloxacin 
7.  
8.2.2 Cyclooctyne-functionalized ciprofloxacin with spacer 10 
The synthesis route of cyclooctyne-functionalized ciprofloxacin with spacer 10 is 
illustrated in Figure 8-7. The compound 9 was first synthesized through nucleophilic 
attack of the ciprofloxacin amine on the 6-((tert-butoxycarbonyl)amino) hexanoic acid 
(Boc-6-Ahx-OH), in presence of the phosphonium salt PyAOP, Trimethylsilyl chloride 
(TMSCl) and N,N-Diisopropylethylamine (DIPEA)  (Figure 8-7, step 1). PyAOP salt is 
a coupling reagent mainly used in peptide synthesis to activate the reaction between 
amine and carboxylic acid. Then, the tert-Butyloxycarbonyl protecting group of Boc-6-
Ahx-OH was cleaved, by trifluoroacetic acid, to obtain the compound 9 (Figure 8-7, 
step 2). Subsequently, the BCN-moiety was installed at the free amino function of 
ciprofloxacin 9 by reaction with the p-nitrophenylcarbonate 6 in the presence of NMM 
as a base to form compound 10 (Figure 8-7, step 3). 





Figure 8-7 Reaction scheme of cyclooctyne-functionalized ciprofloxacin with spacer.  
 
Mechanism of step 1 and step 2 (Figure 8-7) 
The mechanism involves a deprotonation of the carboxylic acid before it undergoes a 
reaction with the phosphonium salt PyAOP. Subsequently, a nucleophilic attack of 
oxybenzotriazol (a) (Figure 8-8) takes place, forming an activated ester (b) (Figure 
8-8). Ciprofloxacin was separately mixed with a base and trimethylsilyl chloride 
(TMSCl) to protect the carboxylic acid and avoid any side reactions. Then, the 
protected ciprofloxacin was added to the compound (b) (Figure 8-8) to undergo a 
nucleophilic attack, after which the elimination of the oxybenzotriazol group yields the 
product 8 (Figure 8-7, step 1). The final product 9 was obtained through deprotection 
of Boc-protected amines using trifluoroacetic acid (Figure 8-7, step 2). More details 
about the synthesis can be found in the experimental part in Chapter 10.6.1. 
Mechanism to form compound 10 (Figure 8-7, step 3) can be described by the 
mechanism presented in Figure 8-6. The synthesis was performed under the same 
conditions as the synthesis of compound 7. 
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Figure 8-8 Reaction mechanism of 9.  
 
Characterization of 9 
The 1H-NMR spectrum was used to identify signals of ciprofloxacin and 10 protons that 
match with the protons of the linker (Attached file 10). The deprotection of tert-
Butyloxycarbonyl protecting group was proven by the disappearance of methyl protons 
at 1.36-1.56 ppm. All signals could be assigned to the corresponding protons and can 
be found in Attached file 10. 
 
Characterization of 10 
The ciprofloxacin derivate 10 was analyzed and validated using various NMRs, 
heteronuclear multiple bond correlation (HMBC, Attached file 16), heteronuclear single 
quantum coherence (HSQC, Attached file 15), correlation spectroscopy (COSY, 
Attached file 13), nuclear Overhauser effect spectroscopy (NOESY, Attached file 14) 
and 1H-15N heteronuclear multiple bond correlation (NH-HMBC, Attached file 12). 
Besides conventional 1H-NMR analysis, two-dimensional NMR methods were used to 
clearly confirm the structure of the molecule. Indeed, those analyses revealed the 
correlation between protons, carbons, proton-carbon and nitrogene-proton, which 
helps to define the structure of complex molecules. Numbers have been assigned to 








Figure 8-9 Chemical structure of 10 with numbered protons. 
 
NH-HMBC was used to identify the signal of the NH proton at 7.00 ppm (Attached file 
12). COSY (Attached file 13) was performed to reveal the direct correlation between 
NH (A) and the proton H1 at 3.11 ppm. H1 correlates to the signal at 1.52 ppm, which 
corresponds to H2. Protons H3 to H5 were identified by their direct correlation. The 
next challenge was to find a correlation between H5 of the grafted linker and H6 
belonging to ciprofloxacin. NOESY (Attached file 14) was used to identify the 
correlation of H5 with four protons representative of H6 protons, which have a direct 
correlation with four other protons, expected to be H7. This proposition was supported 
by the correlation of H7 with a doublet at 7.73 ppm, representing the proton H8 
(NOESY). Furthermore, proton H8 was correlated with two nitrogens, (C) and (D). (C) 
was correlated with H6 and a doublet at 7.97 ppm (H9). (D) was correlated with three 
unidentified signals at 8.74, 1.45 and 1.33 ppm (NH-HMBC, Attached file 12). 
According to the literature, 8.74 ppm represents proton H10. The signals at 1.45 and 
1.33 ppm have a direct correlation with a proton at 3.94 ppm, which was expected to 
be H11[304]. The signals at 1.45 and 1.33 ppm, respectively, were determined to 
represent H13 and H12. HSQC (Attached file 15) and HMBC (Attached file 16) were 
used to identify the correlation between protons H1 and H14. The latter is part of the 
bicyclooctyne moiety. HSQC was used to identify the direct correlation of proton H1 
with carbon at 41.90 ppm. Furthermore, HMQC was utilized to reveal a correlation 
between H1 and the carbon at 158.18 ppm; because no direct correlation with any 
protons was identified, it was speculated to be the carbon of the carbamate link. 
Moreover, the signal at 158.18 ppm correlates with the doublet at 4.09 ppm, standing 
for a methyl group. It was suspected to be the proton H14 of the BCN moiety. 
Furthermore, a correlation between the signals at 4.09 (H14) and 1.31 ppm indicated 
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the proton H15. The proton H15 correlates with two protons at 0.89 ppm, and they 
were expected to be H16. The latter directly correlates with protons at 1.56 and 2.17 
ppm, representing H17 and H18. In addition, protons at 1.56 ppm correlate with the 
signals at 2.17 and 2.25 ppm, standing for H19 and H20. The correlation between the 
protons H18 and H19-H20 cannot be clearly defined. Finally, HMBC was used to reveal 
the correlation between protons H19-H20 and carbons at 100.25, which are not directly 
correlated with any proton. These carbons, appeared in the shifting range of triple 
bonds of cyclooctynes[87], and clearly demonstrated the successful synthesis of 10. 
Electrospray Ionisation Mass Spectrometry (ESI-MS) was used to further confirm the 
synthesis. Peaks were found at 333.14, 643.29, 1263.59, and 1574.24 m/z, which 
represent the following ions: [M + Na]+ = 333.14 m/z (z = 2), [M + Na]+ = 643.29 m/z (z 
= 1), [M + Na]+ = 1263.59 m/z (z = 1/2) and [M + Na]+ = 1574.24 m/z (z = 1/3). M 
represents the calculated mass for C35H43FN4O6 = 620.3 g/mol. 
The predominant ions observed were [M + Na]+ = 643.29 m/z (z = 1) and a dimer 
species [M + Na]+ = 1263.59 m/z (z = 1/2). McNair et al[303] have studied pseudo‐
molecular ion formation in electrospray ionization mass spectrometry (ESI‐MS) of six 
anti‐inflammatory pharmaceuticals with similar functionalities found in ciprofloxacin. 
During the measurement, some of the compounds were able to form dimers through 
the interaction of their carboxylic acid function and a sodium ion. This behavior is 
observed during ESI-MS measurements of ciprofloxacin derivative 10.  
8.3 Synthesis and analysis of peptide conjugated ciprofloxacin 
In this study, PLL9 11 or KKKKGRDNVTEGE 12a peptide sequences and molecules 
such as polyethylene glycol 13a or homoalanine 14a were grafted onto ciprofloxacin 
(Figure 8-1). The goal was to analyse the feasability of the system and to have a deeper 
understanding on why the grafting is affecting the antimicrobial efficacy of 
ciprofloxacin. Further details can be found in each concerned parts below. 
8.3.1 General mechanism of copper-free click chemistry  
Molecules 11, 12b, 13b, and 14b were all synthesized through the same type of 
reaction, called 1,3-dipolar cycloaddition, between a cyclooctyne and an azide 
function. The reaction occurs rapidly and selectively due to ring strain in the 
cyclooctyne function. Moreover, in comparison with the copper-catalyzed Huisgen 
cycloaddition, copper-free click chemistry is an attractive approach to click chemistry 
that is free of cytotoxic transition metal catalysts [301]. 
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It is known that the stability of cyclic alkynes decreases with decreasing ring size. This 
is because the stability is directly correlated with the C-C≡C-C bond angle. In the cyclic 
alkynes, the ideal angle of sp-hybridized carbons is 180°. As shown in Figure 8-10, the 
angles of C-C≡C-C increases with the ring size, leading to more stable compounds.  
 
 
Figure 8-10 Stability of cycloalkynes 
 
Cyclooctyne has a good balance between stability and reactivity. The ideal bond angle 
of 180° cannot be adopted for cyclooctyne (Figure 8-11, a). For this reason, it has a 
high ring strain and thus, instantly reacts with azide functions to generate a triazole 
bond. The newly formed double bond (Figure 8-11, b) exhibited a stable bond angle of 
120°, which is ideal for sp2-hybridized carbons. Therefore, the reaction is strain-
promoted. 
 
Figure 8-11 Reaction mechanism of copper-free click chemistry 
 
8.3.2 Synthesis and analysis of poly-L-lysine-ciprofloxacin 11 
The aim of this study is to synthesize a peptide, which has the ability to link a bioactive 
substance and to generate nanoparticles, with alginate, through ionic gelation. 
Therefore, in the presentation of the peptide design (chapter 5.2, Figure 5-3), lysine 
units have been integrated which can bear positive charges. Since this was a 
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preliminary study, a single PLL sequence was used to link ciprofloxacin and develop 
nanoparticles with alginate. Hence, the hindrance of the conjugated drug to produce 
the nanoparticle could be identified with this experiment.  
As described and explained in chapter 5, copper-free click chemistry was implemented 
to link poly-L-lysine to ciprofloxacin. The reaction described in Figure 8-12, instantly 
occurs between the azide function of poly-L-lysine and the cyclooctyne function of 
ciprofloxacin derivative 7. 
 
 
Figure 8-12 Reaction scheme of CIP-PLL 11. 
 
8.3.2.1 Characterization of ciprofloxacin-poly-L-lysine 11 
1H-NMR (Attached file 27), FT-IR, and UV-Vis were used to characterize compound 
11. Numbers have been assigned to each proton in order to facilitate the 
characterization (Figure 8-13). 1H-NMR spectra revealed the presence of protons 
which can be assigned to ciprofloxacin and poly-L-lysine. Protons H8, H7, H6, and 
H10/H9 belong to ciprofloxacin and the signal at 1.87-1.25 ppm represented protons 
of PLL (H3/4 and H5).  
In addition, FTIR of PLL9-N3 and Poly-L-lysine-Ciprofloxacin was performed to prove 
the disappearance of the signal at 2121 cm-1, which belongs to the reacting azide of 
PLL9-N3 (See Attached file 28). Finally, UV-Vis was used to confirm the presence of 
ciprofloxacin. An absorption peak was observed at 278 nm, which is characteristic for 
ciprofloxacin. The measurements proved the synthesis of compound 11. Compound 
poly-[L-lysine]9 conjugated ciprofloxacin 11 was then used with alginate to demonstrate 
the ability of conjugated peptide to generate nanoparticle.  
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Figure 8-13 Chemical structure of 11 with numbered protons. 
 
8.3.2.2 Alginate/Peptide-Ciprofloxacin Nanoparticles 
Nanoparticle formation and characterization 
Similar to chitosan/TPP nanoparticles system, the alginate/peptide-ciprofloxacin 
nanoparticles were formed by ionic gelation in an aqueous solution by mixing a solution 
of purified alginate and PLL-ciprofloxacin 11. More information can be found in the 
experimental part (chapter 10.6.3). In the final system, as described in chapter 5, L-
lysine residues will be integrated at both sides of the NVTEGE↓ALGSV peptide 
sequence. Due to ionic interactions between the components (lysine and alginate), 
they were able to self-assemble into nanoparticles. As described in chapter 3.1.3, 
various parameters such as the PLL-ciprofloxacin/alginate ratio, the pH, and the 
concentration influenced the particle formation. The influence of the PLL-
ciprofloxacin/alginate ratio was tested by mixing a solution of 11 and alginate at 
different ratios. The concentration of both solutions was fixed at 1 mg/mL in deionized 
H2O. Dynamic light scattering measurements were used to determine particle sizes. 
PLL-ciprofloxacin/alginate ratios of 1:4, 1:3, 1:2 and 1:1 were tested (Figure 8-14). 
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Figure 8-14 Dependence of the size of nanogels prepared with different PLL-ciprofloxacin/alginate ratios at RT in 
deionized water. 
 
In all cases, monomodal particles-size distributions were obtained. As shown in Figure 
8-14, the size decreased as the amount of PLL increased. Indeed, it is known that the 
size of the particle is influenced by different parameters such as concentration of the 
polycation and the polyanion [63]. Giri et al.[305] explained that ionic gelation is based on 
the capability of polyelectrolytes to generate crosslinks with respective counter ions to 
form nanoparticles. In this case, PLL acts as a cross-linker to bind the alginate chains 
to each other. At the same time PLL compensates the negative charges of alginate. 
Therefore, by increasing the amount of positive PLL, negative charges are 
compensated and the repulsive force inside the system is reduced. The direct 
consequence is a decrease of the particle size. 
The  polydispersity  index  for  1:4,  1:3,  1:2,  and  1:1  mixtures  were  found  to  be  
0.488,  0.225, 0.247, and 0.171, respectively. It is clear that the PDI tends to decrease 
with an increasing amount of polycation. This behavior has been observed by Hiorth 
et al. with Zn2+as polycation[306]. This might be explained by the transition from free 
alginate to cross-linked alginate chains.  In  order  to  maximize  the  cost  effectiveness  
while  keeping  a  low  polydispersity index for the NP a ratio of 1:3 was chosen to 
perform the stability and degradation tests. The stability was tested by incubating the 
nanoparticles for 50 h at 37 °C inin phosphate buffered saline (Figure 8-15). 
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Figure 8-15 Size of the nanoparticles (PLL-ciprofloxacin/alginate 1-3) as function of incubation time in phosphate 
buffer saline (pH 7.4) at 37°C. The particle size for the 1-3 mixture here was somewhat higher because of the buffer 
and the higher temperature. 
 
Due to the different conditions (pH, temperature, and salt concentrations) the particle 
size for the 1-3 composition was somewhat higher than in the previous experiment 
(Figure 8-15, 355 nm instead of ~300nm). There was a slight further increase in particle 
size from 355 to 380 nm. However, in general the stability of the nanoparticles was 
confirmed. 
 
Enzymatic degradation of nanoparticles 
The degradability and release of ciprofloxacin were tested by incubating the system 
with trypsin (2.5 µg/mL). This enzyme is known to cleave PLL sequences[209]. The 
incubation led to a substantial increase in particle size (Figure 8-16). As was shown in 
Figure 8-14, a decrease in the amount of poly-L-lysine, thus a reduced PLL to alginate 
ratio led to an increase in nanoparticles size. Indeed, during incubation, trypsin 
converted PLL into monomer moieties, reducing the PLL concentration and as a direct 
consequence an increase in nanoparticle size was observed.     
 Aginate/peptide-NPs 89 
 
 
Figure 8-16 Size of the nanoparticles (PLL-ciprofloxacin/alginate 1/3) as function of incubation time in phosphate 
buffer saline (pH 7.4) at 37°C after addition of trypsin (final concentrations of 2.5 µg/mL). 
 
Release study of Ciprofloxacin from nanoparticles   
The triggered release of ciprofloxacin by cleavage of the peptide sequence was 
confirmed by the following investigations. Different suspensions of nanoparticles were 
incubated with trypsin in PBS at 23°C and dialyzed to filtrate the solutions. The aim 
was to remove the non-degraded particles and to extract the released ciprofloxacin. 
The dialysate was investigated by UV-Vis to quantify the ciprofloxacin at 278 nm. To 
study the influence of trypsin, the experiment was tested with different concentrations 
(Figure 8-17). With regard to the incubation without trypsin (Figure 8-17, blue curve), 
a small amount of the conjugated ciprofloxacin 11 remained unbound in the solution 
and therefore was detected in the dialysate. However, incubation with 2 µg/mL and 5 
µg/mL of trypsin (Figure 8-17) induced a strong increase of the ciprofloxacin 
concentration. During the process, PLL is degraded, causing the release of conjugated 
ciprofloxacin from the nanoparticle. Incubation with higher trypsin concentration led to 
quicker degradation (Figure 8-17, black symbols) and confirmed the possibility of 
controlling the drug release. The nanoparticle suspensions was then used to coat the 
surface of titanium plates, which is a common implant material. 


















 Alg/PLL-cipro NP; ratio 1:3
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Figure 8-17 Absorbance at 278 nm, which corresponds to the ciprofloxacin concentration in the dialysate as function 
incubation time in PBS buffer (pH 7.4) without, with 2 µg/ml or 5 µg/ml trypsin, respectively, at 37°C. 
 
Coating of titanium samples and its stability / degradation 
In addition, to ensure the possibility to employ the system for dental implants, the 
particles were used to coat the surface of titanium plates. Afterwards, stability and 
degradation of the coating were studied. The coating process comprises a spray or 
spin coating, drying and rising[24][307]. During the coating the nanoparticles form a 
homogeneous layer [24][307][308]. More information about the coating process can found 
in chapter 10.6.4. 
While chitosan based nanoparticles directly bind to the negatively charged titanium 
surface [307], for alginate based nanoparticles with a negative zeta potential a surface 
charge reversal is necessary[24]. Here, adsorption of polyethyleneimine was used to 
obtain a positively charged surface. The thickness of the polyethyleneimine layer was 
determined by ellipsometry to be around 3.0 ± 1 nm. Subsequently a PLL-
ciprofloxacin/alginate (ratio 1:3) nanoparticle suspension was spray-coated resulting 
in a dry layer thickness of around 40 ± 6.5 nm. The coating on the titanium was then 
used for degradation. For this purpose, coated titanium plates were incubated in PBS 
buffer with or without addition of trypsin (5 μg/ml) at pH 7.4 and at 37°C. In the absence 
of enzyme the layer thickness does not change, and thicknesses between 35-40nm 
are determined by ellipsometry for the dried coatings (Figure 8-18, red curve). For the 
incubation in buffer with trypsin another coating was prepared, which is slightly thicker 
at the beginning (~45 nm, Figure 8-18, black symbols). Indeed, those differences can 
occur due to the coating process. In this case, the incubation caused an increase in 
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the thickness of the layer in the first few hours (Figure 8-18, black symbols). This was 
interpreted to be due the diffusion of trypsin into the layer. Then, over 109 hours, a 
decrease of 45% of the initial layer thickness was observed, clearly indicating the 
enzymatic degradability of the coatings.  
 
Figure 8-18 Dry layer thickness of PLL-cipro/alginate coatings as determined by ellipsometry after incubation in 
PBS buffer with or without addition of trypsin (5 μg/ml) at pH 7.4 and at 37°C. 
 
In conclusion, degradation and release results discused above, demonstrate a 
controlled degradation (by enzymatic activity) of the system and its capacity to trigger 
drug release by enzymatic degradation (Figure 8-17).  
8.3.3 Synthesis, analysis and antimicrobial efficacy of the conjugated 
ciprofloxacin. 
KKKKGRDNVTEGE 12a peptide sequences and molecules such as polyethylene 
glycol 13a or homoalanine 14a were grafted onto ciprofloxacin to gain a deeper 
understanding on how the grafting is affecting the antimicrobial effeciency of 
ciprofloxacin.  
8.3.3.1 Binding of [N3KKKKGRDNVTEGE] 12a to ciprofloxacin 12b 
The peptide residue KKKKGRDNVTEGE represents the sequence that remains on the 
drug after peptide cleavage. Therefore, to test the efficacy of the released compound, 
peptide 12a was linked to ciprofloxacin (Figure 8-19). The reaction described in Figure 
8-19 instantly occurs between the azide function of petpide 12a and the cyclooctyne 
of ciprofloxacin 10. 
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Figure 8-19 Reaction scheme of CIP-[KKKKGRDNVTEGE] 12b. 
 
Characterization of ciprofloxacin derivate 12b 
Electrospray Ionisation Mass Spectrometry (ESI-MS) was used to further confirm the 
synthesis of 12b. Peaks were found at 453.64, 566.80, 755.40, and 1132.60 m/z, which 
represent the following ions: [M + H]+ (z = 5), [M + H]+ (z = 4), [M + H]+ (z = 3), and [M 
+ H]+ (z = 2). M represents the calculated mass for C101H160FN29O29 = 2262.19 g/mol)]. 
After successful synthesis, the antimicrobial efficacy of the conjugated ciprofloxacin 
12b was investigated against Staphylococcus aureus. 
 
Antimicrobial efficacy of the 12b 
The molecule 12b, expected to be the active ingredient released during the 
degradation process, showed a decrease of antimicrobial efficacy. Indeed, for the 
ciprofloxacin conjugated to KKKKGRDNVTEGE a strong reduction in the inhibition of 
bacterial growth is observed. At a concentration of 12 µg/mL of 12b a bacterial growth 
of 50% was observed. At the same concentration, bacterial growth in the presence of 
commercial ciprofloxacin was 0%. Therefore, to understand the reason of this 
decrease, 13b and 14b have been synthesized. 
As previously mentioned, ciprofloxacin have been grafted to polyethylene glycol and 
L-azidohomoalanine to have a deeper understanding and investigate on why the 
grafting is affecting the antimicrobial efficacy of ciprofloxacin. 
8.3.3.2 Binding of N3(polyethylene glycol)NH2 13a to ciprofloxacin 
The efficacy tests were performed in the tryptic soy broth medium, containing proteins. 
Interactions between the peptide chain of 12b and the proteins might have affected the 
efficacy. Therefore, ciprofloxacin was conjugated to PEG (Figure 8-20, 13b), which is 
known not to interact specifically with proteins. Thence, by testing 13b, the hypothesis 
concerning the involvement of peptide / protein interactions can be clarified. The 
reaction described in Figure 8-20 instantly occurs between azide of polyethylene glycol 








Figure 8-20 Reaction scheme of CIP-(PEG)NH2 13b. 
 
Characterization of 13b 
With the help of two-dimensional NMR methods, the coupling of the ciprofloxacin and 
13a was established. Indeed, those analyses revealed the correlation between 
protons, carbons, protons-carbons and nitrogene-protons, which helps to define the 
structure of complex molecules. Numbers have been assigned to each protons in order 
to facilitate the characterization (Figure 8-21). HMBC (Attached file 21), HSQC 
(Attached file 22), COSY (Attached file 19), NOESY (Attached file 20) and NH-HMBC 
(Attached file 18) were performed to analyze and validate the synthesis of molecule 
13b. 
 
Figure 8-21 Chemical structure of 13b with numbered protons. 
 
The same starting point as that for the analysis of 10 was used to identify compound 
13b. Briefly, the NH signal of the carbamate was analyzed to define the protons H1 
(13a) (13b) 
(10) 
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and H14. Atoms H15 to H20 were identified by means of the correlation with the H14 
protons. After the reaction, a shift of all those protons was observed. The most affected 
protons were H19 and H20, which shifted from 2.17-2.25 ppm to 3.03 and 2.79 ppm. 
Furthermore, HSQC was performed to highlight the direct correlation of H19-H20 with 
the carbons at 24.26 and 27.52 ppm (Attached file 22), which correlate with two other 
carbons at 135.34 and 144.93 ppm and are not directly correlated with any proton 
(Attached file 21). These carbons appear in the shift range of the double bond of 
triazoles. In fact, the synthesis of 13b implies the formation of a triazole ring. NH-HMBC 
(Attached file 18) and COSY (Attached file 19) analyses were performed to identify the 
proton in PEG chains. As evident in the analysis of compound 10, the nitrogen at 
−230.03, −298.01 and −314.84 ppm were identified respectively as (D), (A), and (C). 
The nitrogens of PEG chains (G) and (F) were characterized by the correlation with 
the same protons at 4.49 ppm. Regarding the structure of 13b, the protons at H21 
correlate with two nitrogens: (F) at −25.56 ppm and (G) at −136.76 ppm. Therefore, 
the protons at 4.49 ppm were defined as H21, directly correlating with signals at 3.83 
ppm, which is expected to be H22. 1H-NMR and the NH-HMBC spectrum of N3-PEG-
NH2 were needed to reveal the nitrogen (H) at −353.33 ppm and protons H24 at 3.78 
ppm. Moreover, H24 correlates with protons at 3.25 ppm, which are supposed to be 
H23. Finally, three different points confirmed the bonding of the PEG chains (13a) and 
ciprofloxacin derivate 10. First, the carbon at 135.34 ppm was identified to be part of 
the generated double bond and part of the BCN-CIP, and it correlates with protons at 
4.49 ppm, which was identified as H21 of PEG chains (Attached file 22). Second, 
NOESY (Attached file 20) was carried out to identify the correlation between H21 and 
H19-H20 of 10. Third, nitrogen (F) is shifted at −25.56 ppm (Attached file 18), which 
typically characterizes a shifting of triazole nitrogens[309]. Finally, the analysis 
highlighted the disappearance of the triple bond signal at 100.25 ppm and the 
appearance of C=C double bond signals at 135.34 and 144.93 ppm (Attached file 21). 
After successful synthesis, efficacy tests have been performed on the molecule 13b.  
 
Antimicrobial efficacy of the 13b 
The molecule 13b showed a decrease of antimicrobial efficacy. Indeed, for the 
ciprofloxacin conjugated to PEG a strong reduction in the inhibition of bacterial growth 
is observed. At a concentration of 6 μg/mL of 13b a bacterial growth of 75% was 
observed. At the same concentration, bacterial growth in the presence of commercial 
ciprofloxacin was 0%. In conclusion, as 13b did not show a significant efficacy, it can 
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be speculated that interactions between the peptide chain of 12b and the proteins is 
not responsible for the bacterial growth. 
8.3.3.3 Binding of L-azidohomoalanine hydrochloride 14a to ciprofloxacin 
Ciprofloxacin was conjugated to L-azidohomoalanine 14b, which represents the 
smallest amino acid that can be linked. By testing its efficacy the influence of peptide 
length can be studied. The reaction described in Figure 8-22, instantly occurs between 
azide of L-azidohomoalanine hydrochloride 14a and cyclooctyne of ciprofloxacin 10. 
 
Figure 8-22 Reaction scheme of CIP-L-homoalanine hydrochloride 14b.       
 
Characterization of 14b 
With the help of two dimensional-NMR methods, the coupling of the ciprofloxacin and 
14a was established. Indeed, those analyses revealed the correlation between 
protons, carbons, protons-carbons and nitrogene-protons, which helps to define the 
structure of complex molecules. HMBC (Attached file 26), HSQC, COSY (Attached file 
24), NOESY and NH-HMBC (Attached file 25) were performed to analyze and validate 
the synthesis of molecule 14b. Numbers have been assigned to each protons in order 
to facilitate the characterization (Figure 8-23). 
(14a) (14b) 
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Figure 8-23 Chemical structure of 14b with numbered protons. 
 
The synthesis of molecule 14b was confirmed through the same evidence that helped 
to characterize the compound 13b:  
 Shifting of protons H19 and H20 (Attached file 23, 1H-MNR). 
 Disappearance of triple bond signals at 100.25 ppm, confirming the reaction of 
cyclooctyne (HMBC, Attached file 26). 
 Appearance of C=C double bond signals of 1,2,3-triazoles bond, formed during 
the synthesis of 14b, at 135.34 and 144.93 ppm. (HMBC, Attached file 26). 
 NOESY was used to highlight the correlation between H21 of the grafted 
L-azidohomoalanine and H19-H20 of ciprofloxacin derivate 10.  
 Finally, nitrogen (F) was found to be shifted to −26.63 ppm, which is a typical 
shift for triazole nitrogens[309]. 
The spectrums shows some remains of the reagent L-azidohomoalanine, which could 
not be removed completely by precipitation of the polymer. For L-azidohomoalanine 
no antibacterial effect was observed, therefore, 14b with the small amounts of 
impurities was used for the experiments. 
 
Antimicrobial efficacy of the 14b 
The molecule 14b showed a decrease of antimicrobial efficacy. Indeed, for the 
ciprofloxacin conjugated to 4-azido-homoalanine a strong reduction in the inhibition of 
bacterial growth is observed. At a concentration of 1 μg/mL of 14b a bacterial growth 
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of 80% was observed. At the same concentration, bacterial growth in the presence of 
commercial ciprofloxacin was 0%.  
These results strongly suggest a hindrance due to the resulting bicyclononatriazole 
bond between ciprofloxacin and peptides. In fact, even the binding of a single amino 
acid leads to a reduction of the antibacterial efficacy. This compound 14b did not have 
a KKKKGRDNVTEGE chain, but the same linking group, thus it can be concluded that 
the acylation of the piperazine ring with a bicyclononatriazole as in the linking group of 
compounds 14b and 12b hindered the drug from reaching or interacting with the target 
in the bacteria. While acylation of the secondary amino function has been found to be 
dentrimental for activity against a wide range of Gram-negative bacteria[310][251], in 
which the zwitter ionic structure of ciprofloxacin is important to pass the outer 
membrane pore OmpF, acylation is mostly tolerated for activity in Gram-positive 
bacteria like S. aureus having no outer membrane. In this case acylation can even lead 
to improved antibacterial activities [251]. However, the mechanism of action of 
ciprofloxacin involves an interaction with gyrase and bacterial DNA. Ciprofloxacin 
stabilizes the gyrase and bacterial DNA complex, which results in a DNA break [311]. It 
can be speculated that the linker with its structure of three annelated rings systems are 
too bulky to allow the formation of the complex with gyrase and DNA.  
The residual efficacy of 12b can be explained by the antimicrobial properties of the 
peptides, rich in cationic lysine residues. In general, they act by disrupting the structural 
integrity of the microbial membranes [312][313][314]. 
8.4 Conclusion 
In this study, a new nanogel system was prepared by ionotropic gelation of alginate 
with PLL conjugated with ciprofloxacin. The conjugation of the ciprofloxacin was 
carried out by modification with a cyclooctyne-group suitable for a copper-free 1,3-
cycloaddition with an azide at the peptide sequence. This is a versatile method to link 
small drug molecules to peptide sequences. Ciprofloxacin was therefore modified with 
cyclooctyne to enable the reaction with the azide function attached to different peptide 
sequences and molecules. Ciprofloxacin was modified, both with and without a linker 
comprising five methylene groups. This linker aimed at separating the bulky triazole-
cyclooctyne bond and the ciprofloxacin, to minimize the risk of an efficacy loss. 
However, despite the integration of this linker the antimicrobial activity was affected as 
well. Further derivatives of ciprofloxacin were evaluated to elucidate the role of the 
conjugation chemistry. All of them showed a lower efficacy, suggesting the bulkiness 
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of triazole-cyclooctyne or the acyl conjugation as a possible cause, by hindering 
interactions of ciprofloxacin with the gyrase.  
Then, a poly-L-lysine functionalized with an azide group was bond to ciprofloxacin to 
demonstrate the ability of conjugated peptide to generate stable nanoparticles with 
alginate. The PLL with conjugated ciprofloxacin forms nanoparticles with alginate 
solutions by ionotropic gelation as evidenced by dynamic light scattering. The 
nanoparticles are stable in aqueous suspension, but are degraded upon addition of 
trypsin. The ciprofloxacin was released from the nanoparticles only when the PLL 
sequence was enzymatically cleaved by trypsin. Moreover, the nanoparticle 
suspensions were used to prepare coatings on titanium by spray coating and 
characterized by ellipsometry. The coating was stable and degradable by enzymatic 
activity only. The results clearly demonstrated the intrinsic capabilities of the systems 
for application as triggered release systems for antibacterial agents. In conclusion, 
despite drug efficacy reduction, the introduced system was able to deliver on-demand 
molecules without any burst release. Any active substance with amine function can be 
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9 Conclusion 
Once external materials are implanted into the body, bacteria can attach to their 
surface, grow in biofilms and cause chronic inflammation. As a consequence, it can 
lead to the implant’s failure and implementation of further surgical treatments, 
generating additional costs. To avoid this, smart drug delivery systems, which enable 
the encapsulation and triggered release of a drug substance, in a targeted and 
sustained way, were examined and presented in this study.  
The main focus was to develop a system with a specific release occurring within 
particular enzymatic conditions or inflammatory state. To build up a stable and 
cleavable encapsulation system, different steps were established: 1) the integration of 
a model enzyme-labile peptide into two different polymer-based systems 2) generation 
of particles 3) the implementation of the particles into a coating, on titanium surfaces 
4) the study of stability and degradability of those systems 5) the release of 
ciprofloxacin as model substance. 
The first system was chitosan based (system 1). Chitosan-g-[poly-L-lysine-block-ε-
caprolactone] copolymer was synthesized in four steps: functionalization of chitosan, 
grafting of a poly-L-lysine linker, synthesis of functionalized polycaprolactone, and 
binding of polycaprolactone to the chitosan via the linker. For the second system, 
based on alginate (system 2), a poly-L-lysine cross-linker and a model drug substance 
have been synthesized/modified to enable the binding of both components through a 
bicyclononatriazole link.  
Systems 1 and 2 were able to generate polymersomes and nanoparticles in aqueous 
solution, respectively. Polymersomes (system 1) were formed by a solvent shift 
method, using DMSO as organic solvent. The relationship between the particles size 
and the amount of hydrophobic PCL was demonstrated and revealed an increase of 
the size by increasing the hydrophobic PCL amount. The peptide-alginate 
nanoparticles (system 2) were formed in aqueous solution by ionic gelation between 
positively charged drug-conjugated peptide linker and negatively charged alginate. The 
particle size and structure were characterized by Dynamic Light Scattering and/or 
Cryo-Scanning Electron Microscopy. Cryo-SEM images highlighted well-defined 
spherical and bi-layered core-shell structures of polymersomes. However, for the first 
system, a specific degradation through the cleavage of the polypeptide linker by the 
enzyme trypsin was not demonstrated. Its stability was attributed to the first chitosan 
layer which cannot be penetrated by the trypsin. This was confirmed by the capability 
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of chitosanase to degrade the polymersome by cleaving the external chitosan layer. In 
contrast to the system 1, for the alginate based nanoparticles (system 2), a change in 
particle size could be observed after adding trypsin and was explained by the 
degradation of the nanoparticles through the cleavage of the poly-L-lysine cross-linker. 
Indeed, an influence of the cross-linker amounts could be demonstrated and an 
increase in particle size was observed at lower cross-linker amount.  
Both nanoparticle suspensions were used to prepare coatings on titanium, employing 
a spray coating process. The coating formation was confirmed and characterized by 
using ellipsometry. For both systems, the coating was stable at body simulated 
conditions and degradable by a specific enzymatic activity only. Regarding the coating 
of the second system, a specific decrease in layer thickness could be observed after 
adding trypsin. This enzyme is well known to have poly-L-lysine as substrate. On the 
other hand, for the first system, as for the polymersome in solution, the degradability 
of the coating was revealed only after adding chitosanase, well known to have chitosan 
as substrate. 
As the degradability of the system 2 was directly related to the cleavage of the peptide, 
the triggered drug release by an enzymatic activity has been further investigated. 
Hence, it has been noted that the drug was only released, from nanoparticles, after 
trypsin was added, allowing the poly-L-lysine sequence cleavage. The specificity 
towards trypsin was demonstrated by using different concentrations of the enzyme. 
The increase in concentration revealed an accelerated drug release. This result clearly 
demonstrated a dependence of the system towards enzymatic activities and in other 
words, its capability to trigger specific release. 
Moreover, for the second system, the antimicrobial efficacy of the drug after release 
has been studied. In a view of integrating the aggrecanase (an inflammation relevant 
enzyme) labile peptide, the drug substance was linked to a peptide, which represents 
the sequence that potentially remains conjugated to the drug after the peptide 
cleavage. The activity of the drug conjugated with peptide was strongly affected. 
Further ciprofloxacin derivatives were evaluated to better understand the role of the 
conjugation chemistry. First, a linker has been integrated between the drug and the 
peptide to analyze the influence of the bicyclononatriazol link on the efficacy. Second, 
a PEG chain with no affinity towards proteins has been grafted to the drug in order to 
check if a potential efficacy reduction happened due to the affinity of peptide and 
proteins. Finally, one single amino acid has been grafted on the drug to confirm the 
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influence of the peptide length on the efficacy. However, all 3 derivatives led to a lower 
efficacy of the drug. It can be deduced that the acylation of the piperazine ring of the 
ciprofloxacin, by a bicyclononatriazole linking group, hindered the drug from reaching 
or interacting with the target in the bacteria. It is known from literature that the acylation 
of the secondary amino function can be detrimental for the activity against a wide range 
of gram-negative bacteria[251][310]. Indeed, the zwitter-ionic structure of ciprofloxacin is 
affected and known to be important to pass the outer membrane pore OmpF. 
Nevertheless, acylation is mostly tolerated for activity in gram-positive bacteria, like S. 
aureus, which have no outer membrane. 
In this study, as the acylation had a negative impact on the drug efficacy, alkylation of 
the drug substance could be preferred for further investigations. As a preliminary study, 
the binding via an alkylation at the drug substance showed the same efficacy against 
S. aureus, as the non-modified drug. However, this modified drug was not further 
studied due to the use of copper catalyst to achieve the binding. To avoid copper 
chemistry,  the ciprofloxacin could be alkylated and functionalized with bicyclooctyne, 
through the following steps: i) alkylation of the secondary amino function with 6-(Boc-
amino)hexyl bromide, ii) deprotection of tert-butoxycarbonyl protecting group and iii) 
bicyclooctyne functionalization using the same procedure used in this study. 
For future research, in order to avoid the loss of zwitter-ionic structure of ciprofloxacin, 
the drug could be linked to the carrier through a self-immolative spacer in which, the 
system would release the drug without any residue on the drug-substance. Waldmann 
et. al have designed a new linker which undergo an enzyme-catalysed modification, 
combined with a subsequent intramolecular cyclization, leading to the release of the 
attached substance[315]. For this, the linker embodies three functional groups, i) a group 
or attachment to the polymeric support, ii) a group for the binding of the drug-substance 
and iii) a group which recognized and attacked by penicillin G acylase. Thereby, the 
enzyme releases an intermediate which cyclizes and deliver the target compound in 
its original structure. The example shown by Waldmann et. al proved an interesting  
chemoselectivity of penicillin G acylase, since the enzyme attacks only the 
phenylacetamide unit[315]. The system should then be tested in presence of bacteria 
related to implant associated infection, as well as the kinetic of cyclization leading to 
the release of the drug. 
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Chemicals Purity Supplier 
Chitosan - Sigma-Aldrich 
Acetic acid 100% Sigma-Aldrich 
Propargyl alcohol 99% Sigma-Aldrich 
Tin (II)-2-ethylhexanoate 92.5-100% Sigma-Aldrich 
ε-caprolactone 97% Sigma-Aldrich 




Sodium chloride 99.0% Fisher scientific 
Azido-[Lys]20-SH - Nanosoft Polymers 
Natrium hydrogen carbonate ≥99.0% Roth 
Ciprofloxacin ≥98.0% Sigma-Aldrich 
Propargyl Chloride 98% Sigma-Aldrich 
4-Bromo-1-butyne 97% Sigma-Aldrich 









Pyridine 99.8% Sigma-Aldrich 
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4-nitrophenyl chloroformiate 96% Sigma-Aldrich 
Ammonium chloride ≥99.5% Sigma-Aldrich 
Sodium sulfate ≥99% Alfa aesar 
N-Methylmorpholine 99% Sigma-Aldrich 
N,N-Diisopropylethylamine ≥99% Sigma-Aldrich 








Citric acid ≥99.5% Sigma-Aldrich 
Trifluoroacetic acid ≥99.0% Sigma-Aldrich 
[EGETVNDRG]-N3 - CASLO ApS 
[EGETVNDRGKKKK]-N3 - CASLO ApS 
Azido-[Lys]9 - Klahn Lab 
Alginate - Sigma-Aldrich 
Poly(ethyleneimine) solution - Sigma-Aldrich 
Trypsin - Sigma-Aldrich 
Phosphate-buffered saline - Sigma-Aldrich 
Sodium hydroxide ≥99.0% Roth 
Deuterium oxide 99.9% Deutero 
Deuterated chloroform 99.98% Deutero 
Copper sulfate pentahydrate ≥98% Sigma-Aldrich 
Chitosanase from Streptomyces 
griseus 
- Sigma-Aldrich 
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Deutered Methyl alcohol 99.98% Deutero 
Copper bromide 98% Alfa aesar 
3-maleimidopropionic acid 95% Alfa Aesar 
 
10.1.2 Solvents  
Solvent Purity Supplier 
Toluol HPLC (99.8%) Sigma-Aldrich 
Methanol HPLC (99.8%) Fisher scientific 
Tetrahydrofuran HPLC (99.8%) Sigma-Aldrich 
Dimethyl sulfoxide 99.99% Honeywell 
Hydrochloric acid 37% Sigma-Aldrich 
Dimethylformamide HPLC (99.9%) Fisher scientific 
Dichloromethane HPLC (99.8%) Sigma-Aldrich 
Ethanol 99.8% Sigma-Aldrich 
Chloroform 99.96% Fisher scientific 
Ethyl acetate HPLC (99.8%) VWR 
Petroleum ether 
Analytical  
reagant  grade 
Fisher scientific 
Diethyl ether 99.8% Sigma-Aldrich 
Ultrapure water - - 
 
10.1.3 Titanium substrate 
Titanium plates, with a diameter of 1.1 cm (medical grade 4), provided by BRASSELER 
(Lemgo, Germany) were used as substrates for polymer films. Before being coated, 
the Ti plates were polished with a Phoenix 4000 device (BUEHLER, Esslingen, 
Germany) using the following protocol. The plates were treated with SiC abrasive 
paper (P400) and polished with a polycrystalline diamond suspension (9 µm) on an 
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Ultrapad polish paper and a MestMet colloidal silica polishing suspension (0.02-0.06 
µm) on ChemoMet paper. BUEHLER provided all suspensions and papers used for 
the above procedure. Once polished, the plates were cleaned by ultrasonification, in 
water followed by dichloromethane, acetone, methanol, and, finally, in MilliQ water. 
Afterwards, the plates were dried under nitrogen flow and stored in the refrigerator. 
Prior to each coating process, the plates were thermally treated overnight in order to 
obtain the desired negatively charged titanium oxide layer. 
10.2 Molecule Characterization 
10.2.1 NMR-Spectroscopy 
Instruments AV III HD 300N, AV III 400 and AV 600 supplied by BRUCKER (Billerica, 
USA) were used to perform H-NMR, C-NMR, F-NMR, N-NMR spectroscopy. Those 
instruments applied magnetic fields strength of 300, 400 and 600 MHz, respectively. 
The different deuterated solvents were purchased from DEUTERO (Kastellaun, 
Germany). The evaluation was carried out with the analytical software MestReNova 
from MESTRELAB (Santigo de Compostela, Spain).  
10.2.2 FT-IR-Spectroscopy 
A FT‐IR Equinox 55 instrument from BRUKER (Billerica, MA, USA) equipped with a 
mercury cadmium telluride detector, and an attenuated total reflection accessory with 
a zinc selenide crystal from HARRICK SCIENTIFIC PRODUCTS (Pleasantville, NY, 
United States) was used to perform FT‐IR spectroscopy. The following conditions were 
used: wavelength range between 4000 and 550 cm-1, 10 kHz and 32 scans per sample. 
The evaluation was carried out with the software OPUS from BRUKER (version 
4.0.24).        
10.2.3 Mass-spectroscopy 
Dr. Ulrich Papke from the Institute of Organic Chemistry-University TU Braunschweig 
conducted the Mass Spectroscopy measurements. LTQ-Orbitrap Velos spectrometer 
was used to perform Electrospray Ionisation Mass Spectrometry. A voltage of 2.3 to 
2.8 kV (positive) or 1.7 to 2.5 kV (negative) was applied. The sample was dissolved in 
methanol (C = 50 µg/mL) and 0.1 mg/mL trimethyltetradecylammonium bromide were 
added. A flow rate of 0.1 µL/min was used.        
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10.2.4 Gel permeation chromatography (GPC)   
THF GPC column and a Shodex RI-101 Refractive Index Detector from SHODEX 
(Munich, Germany) were used for measurements:  
 Precolumn 1  PSS SDV, 
 Column 2 PSS SDV 5 µm - 1000 Å, 
 Column 3 PSS SDV 5 µm-1000 Å.  
THF was used as eluent with a flow rate of 1 mL/min. was used. Before injections, the 
samples were filtrated with a PTFE 0.22 µm filter. A 100 µl solution was injected with 
a concentration of 2 mg/mL. The evaluation was done with the software WinGPC 
UniChrom of the company PSS (Mainz, Germany).   
10.3 Characterization of nanoparticles 
10.3.1 Particle size  
Particle size and stability measurements were carried out using a Zetasizer Nano ZS 
from MALVERN INSTRUMENTS (Malvern, UK) as well as to study the degradation of 
nanoparticle. A 12mm Square Disposable sizing cuvettes (DTS0012) were used for 
size measurements. Degradation tests were performed at 37°C. Malvern Zetasizer 
Software Version 7.03 was used for data evaluation. 
10.3.2 Zeta-potential 
Zeta potentials of the nanoparticles were determined using a Zetasizer Nano ZS from 
MALVERN INSTRUMENTS (Malvern, UK). Disposable Capillary Cells (DTS1070) 
were used for zeta potential measurements. The evaluation was done with the Malvern 
Zetasizer Software Version 7.03 from MALVERN INSTRUMENTS. 
10.3.3 Cryo-SEM 
For the morphological characterization the samples were cooled by plunging into 
nitrogen slush at atmospheric pressure and freeze fractured at −180 °C and etched for 
60 s at −98 °C. After sputtering with platinum in the GATAN Alto 2500 cryo preparation 
chamber the samples were transferred into the Hitachi S‐4800 microscope (Chiyode, 
Japan).    
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10.4 Coating process and Characterization 
10.4.1 Dip coating with PEI solution 
Before further treatment, the titanium substrate was coated with a polyethylenimine 
(PEI) layer to obtain a positively charged layer. The substrate was immersed for one 
minute in 5% (w/wH2O) PEI solution, washed with pure water, and dried under nitrogen. 
With regard to the PEI sctructure (Figure 10-1), amine functions enable a positively 
charged coating.  
 
Figure 10-1 Chemical structure of poly(ethyleneimine). 
10.4.2 Spray coating process of Titan plate  
The titanium substrates were then spray‐coated for 180 seconds with an airbrush Aztek 
A470 from TESTORS (Vernon Hills, IL, USA), depositing ≈20 µL of the polymersome 
suspension with a concentration of 1 mg/mL−1. Subsequently, the Ti plates were 
washed with 0.1% acetic acid (AcOH) and H2O in an ultrasonic bath for 15 min. 
Subsequently, the plates were dried under nitrogen flow. During the process, the plates 
were gently manipulated to avoid any scratches and residues on the polished surface. 
Ellipsometry was used to measure coating thickness. 
10.4.3 Ellipsometry  
The optical properties of coatings and thickness were determined using a Multiskop 
from OPTREL (Sinzing, Germany) in the ellipsometry mode. Uncoated titanium plates 
were used as reference. Data were collected in the x, y-mode at 70° as mean value of 
16 data points in total to determine optical constants and the thickness layers. 
Evaluation of the data was carried out using Elli Version 3.2 from OPTREL. 
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10.5 Synthesis for chitosan-g-[poly-L-lysine-b-ε-caprolactone] 
10.5.1 Purification of chitosan 
Season, origin, supplier and conditions of deacetylation are reasons which, cause 
variations of commercial chitosan quality. To overcome this problem and to obtain 
chitosan with a highest purity and integrity, Gan et al. proposed an additional 
purification process. Briefly, 1 g of purchased chitosan (Medium MW, 190-310 kDa, 
75-85% DDA) was soaked in 10 mL 1M sodium hydroxide solution. The suspension 
was then heated at 70°C for 2 hours before the chitosan was filtered off and washed 
with deionized water. Afterwards, the chitosan was dissolved in a 1% acetic acid 
solution. After complete dissolution of chitosan, the solution was filtered, and dialyzed 
against 0.1 M NaCl solution, and deionized water. Freeze drying was used to remove 
the water and to obtain a dried product.  The resulting chitosan was dissolved in a 
mixture of D2O/DCl (500/1) and 1H-NMR was used to analyse chitosan and determine 
the degree of deacetylation (DDA). The follwing equation was used to calculate the 
DDA.   






Figure 10-2 Chemical structure of chitosan. 
 
1H-NMR (400 MHz, D2O) δ [ppm] = 2.00-2.16 (m, CH3, GlcNAc); 3.37-3.03 (s, 1H); 
3.37-4.23 (m, 6H); 5.04-4.78 (m, 1H) 
10.5.2 Sysnthesis of chitosan-maleimide 1 
Chitosan-maleimide was synthesized according to Chirachanchai et al.. Briefly, CS 
(100 mg) and HOBt (91 mg, 0.5 mmol) were dissolved in 3 mL of ultrapure water and 
stirred overnight. To the CS solution, 33 mL of DMSO and a variable amount of 
3-Maleimidopropionic acid were added. Afterward, EDC (114 mg, 0.5 mmol) HCl 
solution (200 μL, pH = 4-5) was added, and the solution was stirred for 24 hours at 
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room temperature. Finally, the reaction mixture was dialyzed against a solution 
containing 10 mM HCl, 1 wt% NaCl, and then against 10 mM HCl. Subsequently the 
solution was lyophilized to obtain 1. The coupling efficiency was optimized by adjusting 
the amount of DMSO, HOBt, chitosan (from shrimp and fungi) and different coupling 
reagents (Table 7-1, chapter 7.1). 1H-NMR and FT-IR spectroscopy were used to 
characterize 1. Degree of substitution was calculated from the 1H‐NMR spectra, using 
the ratio of maleimide protons at 6.85 ppm and the signal at 2.00-2.08 ppm which 
represents 3 protons of the chitosan backbone. The degree of acetylation of unmodified 
chitosan was measured by 1H‐NMR and was found to be 10%. 
1H-NMR (400 MHz, D2O) δ [ppm] = 2.00-2.08 (m, 3H, CH3 of GlcNAc); 3.07-3.24 (m, 
1H, CH of GlcN); 3.43-4.09 (m, 5H, CH on chitosan backbone); 4.52-5.01 (m, 1H, O-
CH-O); 6.85 (s, 2H, HC=CH). (Attached file 1)  
FT-IR [cm-1]: 3248 (O-H); 2875 (C-H); 1704 (C=C); 1645 (C=O); 1556 (N-H); 1422 (CH-
OH), 1699 (C=C), 1045 (C-O)). (Attached file 2) 
10.5.3  Synthesis propargyl-terminated poly-ε-caprolactone 2 
propargyl-terminated poly-ε-caprolactone was synthesized via a general procedure for 
ring-opening polymerization of poly(ε-caprolactone)[201]: ε-caprolactone, propargyl 
alcohol, and Tin (II)-2-ethylhexanoate were dissolved in dry toluene. The solution was 
stirred at 110°C under dry nitrogen gas for 24 hours. The solution was then cooled 
down to room temperature. After cooling, tetrahydrofuran was added to dilute the 
solution. Finally, 2 was precipitated, in a significant excess of methanol, filtered, 
washed with methanol, and dried in a vacuum oven at 40°C for 48h. Molecular weight 
was calculated to Mn = 5755 g/mol by the integration of terminal proton of CH2 at 3.62 
ppm and the corresponding protons of CH2-groups in the chain at 4.03 ppm. 1H‐NMR 
and FT‐IR spectroscopy were carried out to characterize 2. 1H-NMR and FT-IR 
spectroscopy were performed to characterize 2. 
1H-NMR (400 MHz, CDCl3) δ [ppm] = 1.36 (m, 90H, CH2 on PCL backbone); 1.62 (m, 
180H, CH2 on PCL backbone); 2.27 (m, 90H, CH2C=O on PCL backbone); 2.45 (s, 1H, 
CH2−C≡CH); 3.62 (t, 2H, CH2OH); 4.03 (m, 88H, CH2O on PCL backbone); 4.65 (s, 
2H, CH2−C≡CH). (Attached file 3)   
FT-IR [cm-1]: 3265 (C≡C-H); 2944 (C-H); 2855 (C-H); 2098 (C≡C); 1721 (C=O); 1469 
(C-H); 1238 ((C=O)-O); 1171 (C-O-C). (Attached file 2) 
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10.5.4 Synthesis of CS‐[poly‐L‐lysine20‐N3] 3 
Chitosan-maleimide with a DS of 3% or 5% and a molar equivalent amount of Azido-
poly-L-Lysine20-SH were dissolved in a mixture of DMF and phosphate buffer saline 
(ratio: 1-6) with a final pH of 6.5. After the complete dissolution, the mixture was stirred 
for 24 hours at room temperature. Subsequently, the solution was dialyzed against a 
solution containing 10 x 10-3 M HCl and 1 wt% NaCl, and 10 x 10-3 M HCl solution. 
Finally, the solution was lyophilized to obtain CS-[poly-L-lysine20-N3]. 1H-NMR and FT-
IR spectroscopy were performed to characterize 3. 
1H-NMR (400 MHz, D2O) δ [ppm] = 2.00-2.08 (m, 3H, CH3 of GlcNAc); 3.07-3.24 (m, 
1H, CH of GlcN); 3.43-4.09 (m, 5H, CH on chitosan backbone); 4.52-5.01 (m, 1H, O-
CH-O); Poly-L-lysine 4.31 (m, 1H, CH); 2.98 (t, 2H, CH2); 1.7 (m, 4H, -CH2); 1.43 (m, 
2H, CH2). (Attached file 4) 
 FT-IR relevant peaks [cm-1]: 2121 (-N3). (Attached file 2) 
10.5.5 Synthesis of poly-[L-lysine-b-ε-caprolactone] 4 
2 (1.79 μmol) and CS-[poly-L-lysine20-N3]3% (0.01 g) were dissolved in 2 mL DMSO 
and in 1 mL H2O at 37°C, respectively. After dissolution, a mixture of CuSO4·5H2O 
(3.57 μmol) and ascorbic acid (8.93 μmol) were added to the reaction mixture. The 
solution was stirred overnight at 37°C. Finally, the resulted copolymer was dialyzed 
against THF in order to remove unreacted 2, against a saturated aqueous solution of 
EDTA disodium salt, 10 x 10-3 M HCl solution 1 wt% NaCl solution, and against 10 mM 
HCl solution. After lyophilisation, the copolymer was obtained. 1H-NMR and FT-IR 
spectroscopy were performed to characterize 4. 
1H-NMR (400 MHz, D2O/DMSO) δ [ppm] = PCL backbone: 1.30 (m, CH2 on PCL 
backbone); 1.54 (m, 2x CH2 on PCL backbone ), 2.27 (m, CH2C=O on PCL backbone 
); 3.99 (m, CH2); Chitosan backbone: 1.87 (m, 3H, -CH3 of GlcNAc); 2.93 (m, 1H, CH 
of GlcN); 3.73-3.86 (m, 5H, CH on chitosan backbone), 4.95 (m, 1H, O-CH-O); Poly-l-
lysine: 4.24 (m, 1H, CH); 2.80 (m, 2H, CH2); 1.64 (m, 4H, CH2); 1.41 (m, 2H, CH2). 
(Attached file 5) 
FT-IR [cm-1] relevant peaks: Chitosan component: 3287 (O-H); 2876 (C-H); 1646 
(C=O);1526 (N-H); 1045 (C-O); PCL component: 2928 (C-H); 2862 (C-H); 1724 (C=O); 
1466 (C-H)); 1239 ((C=O)-O); 1175 (C-O). (Attached file 2) 
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10.5.6 Polymersome formation 
For polymersome formation, 1 mg/mL CS-graft-copolymer was dissolved in a mixture 
of H2O or 63 x 10-3 M sodium phosphate buffer pH of 7.6 and DMSO (ratio: 1-20) at 
37°C. After dissolution, the solution was dialyzed (molecular weight cut-off 14.000 
g/mol) three times against deionized H2O or 63 mM sodium phosphate buffer pH of 
7.6. After 15 hours, the solution turned turbid, and the polymersomes were obtained. 
Then, particle size, zeta potential and stability measurements were carried out using a 
Zetasizer Nano ZS from MALVERN INSTRUMENTS (Malvern, UK). Disposable sizing 
cuvettes (DTS0012) and disposable folded capillary cell (DTS1070) were used for size 
/ zeta potential measurements. Malvern Zetasizer Software Version 7.03 was used for 
data evaluation. Cryo-SEM images were used to inspect the shape and morphology of 
polymersomes using a HITACHI S-4800 instrument (Chiyode, Japan). 
10.5.7 Spray coating of Titanium plates  
The titanium substrates were then spray-coated for 180 seconds with an airbrush Aztek 
A470 from TESTORS (Vernon Hills, IL, USA), depositing approximately 20 µL of the 
polymersome suspension with a concentration of 1mg/ml. Subsequently, the Ti plates 
were washed with 0.1% acetic acid (AcOH) and H2O in an ultrasonic bath for 15 
minutes. Subsequently, the plates were dried under nitrogen flow. Ellipsometry was 
used to determine the coating thickness.  
10.5.8 Stability / degradation experiment of polymersomes and coatings 
 The degradation studies of the coatings on the Ti plates were carried out by the 
incubation in trypsin (4 μg/ml) or chitosanase (5 μg/ml) containing solution. The tests 
have been performed in distilled water at pH between 5.6-5.8. The solutions were 
renewed daily to ensure degradation capability of trypsin. Before each thickness 
measurement, the samples were washed with 0.1% acetic acid (AcOH) and H2O 
solutions in an ultrasonic bath for 15 minutes and dried under nitrogen flow. 
The degradation of the polymersomes was investigated by the addition of trypsin or 
chitosanase to the suspension. The tests have been performed in 63 mM sodium 
phosphate buffer pH of 7.6 and distilled water (pH = 5.6-5.8). Briefly, 1 mL 
polymersome suspension were filled in a sizing cell. Trypsin or chitosanase solution 
was added in order to obtain respectively final concentrations of 4 and 5 µg/mL. The 
degradation process was then monitored via consecutive size measurements using 
the Zetasizer Nano ZS.  
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10.6 Aginate/Peptid-nanoparticles 
10.6.1 Synthesis of ciprofloxacin derivates 
Synthesis of alkyne-functionalized ciprofloxacin 5 
NaHCO3 (0.187 g, 0.0022 mol) and ciprofloxacin (0.5 g, 0.0015 mol ) were dissolved 
in 150 ml of dry DMF at 80°C. Once a clear solution is obtained, the reaction mixture 
was degassed with N2 for 15 minutes. Finally, 4-Bromo-1-butyne (1 g, 0.0075 mol) was 
added and the solution was stirred 24 hours at 21°C. After 24 hours, the DMF was 
removed under reduced pressure by adding toluene as co-solvent. The resulting solid 
was purified by flash chromatography on silica gel. A mixture of CH2Cl2 and MeOH 
(97-3) was used for the chromatography. A white solid was obtained: 172 mg. Yield = 
29% 
1H-NMR (700 MHz, CDCl3) δ [ppm] = 8.70 (s, 1H); 7.95 (d, J = 13.1 Hz, 1H); 7.29 (d, 
J = 7.2 Hz, 1H); 3.47 (tt, J = 7.1, 3.9 Hz, 1H); 3.35-3.25 (m, 4H); 2.65 (m, 6H); 2.39 (m, 
2H); 1.95 (t, J = 2.6 Hz, 1H); 1.36-1.27 (m, 2H); 1.13 (m, 2H). (Attached file 6) 
 
Synthesis of BCN-O(CO)O(4-NO2-Ph) 6 
First, 100 mg (0.666 mmol) (1R,8S,9s)-bicyclo6.1.0non-4-yn-9-yl-methanol (BCN-OH) 
was dissolved in 17 mL dry CH2Cl2. 134 μL (1.664 mmol) of pyridine and 168 mg 
(0.831 mmol) of 4-nitrophenyl chloroformiate was added to the solution. The mixture 
was stirred for 20 minutes at 22°C before being quenched by the addition of 20 mL of 
saturated ammonium chloride solution. The mixture was extracted with CH2Cl2 (3x20 
mL). The combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. Flash chromatography through silica gel was performed to purify 
the residue. A mixture of light petroleum-EtOAc (95-5) and (90-10) were used for the 
chromatography. 
A white solid was obtained: 180 mg. Yield = 85%  
1H-NMR (300 MHz, CDCl3) δ [ppm] = 8.26-8.31 (m, 2H); 7.37-7.42 (m, 2H); 4.4 (d, 2H); 
2.38-2.26 (m, 4H); 2.25-2.21 (m, 2H); 1.66-1.57 (m, 2H); 1.49 (p, 1H); 1.11-1.02 (m, 
2H). (Attached file 7)  
 
Synthesis of BCN-O(CO)HN-Ciprofloxacin 7 
At 82°C, 42 mg (0.127 mmol) of ciprofloxacin was dissolved in 7 mL of dry DMF. After 
the complete dissolution, 38 mg (0.38 mmol) of N-methylmorpholine (NMM) and a 
solution of 40 mg (0.127 mmol) BCN-O(CO)O(4-NO2-Ph) in 2 mL DMF were added. 
The solution was stirred for 24 hours at 23°C. Then, DMF was evaporated under 
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reduced pressure. It is important to stop the evaporation before the end to keep 0.5 ml 
of the solution. The residue was purified by flash chromatography through silica gel. A 
mixture of CH2Cl2/MeOH (95-5 and 90-10) were used. After vacuum drying, a yellow 
solid was obtained: 45 mg. Yield = 70 %. 
1H-NMR (300 MHz, CDCl3) δ [ppm] = 4.17 (d, J = 8.2 Hz, 2H), 3.70-3.63 (m, 4H); 3.48 
(tt, J = 7.1, 4.0 Hz, 1H); 3.29-3.21 (m, 4H); 2.32-2.10 (m, 6H); 1.62-1.46 (m, 2H); 1.37-
1.29 (m, 3H); 1.17-1.10 (m, 2H); 0.96-0.86 (m, 2H). (Attached file 8) 
MS-ESI (m/z): calculated 507.22 g/mol; found 508.22 [M + H]+; 530.20 [M + Na]+; 
1037.42 [2 M + Na]+ (calculated for C28H30FN3O5= 507.22 g/mol) 
 
2HN-(CH2)5-Ciprofloxacin 9 
Ciprofloxacin 165.5 mg (0.5 mmol) and N,N-Diisopropylethylamine 0.5 mL (2.9 mmol) 
were mixed in 3 mL of dry CH2Cl2 and 185 μL trimethylsilyl chloride. The solution turned 
yellow. Separately, 6-((tert Butoxycarbonyl)amino)hexanoic acid 173 mg (0.75 mmol), 
PyAOP 417 mg (0.8 mmol) and DIPEA 350 μL (2 mmol) were dissolved in 2 mL of dry 
CH2Cl2. The two solutions were combined and stirred overnight at 23°C. 60 mL H2O 
were added and the aqueous solution was extracted with 3x80 mL CH2Cl2. The 
combined organic layers were washed with 60 mL H2O, 10 % w/w citric acid in water, 
saturated aqueous NaHCO3 solution, brine and 2x50 mL H2O. The organic phase was 
dried over Na2SO4 and concentrated under reduced pressure. A yellow solid was 
obtained: 190 mg. Yield = 70 %. 
1H-NMR (CDCl3, 300 MHz), δ 1.18-1.23 (2H, m), 1.36-1.56 (15H, m), 1.63-1.74 (2H, 
m), 2.39 (t, J = 7.5 Hz, 2H), 3.12 (dt, J = 6.7 Hz, 2H). 3.25-3.39 (4H, m), 3.51-3.59 (1H, 
m), 3.67-3.90 (4H, m), 4.56 (1H, bs), 7.36 (d, J = 7.1 Hz, 1H), 7.99 (d, J = 12.9 Hz, 
1H), 8.72 (s, 1H), 14.9 (1H, bs). 
MS-ESI (m/z): calculated 545.28 g/mol; found 567.82 g/mol (z=1, [M + Na]+); 1111.53 
(z=1/2, [M + Na]+), (z=1/3, [M + Na]+). 
The trifluoroacetic acid (TFA) salt was obtained by stirring it overnight, in 16.7 % 
TFA/CH2Cl2, at room temperature and by removing the solvent with methanol as co-
solvent. The resulting solid was re-precipitated with diethyl ether. A yellow pale solid 
was obtained: 110 mg. Yield = 90 % 
1H-NMR (CD3OD, 300 MHz), δ 1.22 (m, 2H) 1.54-1.37 (m, 4H), 1.63-1.77 (m, 4H), 2.52 
(t, J = 7.3 Hz, 2H), 3.05-2.86 (m, 2H), 3.46-3.33 (m, 4H), 3.87-3.70 (m, 5H), 7.55 (d, J 
= 7.2 Hz, 1H), 7.81 (d, J = 13.2 Hz, 1H), 8.72 (s, 1H). (Attached file 10) 19F-NMR 
(CDCl3, 282 MHz), δ -75.36, -121.56.  
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Synthesis of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin 10 
100 mg (0.127 mmol) of 9 was dissolved in 2.65 mL dry DMF. After complete 
dissolution, 78 μL (mmol) NMM and a solution of 56.5 mg (mmol) BCN-O(CO)O(4-
NO2-Ph) in 2 mL DMF were added and stirred for 24 hours at 23°C. DMF was 
evaporated under reduced pressure (it is important to stop the evaporation before the 
end in order to keep 0.5 mL of the solution). The residue was purified by flash 
chromatography through silicagel. Solvent: CH2Cl2/MeOH (95-5 and 90-10).  
A yellow solid was obtained: 50 mg. Yield = 45% 
1H-NMR (DMF, 600 MHz), δ 8.75 (s, 1H), 7.97 (d, J = 13.2 Hz, 1H), 7.73 (d, J = 7.4 
Hz, 1H), 7.00 (t, J = 5.8 Hz, 1H), 4.09 (d, J = 8.1 Hz, 2H), 3.94 (tt, J = 7.3, 4.1 Hz, 1H), 
3.79 (m, 4H), 3.42 (m, 4H), 3.11 (td, J = 7.1, 5.8 Hz, 2H), 2.45 (t, J = 7.5 Hz, 2H), 2.30-
2.14 (m, 6H), 1.66-1.22 (m, 15H), 0.95-0.85 (m, 2H). (Attached file 11) 13C-NMR (DMF, 
600 MHz): 9.15, 19.5, 21.47, 22.41, 26.39, 27.96, 30.5, 31.42, 34.09, 37.64, 42.06, 
42.42, 46.54, 51.17, 51.79, 62.92, 100.21, 108.41, 108.88, 112.62, 141.13, 146.99, 
149.67, 154.23, 155.88, 158.38, 167.66, 172.48, 178.51. 14N-NMR (DMF, 600 MHz): -
314.56, -298.18, -266.90, -229.85. 
10.6.2 Synthesis of Ciprofloxacin conjugated peptides/substances   
Synthesis of ciprofloxacin-poly-L-lysine 11 
PLL9-N3 was synthesized using automated standard solid phase supported peptide 
(SPPS) synthesis utilizing a Syro II Peptide synthesizer from MultiSynTech. The first 
Fmoc-protected lysine was loaded onto a 2-chlorotrityl resin (capacity 0.48 mmol/g) in 
the presence of Triethylamine in dichloromethane at 23°C over 12 h. The loading of 
the resine was determined after Fmoc-cleavage in the presence of a solution of 20 w% 
piperidine in DMF analysing the concentration of the fulvene-piperidine adduct at 309 
nm by UV-Vis spectrometry. Coupling of further Fmoc-protected lysines and 4-
azidobenzoic acid was achieved after Fmoc-cleavage (Piperidine 20w% in DMF) using 
the acid as well as DIC/HOBt/DiPEA:1/1/1 as coupling mixture in 4-fold excess. 
Between all cleavage and coupling steps the resin was washed with DMF. Final 
cleavage of the peptide from the resine was achieved in the presence of TFA at 23°c 
over a period of 5 min and PLL9-N3 was obtained from the cleavage solution by 
precipitation with cold diethylether.  
For this synthesis of 11, 40 mg of PLL9-N3 were added to a solution of 18 mg BCN-
O(CO)HN-Ciprofloxacin (0.035 mmol) in 4 mL. The mixture was stirred overnight at 
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23°C before the product was precipitated with diethyl ether, re-dissolved in DMF, and 
re-precipitated. Finally, the solid was washed with diethyl ether until a white powder 
was obtained. Yield = 81 %  
1H-NMR (700 MHz, D2O) δ [ppm] relevant peaks: 8.55 (s, 1H, CIP); 7.89 (m, 2H, PLL); 
7.13-7.49 (m, 4H, CIP/PLL); 2.99 (m, 24H, PLL); 1.98-1.29 (PLL). (Attached file 27)  
UV-Vis: Absorption peak at ~278 nm. 
 
   
Synthesis of Peptide 12a conjugated Ciprofloxacin 12b 
0.01 mg (0.009 mmol) of peptide: [EGETVNDRGKKKK]-N3 (12a) was added to a 
solution of 5.5 mg BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin (0,009 mmol) in 1 mL 
(DMF),. The solution turned from yellow to transparent. The mixture was stirred over 
night at 23°C before the product was re-precipitated with diethyl ether, re-dissolved in 
DMF and re-precipitated. Finally, the solid was washed with diethyl ether.  
A white-yellow solid was obtained: 13 mg. Yield: 65%.  
MS-ESI (m/z): calculated 2263.56 g/mol; found, 566.80 (z = 4, [M + H+]); 755.40 (z = 
3, [M + H+]); 1132.60 (z = 2, [M + H+]). 
UV-Vis: Absorption peak at ~278 nm. 
 
Synthesis of 13a or 14a conjugated Ciprofloxacin 13b or 14b 
 
Figure 10-3 Chemical structure of 13a and 14a. 
 
0.024 mmol of 13a or 14a (Figure 10-3) were added to a solution of 15 mg 10 (0.024 
mmol) in 1 mL (DMF). The solution turned from yellow to transparent. The mixture was 
stirred over night at 23°C, before the product was precipitated with diethyl ether, re-
dissolved in DMF and re-precipitated. Finally, the solid was washed with diethyl ether 
and a white-yellow solid (80-90%) was obtained. 
A white solid was obtained (13b):  105 mg. Yield:  91%.  
A white solid was obtained (14b): 17 mg. Yield:  87%.  
 
Molecule 13b: 1H-NMR (DMF, 600 MHz), δ 8.76 (s, 1H), 7.98 (d, J = 13.2 Hz, 1H), 7.73 
(d, J = 7.4 Hz, 1H), 7.00 (t, J = 5.8 Hz, 1H), 4.49 (t, J = 5.4 Hz, 2H), 4.17-4.07 (m, 2H), 
3.94 (tt, J = 7.3, 4.0 Hz, 1H), 3.85-3.76 (m, 8H), 3.41-3.36 (m, 2H), 3.26 (dd, J = 5.7, 
4.7 Hz, 2H), 3.14-3.08 (m, 2H), 3.08-3.00 (m, 2H), 2.84-2.76 (m, 2H), 2.45 (t, J = 7.5 
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Hz, 2H), 2.22-2.07 (m, 2H), 1.66-1.14 (m, 15H), 1.06-0.95 (m, 2H). (Attached file 17) 
13C-NMR (CDCl3, 600 MHz): 9.27, 19.43, 21.10, 21.76, 23.49, 24.16, 26.49, 27.49, 
27.92, 30.89, 31.45, 34.09, 37.62, 41.38, 42.15, 42.35, 46.54, 49.07, 51.17, 51.84, 
62.96, 69.02, 71.36, 71.56, 108.70, 112.69, 119.49, 121.00, 135.26, 141.09, 145.28, 
147.03, 149.8, 153.95, 155.7, 158.7, 158.21, 167.87, 172.47, 178.8. 14N-NMR (DMF, 
600 MHz): -352.99, -312.78, -298.18, -266.87, -229.85, -136.07, -25.38. 
UV-Vis: Absorption peak at ~278 nm. 
 
Molecule 14b: 1H-NMR (DMF, 600 MHz), δ 8.75 (s, 1H), 7.97 (d, J = 13.2 Hz, 1H), 7.74 
(d, J = 7.5 Hz, 1H), 7.05 (t, J = 5.8 Hz, 1H), 4.71 (m, 1H), 4.33 (t, J = 6.3 Hz, 1H), 4.12 
(m, 2H), 3.95 (tt, J = 7.3, 4.0 Hz, 1H), 3.83-3.75 (m, 4H), 3.48-3.36 (m, 4H), 3.14-3.08 
(m, 2H), 3.08-3.00 (m, 2H), 2.88-2.81 (m, 2H), 2.60 (m, 2H), 2.45 (t, J = 7.5 Hz, 2H), 
2.23-2.07 (m, 2H), 1.68-1.31 (m, 14H), 1.16 (m, 1H), 1.00 (m, 1H). (Attached file 23) 
13C-NMR (CDCl3, 600 MHz): 7.87, 15.09, 17.9, 19.34, 19.68, 21.73, 22.34, 22.7, 25.04, 
26.07, 26.56, 29.94, 31.07, 32.68, 36.33, 40.78, 41.14, 44.46, 45.19, 49.86, 50.08, 
50.49, 61.66, 107.27, 111.30, 119.62, 133.46, 139.75, 144.30, 145.74, 148.34, 152.93, 
154.66, 157.14, 166.44 170.66, 171.32, 177.31. 14N-NMR (DMF, 600 MHz): -26.63, -
135.18, -230.03, -267.4, -298.01, -314.38. 
UV-Vis: Absorption peak at ~278 nm. 
10.6.3  Nanoparticle formation with alginate 
Purification of alginate  
Alginate was purified according to the method outlined by Tolle et al.[24] 2 g of 
commercial alginate were dissolved in 30 mL of deionized H2O. This solution was 
dialyzed over three days against deionized H2O with three medium changes a day (14 
kDa MW cutoff). The solution was stirred overnight with a ratio of 0.5 g activated carbon 
per gram of alginate. After being stirred for 15 hours, the solution was filtered for 
removal of the activated carbon. Finally, the filtrate was freeze-dried and stored at -
20°C to avoid the hygroscopic phenomenon.  
1H NMR (D2O, 600 MHz): 3.96 ppm (m).  
FT-IR [cm-1]: 3325, 1596, 1407, 1297, 1088, 1028, 625. 
 
Preparation of Alginate/α-PLL conjugated Ciprofloxacin 11 Nanoparticles 
Solutions of 1 mg/ml Alginate (solution 1) and PLL-Ciprofloxacin (solution 2) were 
prepared in filtered pure water. The nanoparticles were prepared by mixing solutions 
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1 and 2 at different ratios. The tested ratios were 1:4, 1:3, 1:2, and 1:1 (Alg:PLL-
Ciprofloxacin). Then, particle size, stability measurements and degradation study were 
carried out using a Zetasizer Nano ZS from MALVERN INSTRUMENTS (Malvern, UK). 
Disposable sizing cuvettes (DTS0012) were used for size measurements. Malvern 
Zetasizer Software Version 7.03 was used for data evaluation.  
10.6.4 Spray coating of Titanium plates   
Coating of Alginate / PLL-Ciprofloxacin Nanoparticles on Ti plate  
Before being coated with alginate nanoparticles, the substrates were polished, and 
cleaned through ultrasonification in water, dichloromethane, acetone, methanol, and 
MilliQ water. The titan substrate was first coated with a Polyethylenimine (PEI) layer. 
The substrate was immersed for one minute in 5% (w/w) PEI solution, washed with 
pure water, and dried under nitrogen. Then, the substrates were spray-coated (three 
minutes) with an airbrush Aztek A470 from TESTORS (Vernon Hills, IL, USA), 
depositing approximately 20 µL of the Alg/PLL-ciprofloxacin nanoparticle solution. The 
particle formation process was carried out in MilliQ water with both 1 mg/mL of sodium 
alginate and peptides. Subsequently, the Ti plates were rinsed with an H2O solution in 
an ultrasonic bath for 15 minutes. After the plates were dried under nitrogen flow, 
ellipsometry was used to measure coating thickness. Layer thicknesses were 
determined using a Multiskop from OPTREL (Sinzing, Germany) in the ellipsometry 
mode. Uncoated titanium plates were used as a reference. Data were collected in the 
x, y-mode at 70° as mean value of 16 data points in total. Evaluation of the data was 
carried out using Elli Version 3.2 from Optrel. More details about ellipsometry 
measurement can be found chapter 6.2.   
10.6.5 Stability of NP coating and NP solution 
Stability of Nanoparticles in aqueous solution 
A solution of Alginate / PLL-Ciprofloxacin nanoparticle was prepared with a ratio of 1:3 
in Phosphate-Buffered Saline solution (PBS) pH = 7.4 and added to the disposable 
sizing cuvettes. The particle's behavior was analyzed via dynamic light scattering with 
a Zeta Nano ZS device at 37°C for 50 hours.    
 
Stability of NP coating on titanium  
The coating stability was tested by immersing the coated substrate in PBS, pH = 7.4 
at 37°C for 109 hours. The test was performed in triplicate to ensure the reproducibility. 
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Before each thickness measurement, the samples were washed with H2O and dried 
under nitrogen flow.  
10.6.6 Enzymatic degradation of Nanoparticles and coatings  
The degradation study was carried out by incubation in trypsin containing buffer 
solution (PBS, pH = 7.4). A PLL hydrolysis reaction was initiated by adding trypsin to 
obtain a final concentration of 5 μg/ml at 37°C. The solutions were renewed daily to 
ensure degradation capability of trypsin. Before each measurement, the samples were 
washed with H2O and dried under nitrogen flow. The test was performed in triplicate to 
ensure reproducibility.  
The degradation of the Alg/peptide nanoparticles was accomplished through the 
addition of trypsin to the nanoparticle dispersion. Briefly, 1 mL Alg/PLL-ciprofloxacin 
nanoparticle suspensions were filled in a sizing cell and maintained at 37 °C. Trypsin 
solution was added in order to obtain final concentrations of 2.5 µg/mL. The 
degradation process was monitored via consecutive size measurements using the 
Zetasizer Nano ZS. 
10.6.7 Enzyme-triggered release 
For the tests 3 x 6 ml of particle solutions were prepared. Two solutions were treated 
with a concentration of 2 μg/ml and 5 μg/ml of trypsin. The last, was not treated with 
enzyme and was used as a control. After trypsin was added, the solutions were 
incubated at 37°C. Then, every 15 minutes, 1 mL of each sample was collected and 
inserted into a Vivaspin tube containing two vertical membranes with a cutoff of 5 kDa. 
The tube was centrifuged, and the ciprofloxacin concentration was determined using a 
V-630 UV-VIS Spectrophotometer from JASCO and a quartz glass Ultra-Micro Cell. A 
calibration curve was prepared by plotting different concentration of commercial 
ciprofloxacin hydrochloride versus their absorbances at λ = 278 nm and found to be 
linear in the concentration range of 2 to 10 µg/mL. This curve was then used to 
determine the concentration of ciprofloxacin released during the degradation process.  
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Figure 10-4 Schematic representation of vivaspin 20 tube. 
10.6.1 Drug efficacy tests 
The antimicrobial efficacy of the conjugated ciprofloxacin were investigated against 
Staphylococcus aureus at different concentrations (DSM 799, German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany). S. aureus was cultured 
in tryptone soya broth supplemented with 10 % yeast extract (TSBY) for 18 hours at 
37 °C. The preculture was adjusted to an optical density (600 nm) of 0.001 in TSBY 
and added to 96-well plate (100 µL/well). The conjugated ciprofloxacin’s were diluted 
1:2 in TSBY as a 5-fold dilution series. In order to prevent nutrient reduction, the first 
dilution was prepared in 2-fold TSBY. In the same way, ciprofloxacin and MilliQ water 
were diluted and served as controls. The dilution series were added to S. aureus in 96-
well plate (100 µL/well) and cultivated for 24 hours under shaking (400 rpm) at 37 °C. 
Afterwards, the optical density (600 nm) was measured by microplate reader (infinite 
M200PRO, Tecan, Männedorf, Switzerland). The absorption values were normalized 
against the positive control, which was a S. aureus culture in TSBY under the same 
cultivation conditions. 
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Attached file 2 FT-IR spectrum of A: Chitosan maleimide, B: propargyl-terminated poly-ε-caprolactone, C: CS-[Poly-
L-lysine20-N3], D: Chitosan-g-[PLL-poly-ε-Caprolactone]. 
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Attached file 5 1H-NMR spectrum and peak assignment for Chitosan-g-[poly-L-lysine-b-poly-ε-Caprolactone] in 
deuterated DMSO/D2O. 
 













Attached file 6 1H-NMR spectrum and peak assignment for modified ciprofloxacin 5 in deuterated CDCl3. 
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Attached file 9 13C-NMR spectrum and peak assignment for BCN-O(CO)HN-Ciprofloxacin in deuterated CDCl3. 
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Attached file 11 1H-NMR spectrum and peak assignment for BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in 
deuterated DMF. 
 
Attached file 12 2D-NH-HMBC spectrum of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 








Attached file 13 2D-COSY spectrum of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
 
Attached file 14 2D-NOESY spectrum of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 








Attached file 15 2D-HSQC spectrum of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
 
Attached file 16 2D-HMBC spectrum of BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
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Attached file 17 1H-NMR spectrum and peak assignment for 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin 13b in 
deuterated DMF. 
 






Attached file 18 2D-NH-HMBC spectrum of 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
 
Attached file 19 2D-COSY spectrum of 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 








Attached file 20 2D-NOESY spectrum of 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
 
Attached file 21 2D-HMBC spectrum of 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 




Attached file 22 2D-HSQC spectrum of 2HN-PEG-BCN-O(CO)HN-2HN-(CH2)5Ciprofloxacin in deuterated DMF. 
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Attached file 24 2D-COSY spectrum of substance 14b in deuterated DMF. 
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Attached file 25 2D-NH-HMBC spectrum of substance 14b in deuterated DMF. 
 
 Appendix 136 
 
 
Attached file 26 2D-HMBC spectrum of substance 14b in deuterated DMF. 
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Attached file 28 FT-IR spectra of PLL9-N3 and Ciprofloxacin-poly-L-lysine  
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